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Alzheimer’s disease (AD) is the most common form of dementia characterized by 
memory loss and other cognitive abilities that worsen overtime to interfere with daily life. 
AD’s incidence and financial burden is rapidly increasing worldwide. Considering brain 
disease pathology starts 20 years before symptoms become noticeable, detecting 
molecules capable of precise diagnosis of disease before development of symptoms is a 
priority. This thesis investigates the possibility of using metabolomics to detect AD 
associated metabolites and to measure the abundance of a range of small molecule 
metabolites in human brain to examine how these metabolites are associated with severity 
of AD pathology and expression of symptoms. A project plan was designed to investigate 
brain metabolic profiling of AD samples. Initially rat brain samples were used to develop 
a method capable of the coverage of a wide range of metabolites using Liquid 
chromatography quadrupole time of flight mass spectrometry (LC- Q-TOF-MS) 
combining two separation techniques reversed phase (RP) and Hydrophilic liquid 
chromatography (HILIC). After this, gas chromatography mass spectrometry (GC-MS) 
analysis was employed with the aim of developing untargeted analysis and expanding the 
metabolome, thus identifying new and novel AD predictor metabolites to help elucidate 
and understand brain metabolism. Later, a brain invial dual extraction (IVDE) method 
was tested and applied to plasma of control and AD groups using a multimodal strategy 
that combines both LC-MS and GC-MS data. Finally, human brain samples from control, 
asymptomatic and AD patients were analysed using the developed untargeted LC&GC-
MS brain IVDE method. Results revealed unsaturated fatty acids and sphingolipid 
metabolism to be significantly dysregulated in the brains of patients with varying degrees 
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1.1 General Introduction 
In human body, the brain along with spinal cord make up the central nervous system 
(CNS). The brain is composed of cerebrum, cerebellum and brainstem. The cerebrum 
consists of two cerebral hemispheres, each hemisphere is composed of four lobes 
(regions), namely; frontal, temporal, parietal and occipital lobe, with each lobe having a 
certain function. The brain’s anatomy can be seen in Figure 1.1. The brain and the central 
nervous system represent a major cause of global morbidity and mortality, with over 600 
recognised neurological diseases [1, 2] including developmental disorders such as 
Down’s syndrome and autism spectrum disorders[3, 4], seizure disorders such as epilepsy 
[5] and neurodegenerative dementias including Alzheimer’s and Parkinson’s disease [6, 
7].  
Recently, ‘metabolomics’ has been introduced as a tool aiming to meausre metabolic 
composition, allowing the measurement of abundance and distribution of metabolites in 
the Biosystems, such as, biofluids (plasma, serum and cerebrospinal fluid(CSF)), cells 
and tissue, using different analytical platforms. Unlike biofluids, brain metabolomics 
entails many challenges including limited accessibility, samples extraction (in terms of 
brain homogeneity), along with other parameters as consistency in selecting analytical 
platform for metabolite analysis and data treatment strategies. In addition, different brain 
areas have different metabolite composition, that is produced in the brain under 
pathological conditions, and also each region has its own specificity to disease pathology 
with some brain regions being more vulnerable to disease than other areas. Mechanisms 
underlying the differential regional vulnerability to disease remains to be elucidated, 
especially in Alzheimer’s disease. 
The work presented in this thesis will focus on studying Alzheimer’s disease (AD) in 
brain. AD is a devastating disease not only to patients but to their families and society, it 
was rated as second leading cause of death in 2015 in the United Kingdom(UK), just after 
ischemic heart disease. A more detailed section on AD and application of metabolomics 









Figure 1.1  Human brain structure showing four main functional lobes of cerebral cortex. . Areas 
highlited in blue in the frontal and temporal lobes are Medial frontal gyrus (MFG) and Inferior 
temporal gyrus (ITG) respectively. These two regions along with cerebellum have been used in 




1.2 Introduction to Alzheimer’s Disease (AD) 
1.2.1 AD Prevalence, incidence and types 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. AD was first 
described by Alois Alzheimer’s in 1970 when he described symptoms he observed in 
Auguste Deter, a 51 years old woman with disorientation and memory loss symptoms 
described as "sometimes stronger, sometimes weaker" [8]. Following her death four and 
half years later, Dr. Alois examined her brain and observed brain atrophy and abnormal 
deposition in and around the nerve cells, these were later identified as " Plaque" and " 
Tangle fibre". These observations lead to further studies in dementia and in particular 
AD.  
 
 AD is the most common form of dementia accounting for around 60% of cases. 
Indicative signs of AD are cognitive impairment, memory loss and disorientation 
resulting in a decline in the person’s ability to plan, solve problems, or undertake daily 
activities [9], [10]. There is still no definitive method of diagnosing AD as the 
pathogenesis of the disease is still yet to be fully understood. Moreover, a slight decrease 
in AD incidence in high income countries was suggested, potentially due to better 
education, treatment and awareness of AD risk factors such as cardiovascular disease, 
excess alcohol, smoking and depression, to lead to less number of people with dementia 
[11]. However, it was estimated that in developed countries around 60 % of people with 
dementia have low income, with this expected to rise to about 70 % in 2040 [12].  
 
 Worldwide, there has been an increase in the prevalence of age related neurodegenerative 
diseases. In Europe, around eight million individuals have AD, and dementia-related 
healthcare is estimated at 113 billion Euros a year. [13]. In the United Kingdom (UK) 
dementia cases are expected to rise to about 76 million by 2030, while at present in the 




There are two main forms of AD, Familial AD and Sporadic AD. Familial AD is known 
as early onset AD (EOAD). It accounts for 5% of all AD cases, occurring in people below 
age of 65yrs [15]. Three genes are currently associated with the onset of familial AD 
namely presenilin 1, presenilin 2 and amyloid precursor protein (APP). Presenilin 1 and 
presenilin 2 were reported to provoke plaque via the γ secretase enzyme complex  [16]. 
Further to this, polymorphisms in the gene coding for APP cause dramatic increase in 
amyloid peptide isoform production [17]. Sporadic AD is the most common form of the 
disease, accounting for over 95% of cases, also known as late onset AD(LOAD). 
Incidence of LOAD occurs at the age of 65yrs or older. There are many risk factors for 
sporadic AD including age, apolipoprotein (APOE) , diet and nutrition. APOE is a risk 
gene, and the e4 allele APOE gene is considered the most significant risk factors of 
AD[18] and has been identified to be associated with late onset AD [19] (more details 
can be seen in section 1.4.2). 
 
1.2.2 Alzheimer’s Disease Pathology 
The extracellular deposition of senile plaques composed of amyloid beta peptide(Aβ) in 
AD brain was documented by Dr. Alzheimer. Later he also described intracellular 
neurofibrillary tangles composed of phosphorylated protein tau. These pathological 
characteristics begin in the entorhinal cortex and Hippocampus and then proceed to other 
cortical areas, leading to neuronal damage and death [20]. In AD brain, these two features 






Figure 1.2 Pathological hallmarks of Alzheimer’s disease: Healthy(left) versus AD(right) brain 
and neurons: both Amyloid plaques and tau tangles can be seen outside and inside neurons 
respectively in AD brain(right) accompanied with brain atrophy (reduction in brain volume). 
Image adapted from psychneuro.wordpress.com   
 
1.2.2.1 Amyloid pathology 
The first hallmark of AD is the extracellular deposition of Aβ peptide around the nerve 
cells. This is known as ’neurotic plaques’. Aβ has 38-42 amino acids which form when 
the amyloid precursor protein (APP) is cleaved first by β secretase 1(BACE 1), releasing 
the APP from the cell [21], the remaining fragments of APP are cleaved by γ- secretase 
[22, 23] causing the release of more Aβ, and the released Aβ will aggregate to form Aβ 
oligomers in the extracellular space. The insoluble form of these oligomers is known as 
‘Aβ Plaques’ [24]. 
 
The two leading isoforms of Aβ (formed during the γ- secretase cleavage) are Aβ40 
(residue with 40 amino acids) and Aβ42 (residue with 42 amino acids). In AD brain Aβ42 
was identified to contribute more to Aβ aggregation and formation due to it is lower 
solubility [25]. The mechanism behind the role of Aβ42 and its high production in AD 
25 
 
brain is still unclear. Some studies proposed that plaque formation is an immune system 
response to microbes in the brain [26, 27], others, suggested a possible role of metal ions 
as plaque initiaton [28, 29]. The hypothesis that Aβ42 is causative of AD is the ‘Amyloid 
cascade model’(Figure 1.3). Low levels of Aβ42 are reported in AD Cerebrospinal Fluid 
(CSF) in comparison to controls [30, 31], these changes in CSF develop even prior to Aβ 
plaque formation in AD brain, and at present CSF levels are a surrogate marker of 
























































































































































































































































































































































































































































































































1.2.2.2 Tau pathology 
The second pathology hallmark in AD brain is known as neurofibrillary tangles (NFT). 
NFT are tau deposits inside neuronal cells formed as a result of abnormal hyper-
phosphorylation or glycosylation of tau protein in AD brain. Tau protein is a microtubule-
associated protein  [33], which binds with microtubulin to help maintain cell structural 
stability. Dissociation of the tau protein from microtubulin causes the aggregation of 
unbounded tau protein leading to tangle formation inside neurons, followed by synaptic 
dysfunction, axonal loss and disruption of intracellular communication[34, 35]. The 
reason for this aggregation is known as the tau hypothesis [36, 37].  The process of tau 
phosphorylation and dephosphorylation is regulated by different phosphatase and kinase 
enzymes and deterioration in this process may contribute to the accumulation of NFT. 
Consequently, more and more AD research is focusing on studying tau (T-tau) and 
phosphorylated tau (P-tau) as a potential AD biomarkers. 
 
1.2.2.3 Other pathological changes 
In addition to Aβ plaque and NFT, oxidative stress, mitochondrial dysfunction, metal 
dyshaemostasis and lipid peroxidation were reported as pathological characteristics of 
AD brain. Oxidative stress involves the production of Reactive Oxygen Species(ROS). 
Many studies observed the overproduction of Hydrogen Peroxide (H2O2, an oxidative 
stress marker) in the presence of Aβ plaque, suggesting Aβ role in promoting oxidative 
stress [38-40]. A possible mechanism is Aβ plaques causing mitochondrial dysfunction 
via cytochrome c oxidase inhibition leading to endoplasmic reticulum (ER) stress and 
cellular dysfunction [41, 42] or by directly disrupting mitochondrial membrane 
permeability as Aβ deposits were found in mitochondria [43, 44].  
 
Mitochondrial dysfunction is linked to deterioration in glucose metabolism [45]. In the 
brain, the energy required for cells to perform adequately is obtained from 
phosphorylation of Adenosine Triphosphate, which is generated in the mitochondria 
through glucose oxidation. Thus, damage in mitochondria causes glucose 
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hypometabolism (reduction in glucose metabolism). Brain glucose hypometabolism has 
been investigated and indeed observed in many studies [46-49]. 
 
Tau pathology has also been associated to oxidative stress. As mentioned previously tau 
phosphorylation is regulated by a balance between tau kinase and tau phosphatase 
activities. Treatment with ROS stimulates tau hyperphosphorylation, this involves the 
increase in activity of kinase (glycogen synthase kinase-3 (GSK3β)) [50] and a decrease 
in the activity of phosphatase (protein phosphatase 2A (PP2A)) [51]. To find therapeutic 
approaches, studies looked at inhibiting GSK3β, but this did not hinder 
hyperphosphorylation of tau or DNA damage in  mitochondria, suggesting 
GSK3β translocation may produce other than tau hyperphosphorylation [52]. In addition 
to mitochondria, microglial cells were recently identified as ROS producers in 
tauopathies. However, the mechanism behind this is unclear and further studies are 
needed to investigate this novel area of research. 
 
Furthermore, metal dyshaemostasis has been linked with oxidative stress. In AD brain 
metal dyshaemostasis has been reported to take place mainly due to the action of three 
metal ions namely; Zinc (Zn+2 ), Cupric(Cu+2 ) and Ferric (Fe+3) [53-55]. High level of 
these three ions were found in Aβ deposits proposing a role in AD pathology. Zn+2 and 
Cu+2 can block Ca+2 influx into neurons inhibiting N-methyl-D-aspartate (NMDA) 
receptors. Zn+2 and Cu+2   can also bind to tyrosine and histidine in Aβ initiating peptide 
aggregation [28, 29, 56]. This interaction is believed to lead to production of ROS [28, 
29, 57, 58]. Fe+3 in its reduced form (Fe+2), is an oxidant agent leading to production of 
H2O2
 and thus causing oxidative stress. This advocates a pivotal function for metal ions 
in AD pathology, possibly through initiating Aβ aggregation and producing ROS.     
 
Recently, there has been a shift in focus towards the role of lipids, mainly phospholipids 
and sphingolipids, in AD brain pathogenesis. This interest has risen from the findings of 
“adipose inclusions” or “lipoid granules” in brain tissue from AD patients. This was 
observed by Alois Alzheimer when he first described the disease pathology. Findings 
suggest that Aβ production relies on cholesterol levels within β- and γ-secretase 
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membrane [59]. Deterioration in phospholipids metabolism has therefore also been 
proposed to contribute to AD pathogenesis, but its mechanism remains unclear.  
 
Phospholipid are the main class of membrane lipids, playing a vital role in regulating cell 
functions [60].  Several studies have shown irregularity in phospholipid levels in AD 
brain, including low concentration of phosphatidylcholines (PC) [61-63], PI [64-66] 
phosphatidyethanolamine (PE) [62, 64], and ethanolamine plasmalogens (PlsEtn) [63, 66, 
67] with these lipid level also observed to be dysregulated in blood [68-70]. Opposite 
trends were observed in the CSF with high phospholipid concentration observed in AD 
patients [71, 72].  
 
Sphingolipids are another lipid class which play important roles in signal transmission 
and cell recognition [73], this class includes ceramides and sphingomyelines.  High 
Ceramides abundance was found in AD brain and plasma [74-76]. In AD brain, 
sphingomyelinase (SMase), is an enzyme that induces the breakdown of sphingomyelines 
to ceramides and thus high Cer and low sphingomyelines level were seen [74, 75]. 
Inhibition of SMase demonstrated to reduce both ceramide and Aβ deposition [77]. Other 
publications reported opposite trends for sphingomyelines in brain [66, 78], which was 
also reflected in CSF of AD samples [79, 80].  
 
The role of cholesterol has been widely studied and it is thought to contribute the most in 
AD brain pathogenesis, with high level of cholesterol measured in AD brain.  Cholesterol 
plays a vital role to maintain the integrity and fluidity of cell membranes, and to facilitate 
cell signalling [81]. Cholesterol is converted to cholesteryl esters via acyl-cholesterol-
acyltransferase-1 (ACAT 1), leading to increase Aβ production due to the cholesteryl 
ester accumulation intracellularly [82, 83]. Moreover, it was reported that cholesterol rich 
environments promote Aβ deposition and affect the γ and β secretase activity [84, 85]  
Further evidence is the reduced level of cholesteryl esters and thus Aβ release by 




1.3 Criteria and methods for AD diagnosis (Diagnosis criteria) 
A set of diagnostic criteria for AD was designed in 1984 by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) [87]. The guidelines indicated that 
diagnosis require assessment of patient’s symptoms, medical history, mental status and 
also neuropsychological testing. AD is deemed a clinical diagnosis as identified by the 
1984 criteria, with definite diagnosis only visible by post mortem examination of the brain 
and the presence of the AD hallmarks. However, it was later found that these pathological 
changes may occur in the brain 20-30 years before the clinical onset of dementia. 
AD is still deemed a clinical diagnosis, though now it is established that AD has a 
symptomatic pre-clinical dementia phase, where pathological changes such as Aβ, T-tau 
and P-tau accompanied with brain atrophy are present but patients have no development 
of cognitive or behavioural problems. Thus, a new criteria incorporating this pre-clinical 
stage was necessary in order to help with early diagnosis and treatment intervention [88].  
In 2011 a new criterion was established by NIA-AA (the National Institute of Aging in 
collaboration with Alzheimer’s Association) [89], this revised criteria provided two main 
improvements. 1) extending AD into three phases, namely an asymptomatic, pre-clinical 
phase, a symptomatic pre-clinical dementia phase (also known as Mild Cognitive 
impairment (MCI)) and a dementia phase. 2) merging the biomarkers research in AD 
diagnosis to enhance our understanding for pathological changes as well as for early 
intervention strategies. The NIA-AA recommendations call for identifying biomarkers 
that can increase sensitivity and specificity in the diagnosis of underlying AD including 
imaging techniques (see section 1.4.1 for more details). AD biomarkers were defined as 
" parameters (physiological, biochemical, anatomic) that can be measured in vivo and 
that reflect specific features of disease-related pathophysiological processes" [90]. 
 
Current diagnostic procedures rely on clinicians to observe a combination of clinical 
examination and neuropsychological assessment and involve evaluating patient’s medical 
history, mental cognition and general physical health. The first step involves history 
taking to eliminate the presence of other causes leading to the dementia. This involves 
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checking existing conditions, such as diabetes, depression or heart disease that is not well 
managed, also reviewing medications and diet habits. Following history taking, cognitive 
impairment can be assessed by several cognitive tests. These tests assess many different 
mental abilities including memory, concentration, attention span, language, 
communication skills and orientation. Specialist carrying out these tests consider that test 
scores may be influenced by different factors including for example a person's level of 
education. 
The Mini Mental State Exam (MMSE) is the most common mental state screening test 
that clinicians use. It comprises 30 questions (with a maximum score of 30) divided into 





Figure 1.4 Mini-Mental State Examination (MMSE)form and score interpretation. Healthy 
controls with non-cognitive impairment are expected to score 30, the greater the impairment the 





Additionally, there are many neuropsychological tests that can help to evaluate both 
cognitive and behavioural functions such as the Alzheimer’s Disease Assessment Scale-
Cognitive subscale (ADAS-Cog), which consists of two parts, one that measures 
cognitive functions and one that measures non-cognitive functions like mood 
and behaviour. This is to differentiate between normal and impaired cognitive 
functioning[92]. Other scales can also be employed such as the Global Deterioration Scale 
[93]  and the Clinical Dementia Rating, applied to assess dementia severity in a score 
range from 0 to 3, and to also assess the effects of cognitive loss on everyday activities 
[94, 95]. Both tests combine mental cognition, functional symptoms and neuropsychiatric 
aspects in a single approach. 
 
Other AD-stage descriptors rely on brain pathology. The staging of AD-related to 
neurofibrillary pathology described in 1991 and defined as ‘braak staging’ can 
differentiate initial, intermediate, and late phases of the disease process in both a 
symptomatic and symptomatic individual [96]. The Neuropsychological Battery for the 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) with criteria for 
Aβ plaque scoring system, which ranks the amount of Aβ plaques identified 




1.4 Biomarkers in AD 
1.4.1 Brain neuroimaging 
 Imaging techniques have been used to measure  brain region volumes. Atrophy was 
observed early in hippocampus and entorhinal cortex is suggested to be associated with 
memory impairment and an increased risk of AD [98, 99]. Imaging techniques, Magnetic 
Resonance Imaging (MRI), uses radio waves and magnets to create a detailed view of 
brain, it is also employed to help diagnose and monitor treatment for various conditions 
in the body including heart, abdomen, chest, and pelvis. In AD, MRI has focused on 
detecting reduced hippocampal volume, this reduction in hippocampal volume was 
reported at 10 % – 15 % and 20 % – 25 % in MCI and AD brain compared to healthy 
brain respectively [100]. MRI comparing healthy and AD brain can be seen in Figure 1.5. 
Further findings show reduction in brain hippocampus volume by 12% in mild AD [101] 
and 37% in moderate AD [102] compared to controls, also calculating AD diagnosis using 
the volume of hippocampus at 85% sensitivity and 82% specificity with higher values 
obtained after correction to age [102].  
 
Besides, Diffusion Tensor Imaging (DTI) has become a leading method in identification 
of white matter integrity in several brain regions.  White matter changes in parietal, 
temporal areas, and also in frontal regions have been detected in persons with AD and 
MCI compared to normal controls [103], suggesting that these changes occur early in the 
disease process and thus with a possibility of applying it to early diagnosis [103-105]. 
DTI could predict conversion from MCI to AD dementia but at present it was only 
recommended for research purposes. 
 
Magnetic resonance spectroscopy (MRS), is a technique which employs the theory of 
Nuclear Magnetic Resonance along with MRI, permitting metabolite quantification in 
vivo by brain tissue scanning. The combination of data from hippocampal brain atrophy 
with MRS has improved diagnostic performance. For instance, this combination enables 
the quantification of N-Acetyl Aspartate (NAA) levels that are shown to be decreased in 
AD [106]. More details about MRS and its applicability for biomarker discovery can be 




Figure 1.5 Example of FDG and PIB Positron Emission Tomography: The upper image is an 
example of fluoro-2-deoxy-D-glucose (FDG) PET imaging. The control demonstrates normal 
FDG uptake, whilst arrows on the AD image shows a typical pattern of FDG hypometabolism or 
Aβ deposition. The lower image depicts Pittsburgh Compound B (PiB) PET imaging of Aβ in 
brain of Control (left) and AD (right), with high Aβ retention observed in AD [108] 
 
An alternative imaging based approach is Positron emission tomography (PET). This 
technique works by identifying a radiolabelled positron emitting nuclei called ”Tracers”. 
Once the tracer is injected in the body, it binds with molecules of interest, then PET is 
applied to obtain 3D of the tracer intensity. PET scanning enables the imaging of Aβ load 
in brain of live patients via Pittsburg compound B(PiB) that binds to Aβ. Furthermore, 
FDG (Fluro-2-deoxy-D-glucose) is a glucose analogue that has been utilized to monitor 
regional glucose metabolism and uptake, it can show glucose hypometabolism in AD 
brain particularly in temporo-parietal [109] and inferior-parietal lobes [110]. These 
changes have been reported as AD features and conversion predictors from MCI to AD.  




1.4.2 Genetic (APOE4) 
APOE is a class of protein involved in the metabolism of fats in the body. APOE comes 
in several forms, or alleles, namely ε 2, ε 3 and ε 4. As stated before, APOE ε4 is the 
biggest genetic risk factor in LOAD. Individuals having at least one APOE ε4 alleles are 
at increased risk of developing AD compared to those carrying ε3 allele (most common 
allele), while the ε2 allele decreases risk. For example, people who inherit two ε4 alleles 
are at seven fold risk of developing AD higher than those with the E3 allele [111].  
 
A study by Mayeux et al. looked into AD diagnosis in 2188 individuals with AD and 
those individuals with other types of dementia. Findings revealed that APOE genotyping 
alone has sensitivity and specificity at 65% and 68% respectively, which is not sufficient 
to be used as a diagnostic test [112]. 
 
 APOE is linked to the production and aggregation of Aβ and tau [113, 114]. However, 
the mechanism behind this is still unclear.  APOE can promote Aβ degradation, APOE ε 
4 apart is the allele found to be less efficient at catalysing the reaction compared to other 
lipoprotein alleles and thus the existence of this allele could be responsible for the Aβ 
accumulation and the dysfunction of cholinergic neurotransmission [115].  
1.4.3 AD protein markers in CSF  
For protein markers such as Aβ and tau to be used successfully in the clinical 
environment, they need to be detected in biofluids like CSF, plasma or urine. In the 
literature, Aβ analysis in urine and plasma were inconsistently reported [116, 117]]. 
However promising results have been acquired from CSF analysis of Aβ [30, 118-120] 
T-tau [118, 120, 121] and P-tau analysis [120, 121]. Despite the difficulty and discomfort 
in CSF samples collection procedure, CSF reflects brain pathology quite well as it is in 
direct contact with brain. 
 
In AD CSF, a decrease in Aβ 42 and increase in both T-tau and P-tau levels are observed. 
The diagnostic power of these proteins ranges between 69% and 91%, combined data of 
the 2 proteins increased diagnostic sensitivity and specificity to range between 86% and 
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96% [122, 123]. Despite the promising accuracy of these proteins, for early AD the 
accuracies are lower and alone they can not be used to assist clinician with differential 
diagnosis like predicting conversion from MCI to AD, however they could be used for 
aiding later stage diagnostics [124]. 
 
1.5 Metabolomics 
The discovery of biomarker in AD can be invisigated using large scale " Omic" 
technologies, which provide universal detection to characterise and quantify thousands of 
molecules in biological systems in a holistic manner. Omic technologies including: 
genomics (The study of the structure, function and expression of all the genes in an 
organism), transcriptomics (The study of the mRNA within a cell or organism), 
proteomics (The study of proteomes and their functions) and more recently 
metabolomics. Overview of the “omics” cascade can be found in Figure 1.6.  
There has been a particular focus on identifying genes and proteins as potential candidates 
in the field of AD biomarkers. So far, no single biomarker has shown to meet the criteria 
for AD biomarker. However, the development in analytical techniques enables the 
detection of small molecule metabolites(<1500Da). This new approach that allow the 




Figure 1.6 overview of omics approaches and systems biology. The upper right part  shows the 
complex biological pathways and interactions that could happen across the entire network [125]. 
 
The terms " metabonomics" and"metabolomics" have been introduced by Nicholson 
Group at Imperial College London and Fiehn group at The Max-Planck Institute of 
Molecular Plant Physiology in 1999 and 2002, respectively [126, 127]. 
 
" Metabolomics refers to the study of the global, dynamic endogenous metabolic profiles 
in a living system (tissue, cell or organism) under a given set of conditions, such as 
diseases (e.g., cancer and diabetes), pathophysiological stimuli (e.g., xenobiotics) or 
genetic modifications" [128], while metabonomics has been described as the “quantitative 
measurement over time of the metabolic responses of an individual or population to drug 
treatment or other intervention” [129]. These two terms are used interchangeably with the 




Metabolomics has become a tool to drive biomarkers research in different areas of life 
sciences including drug development and diagnostic strategies [131-135]. It helps with 
our understanding of disease in different areas including: mechanisms of disease 
diagnostic biomarkers, mechanisms of drug action for drug discovery as well as 
monitoring disease to predict individual variation in drug response phenotypes  [131, 132, 
135].  
 
1.5.1 Metabolomics Approaches  
Approaches for metabolomic biomarker discovery in biological systems can be classified 
as targeted or untargeted metabolomics. The difference between the two approaches 
depends on whether the methodology used is designed to identify and quantify a specific 
number of metabolites of interest (Targeted) or to a larger set of metabolites restricted 
only by the sensitivity and applicability of the analytical platforms and data processing 
employed (untargeted). The nontargeted approach allows for the identification and semi-
quantification of many metabolites in a biological system and without having prior 
knowledge of the nature and the identity of the measured metabolites. It aims to achieve 
qualitative and semi-quantitative information, which can be used to compare fingerprints 
of metabolites that change in response to external stimuli, i.e. exposure to a toxic 
compound. Consequently, untargeted metabolomics can provide a platform to uncover 
the involvement of the metabolic pathways that may not have been predicted. Hence 
untargeted metabolomics is often hypothesis-generating or hypothesis-refining rather 
than having a defined hypothesis [136, 137]. The untargeted approach is employed 
throughout this thesis. 
 
The concept of untargeted approach is to extract and analyse a wide range of molecules. 
Metabolites comprise downstream products of the genomes, transcriptomes, proteomes 
and monitoring these metabolites can help to track the mechanism of disease pathology 
(Figure 1.6). Furthermore, metabolomics is low cost and time efficient and applicable to 
different biological samples like CSF, plasma, cells and tissue [138].  
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Due to the nature of biological systems, metabolites exist at a wide range of 
concentrations and exhibit various physicochemical properties. This can make extraction 
and analysis difficult. For example, the analysis of highly abundant molecules may 
require a dilution step for accurate analysis but those molecules at low concentration will 
be diluted to below their limit of detection. In addition, in untargeted metabolomics, 
problems can arise with coelution of features resulting in mass spectrometry (MS) effects 
known as “ion suppression”. To solve this, improved separation and detection techniques 
are required.   
Another drawback can be the cost and the long time required in data treatment and 
statistical modelling when comparing to a targeted approach. Despite all these 
disadvantages, untargeted approaches are gaining more popularity especially with an 
increase in demand for biomarkers. 
metabolomics is totally dependent in advancements in analytical platforms, particularly 
Mass Spectrometry (MS). Therefore, designing metabolomics using MS has some 
important parameters to consider especially in the study of brain tissue. In the case of this 
thesis, the extraction and analysis of brain tissue is challenging compared to many 
biofluids. Further, additional steps, as sample treatment prior to metabolic analysis is 
needed, this include tissue homogenizationis to guarantee optimal extraction and hence 
optimal separation and detection of metabolites. Besides, in biological samples the 
presence of proteins can influence accuracy, precision and instrument lifetime, hence 
deproteinisation as a pre-treatment step can be incorporated, mainly using organic 
solvents to precipitate proteins.  
Figure 1.7, summarizes the key parameters in designing a metabolomics study. The first 
parameter is the study design also termed as experimental design. This term considers all 
aspects from sampling to data collection. Maintaining consistent study design is essential 
to guarantee the accuracy of the biological variation observed in the metabolome and 
ensure that variation is not introduced during the study, many times due to sample 




Figure 1.7 Overview of metabolomics analysis workflow. 
 
The study design needs to be established by the research team before commencing 
sampling and analysis. This is especially important in large scale studies requiring 
samples for which factors such as age, gender, sample size and randomization need to be 
considered. All these factors help to achieve reliable study results and to avoid 
redesigning due to lack of stringent control [141, 142]. The next step involves selecting 
analytical platforms and usually a combination of analysis platforms are therefore 
necessary for accurate and wide range metabolite measurements.  
 
The next section will discuss Mass spectrometry (MS) and Nuclear magnetic resonance 





1.5.2 Analytical platforms in metabolomics 
Current developments in analytical platforms have enabled the detection and 
measurement of metabolites in biological samples simultaneously. These techniques are 
NMR and MS. The platform of choice applied in this thesis is MS. 
 
1.5.2.1 Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy is a powerful and commonly used analytical technique, it has the 
advantages of high reproducibility and resolution power providing details on chemical 
structure and require minimal sample pre-treatment prior to analysis. [143-145]. The 
working scope involves applying magnetic field around an atom, as a result each atom 
absorbs certain resonance frequency (electromagnetic radiation) thus providing more data 
about molecular structure and marker molecules elucidation. 
 
The main limitations of this technique is the relative insensitivity which can be improved 
by introducing high magnetic field. This consequently would affect the working condition 
of surrounding computers and  monitors equipments [146]. Furthermore, the high cost of 
instrument itself and maintenance, the difficulty in interpreting obtained spectrum would 
add extra expenses as specialist operator required. 
 
Regardless of these limitations, NMR remains a highly powerful biomarker instrument 
for non-invasive thus non-destructive technique allowing reanalysis of the same sample 
again either by NMR or another analytical technique. As a result, NMR has been widely 
used in pharmaceutical and toxicology research [144, 147, 148] 
 
1.5.2.2 Mass Spectrometry 
MS-based metabolomics has contributed to major advances in biomedical knowledge. It 
has, therefore, become a crucial application in biomarker discovery especially in AD  
[149, 150]. MS is an essential and extensively used ionization technique for 
comprehensive profiling of lipids (known as Lipidomics) and other metabolites. MS 
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technology can be time consuming but displays high sensitivity and resolution [151] 
compared to NMR which has lower sensitivity. In this thesis MS was chosen as the 
preferred analytical technique. 
 
MS is an effective technique owing to high sensitivity, specificity, and ability to identify 
either by matching with internal, external standard or database match. One drawback of 
MS is quantification. To achieve accurate quantification of metabolites isotope labelled 
standards need to be added at the time of analysis. This procedure is pricey and 
impractical for untargeted analysis. Therefore, in untargeted metabolomics the relative 
abundance of metabolites (expressed as peak area or peak intensity) is used to compare 
between samples. Another main disadvantage is ion suppression that takes place in the 
ionization stage of analysis resulting in decrease in ionization efficiency. This occurs 
when large number of molecules enter the source and compete for charge and ionization 
causing a molecule not to be ionized and detected. Ion suppression can be overcome by 
introducing separation techniques such as chromatography prior to MS detection as this 
will be discussed in the section below.  
 
1.5.2.3 Chromatographic separation prior to MS analysis 
Metabolomics has been developing alongside other analytical techniques such as 
separation science (often chromatography) coupled to a detector. These chromatographic 
techniques include Gas chromatography (GC), Liquid chromatography (LC), and 
Capillary electrophoresis (CE). 
 
In GC, the mobile liquid phase is replaced with an inert gas (mainly helium) with long 
stainless steel or glass column stationary solid phases. Separation is based on analyte 
volatility and choosing the optimal temperature gradient. Also, a derivatization step 
(alkylation or silylation) is required to improve analyte volatility. This would add extra 
steps to sample treatment which in turn increase analytical variation and analysis time. 
Capillary GC has high resolution and separation efficiency and sensitivity enhancement 
due to the long distances travelled by the analyte. The column length which can reach 300 
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meters, allows separation of isomers like in case of unsaturated fatty acids. The electron 
impact ionization energy usually is set to 70 -80 eV so that the MS spectra could be 
compared with the a gas chromatography-mass spectrometry (GC-MS) library which is 
acquired at the same voltage [152, 153]. 
 
GC-MS is the analytical method that combine the advantages of GC and MS, it can 
effectively separate thermally stable and volatile molecules [154]. GC-MS can identify 
and quantify substance in a sample, providing mass spectrum of each substance and GC 
retention time (RT). It was used in environmental, food and pharmaceutical analysis [154-
156]. GC-MS has many features including capability to separate compounds in complex 
mixture in short time with high reproducibility, selectivity and sensitivity. Table 1.1 
summarize the advantages and disadvantages of different analytical techniques applied in 
metabolomics.  
 
LC has solid stationary phase of derivatised silica particles in stainless steel column. It 
can analyse thermolabile and non-volatile samples (analytes) providing a fast selective 
and sensitive approach without need to derivatization.  Analytes are separated into their 
individual components by distribution between a stationary solid phase and a mobile 
liquid phase. The affinity to both phases is determined based on the difference in 
physicochemical properties of the analyte. The liquid solvent passes at high pressure 
through the column helping molecules in the mixture to interact with both mobile and 
stationary phases. For example, lipids will interact with nonpolar stationary phases and 
move slowly through the column to achieve optimal separation and detection. The term 
LC covers various modes of separation. This depend on the type of analyte, stationary 
phase and mobile phase used which can alter mode of interaction and analyte separation. 
These modes are Normal Phase Chromatography (NPC), Reversed Phase 
Chromatography (RP), and Hydrophilic Liquid Interaction Chromatography (HILIC). 
This current work applied RP and HILIC both coupled to MS. 
 
RP Chromatography: RP is the most commonly used form of LC mainly for non-polar 
compound separation. It accounts for 80% of HPLC separation with high reproducibility 
and applicability and ease of use [157, 158]. Separation is based on analyte partition 
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between a nonpolar stationary phase and a polar mobile phase. The stationary phase is 
composed of silica porous particles where hydrophobic ligands like octadecyl (C18) 
groups are irreversibly bonded. The mobile phase is usually composed of mixture of H2O 
and organic solvent (eg: acetonitrile or methanol) and an aqueous buffer. Non-polar 
analytes are more strongly retained due to interaction with the hydrophobic groups in the 
stationary phases. The more lipophilic a mobile phase the more quickly lipids will elute 
from RP column. HPLC-MS combines the advantage of both HPLC and MS, allowing 
for the separation of metabolites of a wide range of molecular weight and polarity with 
high throughput and high sensitivity. 
 
HILIC Chromatography: HILIC is a modern variant of NPC [159]. HILIC emerges as 
an important technique for the analysis of very polar compounds and is inverse to RP. 
The stationary phase is polar and is used with highly organic mobile phase containing a 
small proportion of H2O or buffer. 
 
The connection of LC with MS and the advancement in developing LC-MS has resulted 
in a collection of ionization modes. Atmospheric pressure (API) includes electrospray 
ionization (ESI), APCI (Atmospheric pressure chemical ionization) and APP 
(Atmospheric pressure photo ionization) [160, 161]. The development of API technology 
in particular ESI has enabled the LC-MS to gain popularity as one of most powerful 
analytical platforms and ionization techniques with broad applicability in the 
metabolomics field. These techniques are common in untargeted analysis because of their 
soft ionization capability that aid identification of unknown metabolites as well as the 
ability to ionize metabolites at broad polarity range.  
 
In the last decade, the improvement of more efficient LC (known as Ultra performance 
LC (UPLC)) offers high pressure flow and enhance peak resolution and capacity. The ESI 
to which large voltage is applied to produce a spray of fine droplets is where the ionization 
occurs. This produces an electric field between capillary and cone (counter electrode). 
Based on the analytes of interest this voltage can be positive or negative ionization. Once 
ions are formed, they are focused into the mass analyser and separated into m/z. Mass 
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analysers separate ions by their m/z, then the electronic current produced is recorded in 
the detector and this result in obtaining mass spectrum. 
. 
 Different types of mass analysers have been developed that can be coupled with LC. In 
the current study, QTOF including tandem and hybrid instrument have been employed 
and  will be briefly discussed below. 
Several mass spectrometers combine different types of analysers, referred to as hybrid 
instruments. Mass spectrometers can be performed in tandem mode (two MS/MS) 
Tandem MS is feasible with a TOF instrument, typically combining quadrupole and 
collision cell between the source and TOF analyser. This hybrid QTOF mass analyser has 
become popular providing ability to select ions for MS/MS fragmentation with high 
resolution and accurate mass measurements. The QTOF has been used for small 
molecules analysis in this thesis. 
 
CE-MS is high efficient analytical platform that is used in metabolomics research. CE is 
inexpensive separation technique that is suitable for separating highly polar and ionic 
metabolites based on charge and size. The use of CE-MS in metabolomics is uncommon 
owing to poor robustness and detection sensitivity [162, 163]. Other techniques such as 
comprehensive two-dimensional chromatography (GC×GC–MS) [164], (LC x LC-MS) 
methods [165, 166], supercritical fluid chromatography (SFC-MS) [167] and Direct 




Table 1.1 Summary of advantages and disadvantages of analytical techniques used in metabolomics 
research. Table reproduced from [125] 




Offers detail on chemical structure of 
unknown compounds, high 
reproducibility and quantification, 
Provide structural elucidation for 
metablites identification.  require 
minimal sample preparation prior to 
analysis like derivatization or 
separation. 







Non-invasive in vivo technique, 
high reproducibility and gives 
information on metabolites chemical 








Highly reproducible, handy to run, 
high sensitive and selectivity, 
structural data confirmation by 







Direct Infusion Mass 
Spectrometry (DI-MS) 
High throughput, high sensitivity, 
confirmation possible with 
comparison to standards, structural 














Easy to run, high sensitivity and 
selectivity, excellent tool for non-
targeted analysis, fragmentation 
provides some structural data 
Need sample pre-




compared to MRS 
and NMR, require 




High-throughput, high selectivity, 
less expensive compared to LC–MS, 




reduction to enable 
detection, large 








High selectivity, separation and high 
throughput, low volume of waste 
solvent produced 
 





were improved in 
current instruments, 
need trained operator 






1.5.3 Data analysis methods in metabolomics 
Following untargeted MS based metabolomics a data matrix is obtained.  This matrix is 
very large and finding data treatment strategies to extract this data and to obtain 
metabolites that are responsible for biological alteration in a cohort is crucial.  
 
Prior to data processing, data need to undergo a set of pre-processing steps including data 
conversion, alignment, scaling and normalization. Software for data pre-treatment in 
untargeted approaches is available such as XCMS and Mzmine for LC-MS, TagFinder 
and metab for GC-MS and JDAMP for CE-MS. This is then followed by data statistical 
analysis where the data matrix will undergo further analysis to select the significant 
features (markers). There are two kinds of data statistical analysis, widely used in 
metabolomics, these are Univariate analysis (UVA) and Multivariate analysis (MVA). 
  
UVA, is used to determine if the variable selected significantly differs between the groups 
in the samples, this is divided into 1) parametric methods which assume that the data 
follows a normal distribution, well known are student’s t-test to compare between two 
groups and one-way Analysis of Variance (ANOVA) to compare between more than two 
sets of samples. 2) non-parametric methods which assume that data does not exemplify 
normal distribution such as the Mann-Whitney test to compare between two groups of 
samples and the Kruskal-Wallis test to compare between more than two groups.  
 
 
 MVA is used to facilitate the process of extracting the metabolites of interest from a large 
data matrix in untargeted metabolomics. The first step involves applying Principal 
component analysis (PCA), an unsupervised method that is used in metabolomics to 
visualise the relationship among groups. This allow to simply evaluate and check trends 
by means of clustering of the data and check for outliers, given the sample identity is 
unknown. Constructing models such as PLS, PLS-DA and OPLS-DA can be used further 
as supervised multivariate analysis to provide superior information in what are the 





Validated predictive tool used to evaluate model quality are R2 (explained variance) and 
Q2 (predicted variance), return scores of R2=0.5, Q2=0.4 (SIMCA online - www. 
http://umetrics.com/manual/simca-online). Later, variable importance in the 
projection'(VIP) [170] and S-plot can be used to estimate the importance of each variable 
in the projection and it can also be used to enable the selection of statistically significant 
variables. An informative table describing the various forms of data analysis in 
metabolomic studies was gathered in a review by Madsen et al [171] and can be found in 
Table 1.2. 
 
Finally, the selected potential markers, can be subjected to the in-house database search, 
such as HMDB (Human Metabolome Database) and Metlin (MS/MS metabolite 




Table 1.2 Data analysis methods frequently employed for disease diagnosis and biomarker 
identification in metabolomics. 
Technique Typical use Description and comments 




Univariate analysis where the 
corresponding p-values are the standard 
scientific measure of significance. 
Multiple testing is prone to false positives 
unless corrected significance limit is used 
Principal component analysis 
(PCA) [173, 54] 
Data 
overview 
Standard multivariate analysis method to 
provide an overview of a large dataset. 
Useful for identifying outliers, clusters 
and trends in the data. Is not a 
classification method 
Partial least squares discriminant 





Classification variant of PLS. Works best 
with homogeneous classes. Biomarker 
identification possible, but not as straight 
forward as with OPLS-DA 
Orthogonal projection to latent 
structures discriminant analysis 





Classification variant of OPLS method. 
Ability to separate between-class from 
within-class variability. Straight forward 
interpretation and identification of 
potential biomarkers 




High flexibility in modeling non-
linearities. Careful model selection 
reduces possibility of overfitting. 
Potential biomarker identification more 
complex compared to linear methods„ 




1.6 Metabolomics applications in AD research  
1.6.1 AD metabolomics in CSF 
The analysis of CSF is very useful in AD metabolomics, this is because CSF is in direct 
contact with brain and its composition is believed to reflect the brain metabolic 
production. Hence it is more likely to observe the changes in AD pathology in CSF 
compared to other biofluids [177]. However, collection procedure requires high skills 
(trained clinician) and can be painful [178]. 
 
In metabolomics, few studies have used HPLC coupled with electrochemical array 
detection (ECA). Kaddurah Daouk,et al has employed LC-ECA to analyse 114 CSF 
samples (38 CN, 36 MCI and 40 AD patients) from three groups. Patients presenting AD 
and MCI showed AD individual to have elevated levels methionine, 5-
hydroxyindoleacetic acid , vanillylmandelic acid, xanthosine and glutathione compared 
to CN, suggesting these metabolites to be associated with AD pathology[179]. Moreover, 
a correlation with the concentration of Aβ1-42, P-tau and T-tau proteins in CSF was 
investigated. Results demonstrated an association of xanthine, vanillylmandelic acid 
abundance with T-tau protein in CSF, indicating that purine pathway may be involved in 
T-tau aggregation and pathology generation. Furthermore, the same study observed 
increase in 5- hydroxyindoleacetic acid in both MCI and AD compared to CN groups, 
suggesting disturbances in these metabolites are related to Aβ42 and thus amyloidgenic 
pathway [179]. 
 
In another study, the same group combined the metabolic information acquired from 
using both HPLC-ECA and GC-TOF MS platforms [180]. CSF Samples from 40 AD and 
38 CN patients were studied. Following GC-TOF MS analysis and statistical evaluation, 
two metabolites with unknown identity were observed at high level, showing association 
with the disease. However, failure to annotate these metabolites prevented biological 
interpretation [180]. Metabolites involved in oxidative stress and neurotransmitter 
pathways have been investigated in post mortem ventricular CSF samples (15 CN with 
autopsy-confirmed diagnoses vs 15 AD) using LC-ECA. Findings showed a decrease in 
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norepinephrine and its related metabolites and suggest further investigation of these 
metabolites in preclinical patient samples [181]. 
 
Complementary chromatographic separation techniques coupled to UHPLC-MS have 
been used in CSF analysis to improve metabolome coverage. Using RP and 
HILIC/UHPLC-MS, a study of 45 CSF samples (15CN ,15MCI and 15AD) revealed 
changes in metabolic pathway by nearly 30% in MCI and 60% in AD compared to CN 
samples. The same results were reflected in plasma samples from the same patients 
showing clear correlation between biofluids [182]. Another study used the same platform 
and identified 17 significantly different metabolites in 4 groups (CN, MCI with 
progression to AD, MCI without progression to AD and AD), thet were able to predict 
AD development with values above 95% for sensitivity and specificity [184].  
 
In MCI patients who progressed to AD, increased levels of dopamine-quinone or 
methylsalsolinol (neurotoxic metabolites) and a decreased level of taurine (a 
neuroprotective metabolite) were reported [183]. Furthermore, the model showed 
changes in histidine level that were previously reported and metabolic fingerprints were 
investigated using CE-MS of 85 CSF samples form patients with four different cognitive 
status (age matched control, MCI patients at time of sample collection and AD patients. 
Some patients with MCI had converted to AD while others remained stable based on two 
years period of clinical follow up. After analysis and data processing, 71 metabolites with 
high importance were selected. Following multivariate analysis, ten polar metabolites 
were selected as potential biomarkers of AD conversion [184].  
 
Other work compared AD and healthy subjects to look at disease phenotype [185]. CSF 
samples (51 CN, 53 mild AD, and 26 moderate AD) were analysed by GC-MS followed 
by LCMS/MS, over 340 metabolites were determined. Discriminant analysis showed 
cysteine and uridine as the best metabolite to predict AD with sensitivity and specificity 
values of 75% [185]. NMR based metabolomics was also used to analyse CSF samples 




1.6.2 AD metabolomics in plasma and serum 
Peripheral blood samples have the advantages of being easy to obtain and non-invasive. 
Samples can be collected repeatedly on intervals to monitor changes but are further away 
from the brain, and in contact with other tissues and organs which affects the 
interpretation of the data (14). In addition, blood can show the altered brain metabolite 
levels in AD in part to the increased porosity of the blood brain barrier causing molecules 
to leak into the blood from the brain and vice versa.   
 
 CSF, plasma and urine samples were analysed and differences in free amino acids(FAA) 
and dipeptides concentration in AD compared to CN groups were determined in the three 
biofluids by LC-ESI-MS2. Highlighting the importance of FAA and dipeptides 
metabolism in the pathogenesis of AD [188]. 
 
Some studies have attempted to investigate to what extent metabolic changes seen in CSF 
reflected in other biofluids. A work by Trushina et al utilised CSF and plasma samples 
(15 CN, 15 MCI and 15 AD) correlation between both biofluids, with results showing 
increase in metabolic pathways affected in MCI and AD samples as disease progressed 
[182]. Interestingly, the same pathways were also altered in the plasma of same patients 
revealing clear correlation between biofluids [182]. 
 
Metabolic fingerprints of plasma samples were carried out by Li et al with the purpose of 
detecting potential metabolic biomarkers. Plasma samples (20 CN vs 20 AD) were 
analysed by UHPLC-MS, they demonstrated 9 metabolites (including 
lysophosphatidylcholines, typtophan and sphingosines) changed between CN and AD 
samples suggesting them as potential biomarkers [189]. Another study  also utilized 
UHPLC-MS (for the analysis of lipids) in addition to GCxGC-MS (for the analysis of 
fatty acids, amino acids, sterols and sugars) to increase metabolic space in order to screen 
biomarkers metabolites that lead to AD progression [190].  
 
As mentioned previously, a close link between lipid metabolism and AD has been 
established leading to special interest in profiling lipids and investigating lipid-related 
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metabolites in blood as potential markers using metabolomics. This interest has risen 
from the findings of “adipose inclusions” or “lipoid granules in brain tissue” as observed 
by Alois Alzheimer when he first described the disease [191, 125]. To study lipids as a 
potential early marker, Tukiainen et al used NMR to analyse serum samples (26 CN VS 
19 MCI). Information from 3 groups of metabolites (lipoprotein, polar metabolites and 
lipids) were compared. Moreover, the same study reported association between AD risk 
factors in MCI patients and low level of omega 3 fatty acids, sphingomyelines and PCs 
[192]. LC-MS analysis of plasma samples reported lysophospholipid (18:1) as early 
marker that decrease with AD progression from CN to MCI to AD patients [166]. 
 
Over 800 lipids were detected in plasma by applying novel untargeted multidimensional 
on MS based shotgun lipidomics approach (MDMS-SL). AD patients showed significant 
depletion in sphingomyelines and elevation in Ceramides, suggesting this may be either 
due to high ceramide production in the brain or increase in sphingomyelines hydrolysis 
[193].  
 
High cholesterol in plasma samples from patients carrying the  APOE e4, was proposed 
as high risk of early  onset at age of less than 65 years old [194]. This matched the results 
in other study presenting cholesterol and demosterol as markers for AD [195]. Both 
metabolites were analysed by LC-MS and quantified. Results showed a significant 
decrease in demosterol and cholesterol in AD samples, with these results proved by 
analysing 109 plasma samples as validation step [195]. More lipids have been reported to 
be associated with AD, these include cholesteryl esters [196], PlsEtn [197, 198].  
 
In addition to RP-MS, DI-MS was used in human studies to perform lipid profiling in 
serum samples, with metabolites detected implicating PUFA, amino acids, and eicosanoid 
pathway [199, 200]. DI-MS was also utilized by other groups for blood metabolites 
profiling and changed concentration of phospholipids [201], diglycerides [202] and 




Another research investigated serum samples and reported depletion in oleamide and 
monoglycerides levels accompanied with increased level of acylcarnitine suggesting the 
findings to be a good ground to further understand disease progression [203]. 
 
1.6.3 Other biofluids  
Urine and saliva have also been examined in the search for AD biomarkers as they are 
very easy to collect [188, 204]. In a study urine samples were analysed and found that 
altered levels of 5- L-glutamylglycine and L-glutamamine were detected in AD compared 
to CN [207].  
 
Altered metabolites in AD pathology were identified and related to various biochemical 
processes including dopamine, L-Dopa and arginine metabolism[188]. A study found 
increased levels of 7- ketocholesterol and sphingosine-1-phosphate as potential predictive 
metabolites in AD conversion. These metabolites were also reported by other groups to 
distinguish CN and MCI from AD patient in saliva samples [205, 206]. 
 
Urine is another biofluid from which potential metabolites have been quantified with 
results consistent with CSF and blood metabolite study in AD. Urine has the advantage 
of being non-invasive and hence ideal for preclinical diagnosis in conjunction with CSF 
and blood biomarkers, however it can also have many drug metabolites.  
 
Cui et al, analysed the blood serum and urine of 46 AD compared to 36 healthy CN 
subjects using (UPLC-QTOF-MS). Significantly three serum and two urine metabolites 
were selected as potential biomarkers namely LysoPC (18:0), LysoPC (18:2), palmitic 
amide, L-glutamine and 5L-glutamylglycine [Area under the curve (AUC ≥ 0.7)].  
Palmitic amide increase was associated with the prevention of the breakdown of 
neuroprotective cannabinoid while in AD; urinal 5L-glutamylglycine was linked to the 
reduced GABA associated with memory impairment, increased L-glutamine level was 




In another study, Peng et al used 12C/13C labelled LC-MS in the analysis of urine from 12 
transgenic mice in comparison to 12 CN mice for the detection of potential biomarkers at 
different mice ages. Significant metabolites biomarkers identified included methionine, 
taurine, desaminotyrosine, N1-acetylspermidine, and 5-hydroxyindoleacetic acid. In the 
plasma, elevated levels of methionine and its product of metabolism homocysteine have 
been associated with increased Aβ aggregation in AD, while decreased taurine levels 
influenced synaptic transmission in the AD brain due to its function as a neurotransmitter. 
The role of the elevated desaminotyrosine was unknown but decreased 5-
hydroxyindoleacetic acid a metabolite of serotonin was linked to AD via neurotransmitter 
alteration and reduced N1-acetylspermidine levels was related to disruption in cell 
membrane [208]. 
 
1.7 Metabolomics studies in AD brain tissue 
Compared to biofluids, brain has different areas and regions making the study of this 
organ very complex. Careful considerations of study design in term of area have to be 
used, together with sample collection interval to post mortem and metabolite extraction.  
 
Metabolomics studies have analysed different brain regions. The scarcity and difficulty 
in obtaining human brain samples is another challenge that hinders the extensive study of 
this organ. Early changes in AD brain are believed to occur first in the hippocampus and 
cortex then to the medial temporal lobe which is involved in the deficits in memory. In 
this sense, the analysis of different regions of brain would provide greater specificity and 
assurance particularly to study the neurophysiological pathway of the disease.  
 
1.7.1 AD human brain tissue studies 
In a study carried out by Graham et al using 1H NMR to analyse the polar metabolites of 
post mortem human brain tissue (15 CN vs 15 AD), there were significantly increased 
levels of alanine (15.4%) and taurine (18.9%) in the neocortex region of  AD brain, with 
the ratio of these metabolites (i.e  alanine/carnitine) suggested to be  powerful 
discriminating as biomarker of AD [ROC and (AUC)=0.76; p<0.01] [209]. Furthermore, 
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the same group have performed metabolic fingerprints of human brain neocortex (15 AD 
vs 15 CN) using UHPLC-MS in the positive and negative ionization modes. Following 
multivariate and statistical analysis, a total of 66 candidate molecules were reported to be 
statistically different [210].  
 
A number of studies have looked at brain lipid metabolites in brain, owing to the brain 
rich fat nature and previously mentioned fat inclusions in AD brain. A study by Farooqui 
et al. found an increase in PlsEtn abundance with age, however this noticeably deceases 
following age of 40 [211]. Selective and marked reduction has also been found in the 
PlsEtn abundance were observed at lower level in AD individuals (70%) compared to 
those with normal brain particularly in the grey matter of brain as disease progress [67]. 
The same findings were reported by Wood et al. when they analysed frontal cortex grey 
matter and reported the decrease in PtdEtn abundance in AD individuals with no change 
observed in MCI individuals [212]. 
 
Another study, included human brain regions from 22 Subjects with no dementia (n=5), 
very mild dementia (n=3), mild dementia (n=4), moderate dementia (n=6) and severe 
dementia (n=4). After analysis by DI-MS a significant reduction in sulfatide levels were 
observed. Sulfatides deficiency by 93% and 58 %  in the gray and white matter 
respectively were seen at the earliest clinical stage of AD [213]. This result were also 
observed on a study of the mouse model [214]. 
 
1.7.2 AD animal models and brain tissue studies 
The use of animal models particularly in AD research tackle the challenges associated 
with obtaining human brain samples and thus animal model studies used in metabolomics 
to study AD pathogenesis are in increase. Many transgenic mouse models (Tg), were used 
in AD investigations. The most widely used models known to develop amyloid plaque 
pathology through the expression of APP are Tg2576 and TgCRND8. Other models 
known as biogenic transgenic mice that express mutant presenilin protein (APP/PS1 or 




Most recently, Pan et al. have performed longitudinal profile of brain and plasma 
metabolome at 8, 10, and 12 months using APPswe/PS1deltaE9 double transgenic and 
wild-type (WT) mice. A panel of metabolites were selected following multivariate 
analysis and metabolic pathway analysis finding perturbed polyamine metabolism in both 
plasma and brain samples [218]. Two years earlier, González-Domínguez et al. reported 
changes in purine metabolism, amino acid, phospholipids, dopamine and energy 
metabolism occurred in the different brain regions. Potential biomarkers identified were 
linked with phospholipid and sphingomyelin components of fatty acids with the 
decreased polyunsaturated fatty acids (PUFA) levels particularly docosa-hexanoic acid 
(DHA). The decreased levels of PUFA implied that oxidative stress was involved in AD, 
while accumulation of short chain fatty acid phospholipids was implicated in AD 
membrane disruption [219]. 
 
A study conducted by Lalande et al, using 1H NMR to discover metabolites in the tissue 
extracts of five different brain regions namely rhinal cortex, frontal cortex, midbrain, 
hippocampus, and cerebellum of the 39 AβPPsweTg2576 mice model compared controls 
at 1, 3, 6, 11 months. Metabolite perturbations were observed with significantly decreased 
levels of myo-inostol, glutamate, creatine, N-acetylaspartate (NAA) and phosphocholine 
in the hippocampus and rhinal cortex at 1 month and 3-months old mice. Low levels of 
metabolites were linked to reduced neuronal function, neurotransmission at the synapses, 
like glutamate, N-acetylaspartate and NAA and creatine reductions were implicated in 
low cellular energy. At 11 months there were metabolite perturbations in all areas of the 
brain with the exception of the frontal cortex [220]. Further brain regions have been 
investigated in AD animal model studies using NMR and MS [2, 219, 221]. Table 1.3 




Table 1.3 animal and human brain tissue metabolomics studies in AD research 
Animal model Analysed region 
Analytical 
platform 
Altered metabolites Ref 
APPTg2576 mice (n=9) 
and WT(n=10) Frontal cortex NMR 
Myo-inositol, Taurine, Choline, GSH, Glutamate, Glutamine, 
Succinate, Aspartate, Lactate, Alanine, gamma-aminobutyric 
acid, N-acetylaspartate. 
[222] 
APP (V717F) Tg , APP Tg, 
Apoe (-/-) , APP Tg, Apoe 
(+/+) mice 
Cerebellum, cortex MS Sulfatide [214] 
APP-PS1(n=10) WT(n=10) 
Parietal, temporal, occipital and 
frontal cortices, Hippocampus 
thalamus 
HR-MAS N-acetyl aspartate, acetate, myo-inositol and scyllo-inositol. [223] 
TgCRND8 mice(n=10) and 
their controls(n=12). 
Cortex, frontal cortex, cerebellum, 
hippocampus, pons, midbrain, 
olfactory bulb and striatum 
NMR 
Gamma-amino butyric acid, glutamine glutamate, N-acetyl-
aspartate, taurine, choline, creatine phosphocholine, 
phosphocreatine, succinate, free fatty acids, iso-leucine, leucine, 
lactate, valine, aspartate, glycine. 
[224] 
TgCRND8 mice (n = 6) 
and controls (n = 6) 
Cerebellum FT-ICR/MS 
Total of 29 metabolites significantly altered i including: 
Phenylalanine, amino acids, amino acid conjugates, Tyrosine 
Tryptophan, Histidine, Methionine, sulfoxide L-











Myo-inositol, Succinate, glycerophosphocholine and choline. [226] 
Tg AAP/PS1 mice (n = 30 
and WTC57BL/6 controls 
(n = 30) 
Hippocampus, cerebellum, cortex, 





N-acetyl-aspartate, valine, 2, adenine, adenosine, cholesterol, 
glutamate, dopamine, glucose-6-phosphate, taurine, glycerol, 
Phosphoribosyl-AMP, hypoxanthine guanosine, histidine, 
aspartate, inosine, myo-inositol, maleate,  serine, creatinine, 
pyroglutamate, Pyrophosphate, lactate, urea, xanthine. 
[219] 
senescence-accelerated 
mouse prone 8 (SAMP8) 
(n=18) 
Hippocampus GC-MS 
Cholesterol, oleic acid, and phosphoglyceride, alanine,serine, 
glycine, aspartic acid, glutamate, and gamma-aminobutyric acid, 
malic acid, butanedioic acid, fumaric acid, and citric acid, N-
acetyl-aspartic acid and decreased pyroglutamic acid, urea, and 
lactic acid. 
[227] 
APPswe Tg2576 mice (n = 
39) and WT (n = 44) at 1, 
3, 6 and 11 months of age 





glutamate (Glu) and N-acetylaspartate (NAA), myo-inositol, 
creatine, phosphocholine, and gamma aminobutyric acid, 




M146L(n=3), WT (n=6) 
Hippocampus RP/GC-MS 
Alteration in carbohydrates, amino acid s, nucleotide, energy and 
neurotransmitter metabolic pathway. 
[221] 
TgTASTPM mice (n = 16) 
and WT (n = 5) 
Whole brain GC-EI-MS Threonine, L-serine, D-fructose, L-valine, L-, zymosterol. [228] 
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APP/PS1 (n=6) and 
WT(N=6) mice 
Whole brain NMR 
N-acetyl aspartic acid, gamma aminobutyric acid, creatine, 
ascorbate. 
[229] 
TgCRND8 mice Hippocampal tissue 
LC-LTQ-
Orbitrap 
Disturbance in eicosanoids in arachidonic acid metabolism, fatty 
acid beta-oxidation disorders as well as glucose metabolism. 
[230] 
Transgenic AAP/PS1 mice 
(n = 30) and WT C57BL/6 
controls (n = 30) 




Acylcarnitines, amino acids, steroids choline, dopamine, acetate 
glycerol-3-phosphate, phospholipids lyso-phospholipids, acetyl-
spermidine, nucleotides, Pyruvate, tyrosine and urea. 
[231] 
APP/PS1deltaE9 mice  (n = 
8) and WT C57BL/6 J (n = 





Biogenic amines (phenylalanine, tryptophan and Tyrosine), 
lysophosphotidylcholines, phosphotidylcholines, sphingolipids. 
Acylcarnitines(a (C10:1 and C12:1), (Putrescine,creatinine, 
hydroxyproline and proline), spermidine and spirmine. 
[232] 
TgAPP/PS1 mice and WT 
composed of controls (n = 
10), AD (n = 10), G-Rg1 (n 
= 10) and G-Rg2 (n = 10) 
Whole brain LC/MS 
hypoxanthine, dihydro-sphingosine, hexadeca-sphinganine, 
phyto-sphingosine, LPC C 16:0, LPC C 18:0 , LPC C 13:0, LPC 
C 15:0, LPC C 18:1, and LPC C 18:3 in AD mice. 
[233] 
Human Samples Brain regions used 
Analytical 
platform 
Altered metabolites Ref 
AD (n = 21) and age 
matched controls (n = 19) 
Whole brain, region not specified 
UHPL-ESI-
MSE 
Cystine arginine, pentose 5-phosphate Aspartic acid, glutamic 
acid, Glutamine, uric acid, guanosine, Serine, hypoxanthine, 
Pantothenic acid, pyruvate, succinate, tryptophan, valeine, 




AD (n=17), CN (n=5) 
Hippocampus, entorhinal cortex, 
inferior parietal, superior temporal 
and middle frontal gyrus. 
DI-MS Ceramide, Sulfatide [213] 
AD (n = 15), healthy age 
matched controls (n = 15) 
Brodmann and neocortex region NMR 
Hypoxanthine, acetate, carnitine, ethanolamine choline, creatine, 
alanin, aspartate, Inosine, lactate, taurine leucine, myo-inositol, 
tyrosin, N-acetyl aspartic acid, nicotinate, succinate, valine and 
serine. 
[209] 
AD (n=13), CN (n=4) 
Hippocampal region and the 
cerebellum 
MRS N-acetyl aspartate, gamma-aminobutyric acid. [214] 
AD (n = 15) and elderly 
controls (n = 15) 
Brodmann and neocortex region 
LC-ESI- 
QTOF-MS 
66metabolites in + and – ESI mode identified as significantly 
altered ions. 
[210] 
AD (n=9), CN (n=9) 
Cingulate, middle-temporal gyrus,  
sensory,  motor, entorhinal cortex, 
hippocampus and  cerebellum 
GC-MS 
Alteration in glucose clearance/utilization, the urea cycle, and 
amino-acid metabolism. 
[235] 
Samples composed of AD 
I–II (n = 7), AD III–IV (n = 
27), AD V–VI (n = 40) of 
Braak and Braak stages and 
controls (n = 38) 




Glycine, xanthosine, inosine, and deoxy-guanosine di-phosphate 
guanine. 
[236] 
AD (n=34), MCI (n=19) 
and CN (n=28) 
Frontal cortex white and grey 
matter 
DI-MS 
Mono and diacylglycerols (DG), the very-long-chain fatty acid 




AD (n=16). CN (n=8) 
Temporal, parietal, cerebellar 
cortex and Caudate nucleus 
HPLC Glycerophosphocholine and glycerophosphoethanolamine. [237] 
Patients with gradual pre-
mortem memory loss (n = 





l-phenylalanine and l-lactic acid were identified as biomarker 
candidates in AD brain. 
[238] 
AD (n=10), CN (n=10) Frontal, occipital and parietal lobe RP-MS spermine and spermidine. [239] 
80 years old AD (n = 12) 
and controls (n = 12), and 
60 years controls (n = 11). 





Gamma aminobutyric acid, glutamine, glutamate L-arginine, 
agmatine, putrescine L-citrulline, L-ornithine, spermine, 
spermidine. 
[240] 
AD (N=6), CN (n=8) Frontal gyrus DI-MS Sulfatide [241] 
AD (n = 8), ALS (n = 11) Frontal cortex 1H NMR Glutamine, acetate, lactate, alanine, glutamate, creatine [242] 
AD (=7), CN (n=9) Frontal and parietal region 31P NMR 
Phosphomonoesters, phosphocholine, phosphodiesters 








1.8 Aims of the thesis 
Considering the outcomes of this literature review, a project plan was designed to 
investigate metabolic composition of AD brain samples. Initially, rat brain samples were 
used to develop extraction methods capable of comprehensive coverage of wide range of 
metabolites using UPLC-MS Q-TOF combining two separation techniques (RP and 
HILIC) (chapter 2). As the project progressed, more coverage of metabolites with 
different physical properties was studied using multi-analytical platforms, here GC-MS 
analysis was employed with the aim of developing another untargeted analysis method 
and to expand the metabolome (chapter 3).  Until this stage, the focus was on brain tissue. 
In addition, the applicability of the developed LC& GC-MS method was tested using 
plasma of control and AD groups (chapter 4).   
 
The overall aim of the thesis was to identify a panel of candidate metabolites which would 
enable understand disease mechanisms and/or monitor disease progression in humans. 
Hence in the last chapters (chapter 5 & 6) human brain samples from control, 
asymptomatic and AD were analysed using the developed untargeted LC&GC-MS brain 











CHAPTER 2: Comprehensive LC-MS analysis of 











Despite the importance of the brain and the pathological burden associated with it, we are 
still relatively ignorant of its mechanisms, as such it is hoped that developing a better 
understanding of cerebral metabolism will help to unlock the secrets of the brain. The 
biggest challenges of working with both human and animal brain tissue are twofold; 
firstly is the lack of available sample material, and secondly reproducible extraction of 
metabolites from the sample tissue. These obstacles make the development of analytical 
approaches that maximise the metabolites that can be reproducibly measured from small 
tissue samples an important challenge.  
Due to the wide range of concentrations at which these metabolites are present and their 
diverse chemical structure, it is challenging to obtain comprehensive analysis of all 
metabolite classes using a single metabolomics method [244-247]. Therefore, many 
comprehensive metabolomic approaches that aim to maximise metabolite coverage utilise 
a combination of analytical platforms including, NMR and MS (coupled to separation 
chromatography such as GC, LC and CE [248, 249]. These multi-platform approaches 
will measure metabolites with a wide range of concentrations and physiochemical 
properties, however applying more platforms to increase metabolite coverage will 
significantly increase both the cost and time required for the analysis, and more 
importantly a greater amount of tissue will be required. As a result of this it is important 
to maximise the number of metabolites measured from a single sample. 
LC coupled to MS is one of the most widely-used analytical techniques for metabolite 
fingerprinting and has been used to analyse a range of metabolite classes in a variety of 
biological matrices. Advantages and selection of this analytical technique was explained 
in detail in the introduction. Mainly related to the advance in MS technology that is time 
consuming with high sensitivity and resolution [151]. LC-Q TOF-MS has been therefore 
used to achieve an assorted number of scan modes to help detect specific polar and non-
polar metabolites. 
 
As discussed in the previous chapter, metabolomics uses modern techniques to analyse 
various biological samples by enhancing the separation and detection process. Moreover, 
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it is important to point out that different metabolites significantly differ in their 
physicochemical properties (solubility, polarity, and molecular weight). To date there 
have been a small number of metabolomic studies that have looked at the metabolite 
composition of brain tissue of post-mortem human brain[210, 250, 251] for the screening 
of neurodegenerative disorders while recently animal models have been widely used in 
AD [2, 252, 253], opening new research directions and leading the way toward the 
detection of specific biomarkers for the development of personalized diagnostic tools and 
treatments [254]. 1H-NMR was used to measure the metabolite composition in the 
hippocampus, cortex, frontal cortex, midbrain and cerebellum of CRND8 mice 
identifying 23 metabolites from tissue samples ranging in mass from 10 - 50 mg [2]. 
Graham et al. lyophilized and milled ≈5 g of human post mortem brain tissue from which 
50 mg was taken forward for extraction and subsequent analysis by UPLC-TOF-MS, 
from which 1264 ions were detected [255].  
 
The whole process of extraction and analysis was prepared to be carried out in the same 
vial, thus reducing analytical variation and sample lose by reducing extraction steps. Each 
phase was analysed separately by LC-MS (RP for non-polar upper layer and HILIC for 
polar lower layer), using an optimal gradient, the method was designed to expand 
metabolic coverage from low sample aliquot and to enhance the reproducibility of the 
overall process. Furthermore, minimizing the risk of metabolite loss by external factors 
like drying. In this chapter, focus was placed on upper phase of the analysis of non-polar 
component in the brain IVDE method as well as polar metabolites present in the lower 
layer are of great interest, thus HILIC analysis was performed. The methodreveal the 
ability to extract wide variety of non-polar metabolites (i.e. Sphingolipids metabolism, 
phospholipids metabolism and glycerol esters) and polar metabolites (i.e. Carnitines, 
amino acids metabolism, neurotransmitter metabolism, tricarboxylic acid cycle and 
energy metabolism) with high reproducibility.  
Aims of this chapter therefore was firstly to develop a modified version of the two phase 
in-vial dual extraction (IVDE) method described by Whiley et al. [256]  to obtain both 
polar and non-polar metabolites from a single small sample of brain tissue. Secondly, to 
develop a robust hydrophilic liquid interaction chromatography (HILIC) method to 
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analyse polar metabolites of the aqueous phase, and a reversed phase (RP) method for the 
analysis of the non-polar metabolites of the non-aqueous phase of the IVDE. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
All solvents, water, methanol, acetonitrile, ammonium formate, formic acid and methyl 
tertiary butyl ether (MTBE), were LC-MS grade purchased from Sigma-Aldrich (Poole, 
UK). Four internal standards, heptadecanoic acid (≥ 98% purity), tripentadecanoin (≥ 
98% purity) for the reversed phase, and L-serine13C3
15N (95%) & L-valine13C5
15N (95% 
purity) for HILIC, were purchased from Sigma-Aldrich. In-vial dual extractions were 
performed in amber glass HPLC vials with fixed 0.4 mL inserts (Chromacol, Welwyn 
Garden City, UK).  
 
2.2.2. Samples 
Experimental tissue material was obtained from the cerebellum of adult male Sprague 
dawley rats obtained from the Biomedical Services Unit, King’s College London, which 
had been dissected from rats euthanized as per Schedule 1 of the Animal (Scientific 
Procedures) Act 1986. The cerebellum was isolated according to the Springer protocol 
for the dissection of rodent brain regions [257] , samples were weighed and subsequently 
stored at -80oC. The cerebellum was sectioned on sterile glass slides (Thermo Scientific, 
Menzel-Glazer slides) using a sterile scalpel; both scalpel and slide were cooled in liquid 
nitrogen to reduce sample thawing during sectioning. Sectioned tissue samples were 
transferred to Eppendorf tubes containing a clean, pre-cooled, 5mm stainless steel ball 
bearing.  
 
2.2.3 Experimental Design 
In this study two primary experiments were performed to assess the precision and 
sensitivity of the IVDE, instrument methods and tissue homogenisation as well as to 
determine the effect of sample mass on metabolite recovery. The first experiment was 
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designed to assess the combined variability of the IVDE and instrument methods. This 
was done by homogenising a single piece (18 mg) of rat cerebellum, removing sample 
mass and tissue homogenisation as sources of variability. The homogenate was split into 
7 aliquots of 50 μl which underwent parallel extractions prior to injection on both HILIC 
and RP methods (Figure 2.1A). The second experiment was designed to assess the effect 
of the mass of tissue extracted and tissue homogenisation on method sensitivity and 
precision. To do this 15 tissue samples ranging from 3 - 17 mg were homogenised and 
extracted in parallel prior to analysis (Figure 2.1B). Sensitivity was assessed in terms of 
the number of metabolite features that were routinely detected, whilst precision was 
assessed in terms of the variability (coefficient of variation) of the abundance of internal 
standard and metabolite peaks, as well as the degree of compositional similarity between 
samples as determined by principal component analysis (PCA). A graphical description 
of the analytical workflow used in this study is shown in Figure 2.1 
 
 
Figure 2.1 Graphical representation of the experimental designs used. A) Experiment 1, a single 
18 mg brain section was homogenised then 7 parallel extractions were performed on 50 μl aliquots 





2.2.4 Tissue  homogenisation 
Prior to homogenisation 20 μl of methanol and 5 μl of HILIC internal standard cocktail 
(2.5 mM L-serine13C3
15N and L-valine13C5
15N in methanol:water (4:1)) were added per 
mg of sample material. The tissue was then homogenised using a Tissueyzer (Qiagen-
Germany) in 10 cycles of 30 seconds at 25 KHz, subsequently a 50 µl aliquot of 
homogenate was transferred to a Chromacol HPLC vial (400 μl fixed insert). 
 
Figure 2.2 schematic representation of the applied analytical pipeline from tissue sectioning to 
IVDE and onto data processing and analysis. 
  
 
2.2.5 In-vial dual extraction of brain tissue 
Subsequently 10μl of water was added to the homogenate, vials were then vortex for 5 
min, after which 250μl of MTBE containing tripentadecanoin (10 μg/ml) and 
heptadecanoic acid (10 μg/ml) was added, after which samples were again vortexed at 
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room temperature for 60 minutes. Following the addition of a further 40 μl of water 
containing 0.15 mM ammonium formate to enhance phase separation, samples were then 
centrifuged at 2500 × g for 30 minutes at 4° C. This resulted in a clear separation of 
MTBE (upper) and aqueous (lower) phases, with protein precipitate aggregated at the 
bottom of the vial.  
 
2.2.6 LC-MS analysis of IVDE non-polar phase 
LC-MS analysis was performed on a Waters Acquity ultra-performance liquid 
chromatogram (UPLC) system coupled to a Waters Premier quadrupole time-of-flight 
(Q-TOF) mass spectrometer (Waters, Milford, MA, USA). The needle height in the 
autosampler was set to 13 mm, with 5 μl of sample extract injected onto an Agilent 
Poroshell 120 EC-C8 column (150 mm × 2.1 mm, 2.7 μm). Separation was performed at 
55 oC with a flow-rate of 0.5 ml/min using 10 mM ammonium formate in water (mobile 
phase A) and 10 mM ammonium formate in methanol (mobile phase B).  For analysis in 
the positive mode, the gradient began at 80% mobile phase B, increasing linearly to 96% 
B after 15 minutes and was held isocratic for 13 minutes, after which initial conditions 
were restored in 2 minutes ahead of 7 minutes of column re-equilibration. For analysis in 
the negative ionisation mode the gradient began at 75% B, increasing linearly to 96% B 
at 23 minutes, then increasing further to 100% B by 35 minutes, after which initial 
conditions were restored to allow 7 minutes of column re-equilibration. In the positive 
mode, a capillary voltage of 3.2 kV and a cone voltage of 45 V was applied. The 
desolvation gas flow was 400 L/hour and the source temperature was 120 °C. In the 
negative mode, a capillary voltage of 2.6 kV and a cone voltage of 45 V were used. 
Desolvation gas flow and source temperature were fixed at 800 L/h and 350 ºC, 
respectively. All analyses were acquired using the lock spray to ensure accuracy and 
reproducibility; A reference solution (leucine-enkephalin) was used as lock mass (m/z 
556.2771 and 278.1141) at a concentration of 200 ng/mL to update accurate mass data 
values and a flow rate of 10 μL/min. Data were collected in the centroid mode over the 
mass range m/z 50–1000 with an acquisition time of 0.1 seconds/scan. Analysis settings 




2.2.7 LC-MS analysis of IVDE polar phase 
The auto sampler needle height was set at 2 mm, with analysis of 5 μl of aqueous phase 
extract being analysed on a Merck Sequant column (150 × 4.6 mm, 5 μm particle size) 
coupled to a Merck Sequant guard column (20 × 2.1 mm). A 40 minutes room temperature 
gradient (0.3 ml/min) was applied using 0.1% formic acid in water (mobile phase A) and 
0.1% formic acid in acetonitrile (mobile phase B). The gradient began at 80% mobile 
phase B, followed by a linear reduction to 20% mobile phase B after 30 minutes, initial 
conditions were then restored to allow 10 minutes of column re-equilibration. Mass 
spectral data was acquired between 75-1000 Da in both positive and negative ionisation 
modes. The applied mass spectrometry conditions were the same as for the reversed non-
polar phase method. 
 
2.2.8 Data processing and metabolite identification 
The generated data was processed using MarkerLynx (Masslynx 4.1-Waters Corporation) 
which provides automated peak detection based on peak alignment and normalization to 
total peak area. The reversed phase data were processed with a mass tolerance of 0.01 
daltons (Da), a mass window of 0.05 Da, and a RT window of 12 seconds and a peak 
width of 10 seconds. The HILIC data was processed with a mass tolerance of 0.01 daltons 
(Da), a mass window of 0.05 Da, RT window 18 seconds, and peak width of 20 seconds. 
Processed data was evaluated using principal component analysis (PCA) performed using 
SIMCA 13.0.3 (Umetrics, Umeå, Sweden). The data in all the generated PCA models was 
logarithmically transformed (base 10) and scaled to unit variance (UV).  The performance 
of the PCA models generated was assessed based on the cumulative correlation 
coefficients (R2Y[cum]), and predictive performance based on seven-fold cross validation 
(Q2[cum]). Hotelling’s T2 plots were used to assess the departure of samples from the 
origin in the model plane, which will show the distance of a sample to calculate average 
observation (i.e. an average metabolite composition). The DModX plots corresponds to 
the residual standard deviation of an observation in the x-variables, it was used to assess 
the distance of an observation to the fitted model. 
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Metabolite annotation was performed by searching the m/z of measured metabolite 
features in a range of publicly accessible metabolite databases including the human 
metabolome database (HMDB), METLIN and LipidMaps. Once potential explanatory 
metabolites had been identified an annotation was confirmed by matching the 
fragmentation pattern of the peak being annotated to the fragmentation pattern shown for 
given metabolites within the databases. This method of annotation does possess a small 
inherent bias towards common well-studied metabolites, as standards are readily 
available for these compounds thus allowing fragmentation spectra to be more easily 
generated than less common metabolites. 
 
2.3 Results and Discussion 
2.3.1 Assessing the precision and performance of IVDE and instrument methods 
(Experiment 1) 
The first step in assessing the precision of the (IVDE) and both the RP and HILIC 
methods was to determine the recovery of the four internal standards (Figure 2.3). In the 
RP method heptadecanoic acid was measured in the negative mode and tripentadecanoin 
was measured in the positive. The recovery of both standards was consistent, with CVs 
of 2.5% and 4.4% for heptadecanoic acid and tripentadecanoin respectively (Figure 
2.3A). In the HILIC method the internal standards were measured in both the positive and 
negative ionisation modes. In the positive data, the recovery of internal standards is highly 
consistent, with coefficient of variation (CV) of 2.4% and 3.7% (Figure 2.3B) for the 
serine and valine standards respectively. In the negative mode, recovery is more variable 
than the positive mode, with CVs of 9.1% and 5.7% (Figure 2.3C) for serine and valine 
respectively. The standard recoveries suggests that the IVDE and both HILIC and RP 
methods have good precision with all internal standard measurements having CVs less 
than 15% [258], with mass spectrometry in the negative mode adding more variability 




Figure 2.3 Recoveries of HILIC and RP internal standards in experiment 1. A) Plot of intensity 
of RP internal standards heptadecanoic acid (negative) and t ripentadecanoin (positive), B) plot 
of intensity of HILIC internal standards in positive ionisation mode,  C) plot of intensity of HILIC 
internal standards in negative ionisation mode, D) average intensity and coefficient of variance 
of all internal standards. 
 
The next step in determining the method’s performance was to identify the number of 
metabolite features measured following HILIC and RP separation and to assess the 
precision of these peaks. This was done by initially identifying the features present in all 
samples, then identifying those features measured in at least 85% of samples, with a 
minimum cut-off of peaks present in at least 70% of samples analysed (Table 2.1 and 
Table 2.2). In total, 5,841 metabolite features were measured in 100% of samples for both 
the HILIC (3713 metabolite features) and RP (2128 metabolite features) methods. When 
a 70% sample presence cut off was applied, 12,274 metabolite features were identified 
with 6,570 and 5,704 metabolite features measured in the HILIC and RP methods 
respectively. The measured metabolite features show good precision, with 3,468 of the 
5,841 (59.4%) peaks observed in 100% of samples, and 6,362 of the 12,274 (51.8%) of 
the peaks measured in at least 70% of samples have CVs of <15%. In general, the features 
with CV’s of ≥15% are lower in abundance, with peaks with CVs <15% with an average 
abundance 6.62, with peaks with CVs ≥15% having an average of 1.93 potentially 
accounting for the lower precision. It is also interesting to note that the metabolite features 
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that are measured in all samples have a higher average abundance (4.76) than those 
measured in 85% (2.04) and 70% (1.83). This is due to these groups possessing more 
peaks that are close to the limit of detection (LOD), with the peak falling below the LOD 




Table 2.1 Measured metabolite features in the HILIC method in experiment 1. Showing the number of metabolite peaks identified and their relative 
variability in 100%, 85% and 70% of 7 sample replicates. a percentage of samples a peak is detected in, b coefficient of variance of peak intensity between 
samples. 
 HILIC Positive HILIC Negative HILIC Total 
%RSD 100%a 85%a 70%a 100%a 85%a 70%a 100%a 85%a 70%a 
< 5b 141 155 170 103 113 127 244 268 297 
5-10b 416 507 598 605 668 726 1021 1175 1324 
10-15b 305 436 582 460 618 726 765 1054 1308 
15-30b 417 635 889 803 1204 1539 1220 1839 2428 
> 30b 149 286 406 314 540 807 463 826 1213 
Total 1428 2019 2646 2285 3143 3925 3713 5162 6570 
 
Table 2.2 Measured metabolite features in the RP method in experiment 1. Showing the number of metabolite peaks identified and their relative variability 
in 100%, 85% and 70% of 7 sample replicates. a percentage of samples a peak is detected in, b coefficient of variance of peak intensity between samples. 
 RP Positive RP Negative RP Total 
%RSD 100%a 85%a 70%a 100%a 85%a 70%a 100%a 85%a 70%a 
< 5b 124 261 278 202 253 455 326 514 733 
5-10b 193 418 450 504 628 1112 697 1046 1562 
10-15b 69 115 197 346 418 941 415 533 1138 
15-30b 112 246 329 402 484 1009 514 730 1338 
> 30b 50 134 226 126 340 707 176 474 933 






Table 2.3  Measured metabolite features in the HILIC method in experiment 2. Showing the number of metabolite peaks identified and their relative 
variability in 100%, 93%, 87%, 80% and 73% of 15 samples replicates. a percentage of samples a peak is detected in, b coefficient of variance of peak 
intensity between samples. 
 HILIC Positive HILIC Negative HILIC Total 
%RSD 100%a 93%a 87%a 80%a 73%a 100%a 93%a 87%a 80%a 73%a 100%a 93%a 87%a 80%a 73%a 
< 5b 38 49 56 68 81 33 39 44 55 61 71 88 100 123 142 
5-10b 322 408 431 467 509 217 302 283 344 372 539 710 714 811 881 
10-15b 426 566 601 644 685 222 353 386 495 566 648 919 987 1139 1251 
15-30b 406 583 742 793 884 501 751 1115 1142 1348 907 1334 1857 1935 2232 
> 30b 454 610 827 1078 1254 219 362 514 735 977 673 972 1341 1813 2231 
Total 1646 2216 2657 3050 3413 1192 1807 2342 2771 3324 2838 4023 4999 5821 6737 
  
 
Table 2.4  Measured metabolite features in the RP method in experiment 2. Showing the number of metabolite peaks identified and their relative variability 
in 100%, 93%, 87%, 80% and 73% of 15 sample replicates. a percentage of samples a peak is detected in, b coefficient of variance of peak intensity between 
samples. 
 RP Positive RP Negative RP Total 
%RSD 100%a 93%a 87%a 80%a 73%a 100%a 93%a 87%a 80%a 73%a 100%a 93%a 87%a 80%a 73%a 
< 5b 168 184 195 229 238 9 9 14 14 14 177 193 209 243 252 
5-10b 203 213 220 231 235 7 11 30 38 38 210 224 250 269 273 
10-15b 65 72 93 140 156 46 81 127 191 196 111 153 220 331 352 
15-30b 103 119 147 166 182 267 271 754 1314 1363 370 390 901 1480 1545 
> 30b 49 62 89 135 184 266 388 901 1524 1591 315 450 990 1659 1775 




Having considered the behaviour of individual metabolite peaks, the final step in 
assessing the method performance was to look at the similarity of the overall composition 
of the analysed samples. Principal component analysis (PCA) was performed on all 
12,274 metabolite features that were identified in at least 70% of samples (Figure 2.4A). 
This PCA revealed little structure within the data, with the first component accounting 
for only 25.3% of the total variability with a predictive performance of Q2 = -0.10, with 
the first two components accounting for just 43.9% of variability with a predictive 
performance of Q2 = -0.21. The distance of a sample’s metabolite composition to a 
calculated average composition was assessed using the Hotelling’s T2 range plot (Figure 
2.4B). This plot shows that all of the samples were compositionally similar both to each 
other and the calculated average, with all samples having a T2 of < 5 with the 95% 
confidence interval set at 13.88. The distance of samples to the model was assessed using 
the DModX plot (Figure 2.4C), which showed that the samples had a low residual of 
difference to the fitted model, with all of the observations falling below the Dcritical 
(0.05) threshold. This combined with the Hotelling’s T2 showed that all of the samples 







Figure 2.4 Principal component analysis (components = 2, R2 X – 0.439, Q2 –0.210) of metabolite 
features identified in at least 70% of samples in experiment 1. A) Scores plot and B) Hotelling’s 
T2 and C) DModX plot. 
 
2.3.2 Assessing the effect of tissue homogenisation and sample mass on method 
performance and precision (experiment 2). 
As with assessing the performance of the IVDE and instrument methods, the first step in 
assessing the effect of tissue homogenisation and sample mass is to look at the recovery of 
the internal standards. As in experiment 1 both HILIC internal standards were observed in 
positive and negative ionisation modes (Figure 2.5B and 2.5C). In the positive mode, the 
CVs of the internal standard recoveries were 13.5% and 14.7% for serine and valine 
respectively. In the negative mode CVs of the internal standard recoveries were 14.9% and 
14.4% for serine and valine respectively. In the RP data heptadecanoic acid was measured 
in the negative mode with a CV of 13.4%, and tripentadecanoin was measured in the 
positive mode with a CV of 3.8%. The recovery of the HILIC internal standards was more 
variable in these samples than in experiment 1, suggesting that the tissue homogenisation 
step was contributing significantly to analytical variability. This is further supported by no 





homogenisation. The recovery of the HILIC internal standards in the quality control 
samples, which are pooled after tissue homogenisation, were more consistent than in the 
analytical samples, and comparable with experiment 1 with CVs of 3.8% and 4.8% in 
positive and 5.3% and 7.1% in negative for serine and valine respectively, further 
supporting the hypothesis that tissue homogenisation is contributing significantly to the 
observed variability. Having shown this, it was important to assess the relationship 
between the mass of tissue extracted and the recovery of the internal standards (Figure 
2.5). Spearman’s correlation was used to assess the relationship between standard recovery 
and sample mass, this analysis revealed no significant correlations showing that internal 
standard recovery is independent of the sample mass extracted. 
 
Figure 2.5 Recoveries of HILIC and RP internal standards in experiment 2. A) Plot of intensity of 
RP internal standards heptadecanoic  acid (negative) and tripentadecanoin (positive), B) plot of 
intensity of HILIC internal standards in positive ionisation mode,  C) plot of intensity of HILIC 
internal standards in negative ionisation mode, D)  average intensity and coefficient of variance of 
all internal standards. 
 
 
The next step in assessing the method performance was to determine the number of 





initially done by identifying peaks that were measured in all samples, working down to a 
cut-off peaks present in at least 73% of samples (Table 2.3 and 2.4). In total 4,021 peaks 
were measured in 100% of samples, with 2,838 and 1,183 measured in HILIC and RP 
methods respectively, 10,934 peaks measured in 73% of samples with 6,737 and 4,197 
measured in HILIC and RP data respectively. The precision of the measured peaks was 
lower than was observed in experiment 1 with 1,726 of 4,021 (43.7%) of the peaks 
observed in 100% of samples and 3,151 of 10,934 (28.8%) of peaks observed in 70% of 
samples having CVs of <15%. The finding of higher sample-to-sample variability of the 
measured metabolite features lends further support to the hypothesis of tissue 
homogenisation as a source of variability within the method. 
 
Having considered metabolite features individually it was important to consider the 
composition of samples as a whole. As in experiment 1 PCA was applied to all metabolite 
features that were measured in at least 73% of samples (Figure 2.6). The analysis revealed 
little structure within the data, with the first component accounting for only 22.3% of total 
variability with a poor predictive performance of Q2 = 0.07, with the second component 
only explaining a further 13.1% of variability (Q2 = 0.05) (Figure 2.6A). The Hotelling’s 
T2 plot (Figure 2.6B) shows that all samples fall within the 95% confidence interval (T2 = 
8.19), with all bar one sample having a T2 < 4, demonstrating that the samples were 
compositionally similar both to each other and to the calculated average. The DModX plot 
(Figure 2.6C) showed that all samples had a low residual of difference to the fitted model 
with all of the observations falling below the Dcritical (0.05) threshold. This combined 
with the Hotelling’s T2 plot showed that all samples were compositionally similar and that 
there were no outliers to the model.  
 
Whilst all samples were compositionally similar it was important to determine the effect 
of the extracted tissue mass on metabolite composition. Looking at the PCA scores plot 
(Figure 2.6A) it can be seen that there was no bias in the distribution of samples based on 
the tissue mass, with low and high mass samples clustering together within the plot 
showing that they possessed high levels of compositional similarity. As well as looking at 
the effect of sample mass on the compositional similarity it was important to assess its 





annotated metabolites from both HILIC and RP methods plotted against the tissue mass, 
these plots show no relationship between metabolite abundance and sample mass, with the 
strongest correlation being for glutamate (r = -0.24). This data shows that using between 
3-17 mg of sample material had no effect on the overall sample composition or the 
abundance of individual metabolites, showing this method can provide broad metabolite 
coverage when sample material is limited.  
 
 
Figure 2.6 Principal component analysis of 15 brain samples ranging from 3 – 17 mg (components 
= 2, R2X  0.354, Q2 0.049) of metabolite features identified in at least 73% of samples in experiment 
2. A) Scores plot where point labels represent sample mass B) Hotelling’s T2 and C) DModX plot 








Figure 2.7 Plots of sample mass in mg against intensity for 9 annotated metabolites. A) taurine B) 
hypoxanthine C) glutamate D) pantothenate E) aspartate F) glcosylceramide (36:1) G) 
phosphatidylethanolamine (38:4) H) ceramide (38:1) I) triglyceride (48:3). 
 
2.3.3 IVDE method optimization 
Extraction solvents 
For the extraction of metabolites from human brain, there are various methods. Traditional 
method includes Folch “a gold standard” method which involves lipids extraction using 
chloroform as the extraction solvent. The traditional Folch method procedure results in 
formation of protein precipitate in the middle between the chloroform lower layer and 
methanol upper layer [259]. This makes the sample collection a hard process. In contrast, 
in IVDE, MTBE results in protein pellet formation at the bottom of the vial with two 
solvents layers located above protein precipitate, allowing for low risk of column blockage 
by protein and direct and simple injection of solvent layers in to the LC-MS, which in turn 
minimises analytical variability due to sample collection and transfer (This is managed by 






The traditional Folch method using chloroform with a glass-glass homogenization method 
has been compared to bead mechanical homogenization with  MTBE, with the later 
providing significantly improved efficiency and reduced time for sample preparation 
[260].However, no change in term of lipid species composition were observed when 
comparing the two extraction methods.  Extensive testing of  MTBE extraction performed 
by Matyash et al  [261], shows that the use of MTBE  provides similar or better recoveries 
of species of most lipid classes when compared with the  Folch or Bligh and Dyer methods 
[259, 262]. 
 
MTBE was used as extraction solvent for the upper lipidome phase as in the original 
plasma IVDE method. Furthermore, the described brain IVD Extraction method has the 
advantages of performing extraction and analysis within the same vial. A study examined 
seven extraction methods along with series of chromatographic and detection methods, this 
resulted in the design of “all in one” extraction and increasing metabolic coverage. This 
emphasized the importance of expanding metabolic range through sample pre-treatment 
optimization [263]. Another study has investigated combining the polar and non-polar 
fractions ”Dual Extraction” concluded the that the best protocol for non-polar and polar 
metabolite profiling is by aqueous extraction using water: methanol preceding extraction  
using organic solvent of dichloromethane: methanol [264]. Chen et al 2013 also developed 
a MTBE extraction protocol using limited amounts of tissue, resulting polar and non-polar 
fractions were pooled, evaporated and reconstituted in the appropriate solvent for 
UHPLC/MS analysis. However, this required separate extraction, drying down, and 
multiple transfer steps that will increase the risk of variability and probably sample 
contamination [265]. In this regard, unsaturated lipids species for example can be easily 
oxidized, thus steps of drying down and transfer must be carried out carefully to avoid 
metabolite modification and sample loss. 
 
Development of LC-MS parameters  
Although the injection of pure organic solvent (MTBE) is not recommended, no effect was 
noticed in terms of separation and reproducibility of early eluting peaks. Apart from the 





importantly, it eliminates the drying and re-suspension step that would reduce the 
instrumental variability and oxidation effect on lipids species. High throughput analysis is 
being widely preferred. The gradient length for the positive mode RP analysis has a run 
time of 51 min with the negative having a shorter run time of 35 min due to fewer species 
ionising in the negative mode such as DG species that do not ionise well in this mode and 
thus less separation time was needed.  
 
2.3.4 Putative metabolites annotation 
Having demonstrated the sensitivity and reproducibility of the metabolite features 
measured by the analytical method, the final step is to demonstrate its biological relevance 
by linking the data directly to metabolism by annotating metabolites from a variety of 
chemical classes and across a range of concentrations. To do these 200 metabolites, 100 
from both the HILIC and RP methods were annotated (Appendix A Tables 2.1 and 2.2). 
The annotated metabolites come from a wide range of metabolite classes including amino 
acids, purines, phospholipids and glycerides, across 3.5 orders of magnitude ranging in 
abundance from 0.1 to 576.9. There is limited overlap between the two analytical methods 
with no identified metabolites in common, this limited overlap demonstrates the necessity 
of using complementary separation techniques like HILIC and RP chromatography to 
obtain a comprehensive view of all chemical space. These annotations enable the method 
to be easily compared as basal metabolite abundance in the rat’s healthy cerebellum and 
provide valuable information allowing the method to be accurately replicated by other 
laboratories. 
 
The features were preliminary identified using open access databases such as human 
metabolome database (HMDB) (www.hmdb.ca/) and the equivalent METLIN 
(METaboliteLINK) database (http://metlin.scripps.edu/). Using the HMDB allowed an 
indication of the molecular classes.  
 
A set of rules were enforced in the identification database searching process to be as 





• 0.05 Dalton (Da) error 
The use of 0.05 Da as mass error for database search. This falls within the accuracy of the 
Waters Xevo® MS and confirmed by our external calibration. 
• Polarity 
The features in each instance realistically ionise in the polarity being observed. For 
example, Triacylglycerides generally only observed in positive ionization mass 
spectrometry (unless they have formed adduct in the ionization source). 
• Human Biology 
HMDB search retrieve feature search and indicates the human biology of whether  this 
feature has been extracted from human tissue and reported in the literature. 
• Retention Time 
RT and chemical properties of the feature like partition coefficient were considered. For 
example, molecules with similar polarity often elute in the same region of the 
chromatogram and metabolites with small or even negative log(p) elute early in the RP 
chromatogram. This was taken in consideration when completing database search. 
• MS2 fragmentation 
All data was collected by Waters Xevo QTOF which used MSe technique, two collision 
energies applied that grant data collection at two levels. The first level obtained data using 
5 V of collision energy, the second level obtained data at higher collision energy of 50 V. 
This can assist in structural elucidation and to simultaneously collect accurate mass, parent 
ion and fragmentation data. 
From identification results listed in Appendix A, Table 2.1 & 2.2, annotation suggests 








The method described in this chapter combined both RP and HILIC is shown to be capable 
of measuring over 4,000 metabolite features from as little as 3 mg of tissue with a high 
degree of reproducibility. This performance is an improvement on previously described 
methods in both the number of metabolite features measured and the sample mass from 
which they were extracted. A single extraction method producing both a polar and non-
polar phase will reduce the required sample mass as well as reduce analytical variability 
by reducing the number of steps involved in sample preparation. The polar phase was 
analysed in positive and negative modes following separation on a HILIC in which 2,838 
metabolite features were consistently measured, representing metabolites including amino 
acids, sugars and purine bases. The non-polar phase was also analysed in positive and 
negative modes following separation on reverse phase from which 1,183 metabolite 
features were consistently measured, representing metabolites such as 
phosphatidylcholines, sphingolipids and triacylglycerides. It is hoped that the low required 
sample mass and improved sensitivity of this method will provide a valuable tool with 
which to analyse the previously poorly explored area of cerebral metabolism, hopefully 
providing new insights into the functioning of the brain as well as the mechanisms of 
pathology of neurological disorders. 
In the next chapter, the aim was to expand the metabolome range using GC-MS analysis. 
This is to test the applicability of using the remaining extract volume from the LC-MS 
brain IVDE method (presented in this chapter). Brain tissue is very precious and i wanted 
to explore the ability to develop a GC-MS method directly from the same vial to extract 














Chapter 3: GC-MS Metabolomics of rat brain 
















Multi-parallel techniques are required in metabolic fingerprinting in order to gain a broad 
metabolic profile, especially in tissue, which contains both non-polar and polar metabolites 
[244, 266]. Among all these techniques, NMR and MS are the main detection techniques 
used in metabolomics research [249, 267, 268].  
 
MS is often coupled to chromatographic technology and this called combined techniques 
which combine the advantage of separation power of chromatographic technology (i.e. LC, 
GC and CE) and the high sensitivity and selectivity of MS spectrometry, allow a much 
finer degree of compound identification than each unit used separately [249, 269]. 
However, the downside to increasing metabolite coverage will be a significant increase in 
the amount of tissue required. 
 
 The first combined instrument was the GC-MS in 1950s and has been described as the 
gold standard in metabolomics allowing quantification and identification of thousands of 
compounds in biological samples. It is a quick and accurate technique that offer screening 
of hundreds of metabolites from different chemical groups after sample extraction and 
derivatization making it  an efficient technique for diagnosis and screenig [270-272]  even 
though it has its own limitations [273, 274] .  
 
GC-MS is still one of the most popular global analysis methods due to the fact that GC 
offers a stable, sensitive and high-resolution separation system and electron impact (EI) 
and a mass spectrometer providing each component a mass spectrum. EI is a hard 
ionisation method which can offer a lot of information about the identity of a compound 
through fragmentation and there are a number of databases available assisting with 
compounds identification. In the case of LC-MS, metabolite identification is more time 
consuming as the ESI interface does not cause fragmentation of molecular ions as EI does 
and there are few available ESI mass spectral libraries. The major disadvantage of GC-MS 
is that compounds must be volatile and thermo-stable. Non-volatile, polar compounds 
could be converted into volatile compounds through derivatization prior to analysis, this 






The aim of this chapter therefore was to develop GC-MS method to maximise brain 
metabolite coverage analysis for comprehensive metabolomic approaches. This involve 
using remaining extract of brain IVDE LC-MS analysis (discussed in Chapter 2). 
Extraction solvent was directly analysed using GC-MS following derivatisation. Firstly, 
the analysis conditions were optimized and tested. Secondly, large number of metabolites 
including sugars, sterols, organic acids, fatty acids and other cyclic metabolites were 
efficiently detected by this GC-MS method. The unique identity of metabolites identified 
demonstrates the need to combine complementary separation techniques (e.g. HILIC-
LCMS, RP-LCMS and GC-MS) in the study of chemical composition of tissue to obtain a 
global view of metabolome. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents 
LC-MS grade water, LC-MS grade acetonitrile, were purchased from VWR international 
(UK), LC-MS grade methanol, N, O-Bis(trimethylsilyl)trifluoro-acetamide (BSTFA) with 
1% trimethylchlorosilane (TMCS), N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA), and LC-MS grade toluene were purchased from Sigma-Aldrich (UK). 
 
3.2.2 Brain Materials 
Brain tissue samples used for the experimental design were obtained from rat cerebellums 
which were harvested as per Schedule 1 of the Animal (scientific procedures) Act of 1986-
King’s College London. 
 
 3.2.3 Extraction procedure 
The extraction procedure involved brain preparation according to brain IVDE method 
(described in Chapter 2), the remaining of both non-aqueous (NAQ) and aqueous (AQ) 
phase extract after the LC-MS analysis was split for the purpose of derivatization prior to 
GC-MS analysis. Since very few studies have used GC-MS for the analysis of brain tissue, 






3.2.3.1 GC-MS derivatisation Procedure of NAQ and AQ phase  
The derivatisation procedure involved adding 80 μL of upper NAQ phase or 40 μL of 
lower AQ phase into separate vials. This amount was dried down under a stream of 
nitrogen gas at 37oC. Samples were then re-suspended in 1:1 solution of acetonitrile and 
the derivatising agents N, O-Bis (Trimethylsilyl) trifluoroacetamide (BSTFA) and 1% 
Trimethylchlorosilane, and were incubated at 37oC for 1 hour using Thermo-scientific 
Reacti-therm III heating module. Following incubation, samples were again dried down 
under nitrogen using Thermo-scientific Reacti-VAP III evaporation unit and were 
subsequently re-suspended in 25µl of toluene for analysis. Full details of the experimental 
design and optimization process performed to obtain the above-mentioned GC-MS 
derivatisation procedure for NAQ and AQ phase can be found below in Section 3.2.4.   
 
3.2.4 Experimental Design of GC-MS brain IVDE method  
In this study we performed four experiments for GC-MS method optimization. Experiment 
One, was designed to assess the impact of sample volume on method performance. This 
was done by preparing 5 individual IVDE, then different sample volume ranging from 20 
μL to 80 μL for the NAQ (Upper phase) and 10 μL to 40 μL for the AQ (Lower phase) 
were taken, this underwent parallel derivatization (02:01 sample: reagent) and injected into 
the GC-MS (Figure 3.1). 
Experiment two, was designed to assess the effect of derivatising agent volume on method 
performance. This was done by preparing 5 individual IVDE. Different sample volume to 












Figure 3.1: Graphical representation of the experimental designs used. A) Experiment 1, 
involved preparing 5 independent  IVDE extracts followed by 5 parallel derivatization using 
different sample volumes. B) Experiment 2, involved preparing 5 independent  IVDE extracts 
followed by 5 parallel derivatization prior using  different sample volumes to derivatising agent 
ratio. B) Experiment 3, involved preparing 5 independent IVDE extracts followed by 5 parallel 
derivatization using different sample injection volumes into the GC-MS. B) Experiment 4, 
involved preparing 5 independent IVDE extracts followed by 5 parallel derivatizations prior using 
different gradient lengths. 
 
 
Experiment Three, aimed to determine the effect of increasing the volume of sample 
injected (0.5 μL, 1 μL, 2 μL and 4 μL) on the number and intensity of metabolite peaks 
(Figure 3.2). While experiment Four, aimed to determine the effect of gradient length on 
the observed metabolite peaks number and abundance. To do this, 5 parallel derivatisation 
of both Aqueous (short= 22mins, medium= 33mins and long= 50mins) and Non-Aqueous 




Further experiment, involved applying the optimal parameters selected from experiment 
1,2,3 and 4. This experiment purpose is to identify the number of metabolite features 
measured following GC-MS analysis and to assess the precision of these peaks. This 
involved preparing seven independent IVDE’s and derivatisation of both AQ and NAQ 





to noise threshold (S/N) followed by Total Ion Count (TIC) normalization. To do this, 
extraction blanks were prepared by performing IVDE extraction without adding plasma or 
tissue homogenate and this was used to perform noise filtering based on signal to noise 
ratio>5 to remove features (mass/RT) that could interfere and give false signal of 
metabolites.  
 
3.2.5 GC-MS Analysis Set-up  
GC-MS analysis was carried out on a Shim adzu QP-2010 with an AOC-20S auto sampler 
and AOC-20i auto injector (Shimadzu, Kyoto, Japan).  The aqueous (AQ) phase was 
analysed in split less mode with 4µl of sample injected on a BP5MS capillary column 
(length 30m, thickness 0.25mm, diameter 0.25mm). The carrier gas (helium) pressure was 
79.5Kpa, with a total flow of 125ml/min, a column flow of 1.18ml/min, a linear velocity 
of 40cm/sec and a purge flow of 6ml/min. The gradient temperature started at 80oC and 
was held for 5 minutes followed by a linear increase of 10oC per minute to 200oC, where 
the rate of increase was slowed to 2oC per minute to a final temperature of 225oC and was 
held for 4 minutes.  Analysis of 1µl non-aqueous phase (NAQ) was performed in the split 
less mode on the same column. The carrier gas (helium) pressure was set to 86.2Kpa with 
a total flow of 122.8ml/min a column flow of 1.16ml/min, a linear velocity of 40cm/sec 
and a purge flow of 6ml/min. The gradient temperature started at 100oC and was held for 
5 minutes followed by a linear increase of 15oC per minute to 250oC, where the rate of 
increase was slowed to 2oC per minute to a final temperature of 310oC where it was held 
for 4 minutes. Mass spectral analysis of both phases was performed using electron 
ionisation between 50 and 600 m/z with an ion source temperature of 200oC, an interface 
temperature of 280oC with a scan speed of 833 and an event time of 0.2 seconds. 
 
3.2.6  Data Processing and Analysis 
GCMS Real Time Analysis (Shimadzu, Kyoto, Japan) was used to acquire GC-MS data. 
This later imported to GCMS Postrun Analysis file converting utility where GC-MS raw 
data were converted to mzXML format. Next, the converted data files were imported into 





to total peak area (S/N=3 and S/N=5) in Excel. Both raw and normalized data were used 
to test the reproducibility of the optimized GC-MS protocol. The workflow proposed here 
is shown in Figure 3.3. Metabolite identification was achieved by using NIST and IEM 




Figure 3.2 Proposed workflow of GC-MS Data processing. 
 
 3.3 Results and Discussions 
 
3.3.1 GC-MS materials selection 
- AQ phase sample volume optimization 
Sustainable use of sample further itself and therefore LC-MS over fill loop optimization 
of the IVDE lower AQ phase was tested. The AQUITY UPLC® system was set to different 


















Loop with Needle Overfill (PLNO). Both injection modes were compared using LC-MS. 
This was only applied for the AQ phase due to the small volume of the lower AQ phase 
(50μL) returned after LC-MS analysis. To recover more sample volume, PLNO was 
applied and I.S recovery (% RSD) and signal intensity were observed and compared with 
FL (which was used for the LC-MS brain IVDE method in Chapter 2). It was observed 
that using PLNO mode caused 11% drop in signal intensity which would cause loss of the 
low concentration metabolites with low reproducibility also for IS compared to that 
observed with FL. This showed that FL provided better recovery than PLNO. Therefore, 
FL was selected and the method optimization for the AQ phase was carried out using the 
50μL volume.  
 
- Derivatization procedure selection 
The method used for derivatisation was based on previously published sterol targeted GC-
MS method [260] and this method was adapted and modified. This method needs a long 
extraction time, often for several hours and requires large quantities of samples and organic 
solvents, some of which are toxic. Moreover, this method can also expose samples to 
excessive heat or oxygen which might cause the oxidation of active ingredients and the 
reaction between different components. Modification of this method to a simple 
derivatisation step was applied to both the NAQ and AQ phases (for details see section 
3.2.3.1). We were able to detect many compounds including but not limited to sugars, 
sterols and fatty acids with high reproducibility.  
 
GC-MS in full scan mode is used for untargeted metabolic profiling and the detection of 
new metabolites [279]. As mentioned previously, GC-MS has limitations in the analysis 
of polar compounds due to their low volatility therefore compounds for analysis must first 
be derivatised to increase volatility and stability. Prior to analysis by GC-MS, derivatisaing 
agents like a silylating reagents are used to derivatise amine, and thiol groups. There are 
two main classes of silylating reagents: those producing trimethylsilyl (TMS) derivatives 
including N,O-bis-(trimethylsilyl) trifluoroacetamide (BSTFA) and N-methyl-N-
(trimethylsilyl)-trifluoroacetamide (MSTFA), and those producing tert butyldimethylsilyl 





butyldimethylsilyl) trifluoroacetamide (MTBSTFA) [280]. Often higher reproducibility 
and resolution can be achieved by GC-MS when compared to LC-MS with the latter 
advantage over the classical GCMS procedures is the reduced complexity in sample 
preparation by elimination of derivatisation steps before the chromatographic separation. 
Several parameters were investigated at this stage including the selection of the 
derivatising reagent, reconstitution solvent, incubation temperature and time. The selection 
of these parameters are important aspects to achieve the optimal metabolites analysis using 
GC-MS. 
 
To start with, two silylation reagents MSTFA and BSTFA were compared. This 
accomplished by samples dried by nitrogen then, 40µL of derivatizing reagent was added 
to the NAQ and AQ residue, then peaks were integrated with no significant difference were 
observed. Owing to BSTFA low cost, it was decided to be used in this study.  
 
Toluene and acetonitrile were tested as reconstitution solvents for polar as well as catalyst 
in the derivatization reaction. Figure 3.4 shows the GC-MS analysis results.  It can be 
clearly seen that under the same GC-MS condition, toluene provides a better peak shape 
and more information than acetonitrile. In chromatogram A (Acetonitrile), peaks are 
fronting and not separated while in chromatogram B (Toluene), peaks are sharp and well 
separated. Thus, toluene was chosen as the dissolving solvent. Additionally, different 
reaction time (includes 30-60 and 120 mins) and temperature (37°C -57°C and 75°C) were 
employed and 37°C for 60min was selected to be the optimal reaction conditions. Hexane 
is usually favoured as an extraction solvent for GC-MS analysis of non-polar metabolites, 
For the non-polar (MTBE) phase, toluene and hexane were tested as reconstitution solvent 
to extract the non-polar and semi polar metabolites. Following derivatization and drying 
down, both toluene and hexane were tested as reconstituting solvents and no difference 
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Figure 3.3 Total ion current chromatograms of rat brain A) Acetonitrile as the redissolving solvent. 
B) Toluene as the redissolving solvent. 
 
 
3.3.2 GC-MS Method Optimization and parameter selection 
• Sample Volume (Experiment One):  
The first step in validating the method was to determine if increasing the volume of sample 
material derivatised would increase the number and intensity of the observed peaks. 80uL 
for the NAQ and 40uL for the AQ was used as the maximum sample volume that can be 
recovered from the IVDE after it being injected in to the LC-MS. It can be noticed that the 
effect of increasing sample volume was proportional to the number of peaks and abundance 
of metabolites peaks. Additionally, applying normalization using S/N cut off of 3 and 5 
has improved the number of peaks (Figure 3.5). The abundance of five identified 
metabolites were also reported (Figure 3.6). Metabolites relative abundance was 






Figure 3.4  Number of peaks obtained at different sample volumes for AQ and NAQ phase with 









Figure 3.5 Peak intensity of 5 annotated metabolites using different sample volumes. Error bars 
signify standard deviation. 
 
• Derivatising reagent (Experiment Two):  
A slight increase can be seen in the number of peaks detected at 02:01 ratio compared with 
04:01 ratio, with no difference or less peaks detected in 01:01 compared to 02:01 ratio 
(Figure 3.7). Furthermore, up on observation of individual metabolite abundance (Figure 
3.8), the 04:01 ratio showed inconsistent trends, hence better peak intensity was reported 







Figure 3.6 Number of peaks at different sample to derivatising agent ratio following signal to noise 




Figure 3.7  peak intensity of 5 annotated metabolites using different sample to derivatising agent 





• Injection Volume (Experiment Three):  
A significant increase in number of peaks in order of 0.5μL<1μL<2μL < 4μL of injection 
volume (Figure 3.9) were obtained. The same observations were seen in term of peak 
intensity (Figure 3.10). 
 










• Gradient Length (Experiment Four):  
This study shows that increasing the gradient length increased the number of peaks 
detected. The short gradients (AQ=22mins and NAQ=34mins) measured the most peaks 
per minute, even compared to the 38 mins combined gradient (Figure 3.11). Moreover, we 
tried combining both phases, however, few peaks were obtained and therefore both phases 
were analysed separately. It can be clearly seen that less number of peaks were obtained 
using combined gradient compared to short, medium and long gradient lengths (Figure 
3.12). 
 
Figure 3.10  Number of peaks detected based on using different gradients length. Error bars signify 
standard deviation. 
 
Figure 3.11 Number of peaks obtained when analysing both aqueous and non aqueous phase at 





3.3.3 Reproducibility test of the proposed method (Experiment Five):  
• Raw data reproducibility 
This experiment aimed to study the reproducibility of the optimized GC-MS IVDE 
method. Based on the results obtained out of the optimization steps in section 3.3.2. The 





This experiment was performed by preparing 7 independent IVDE samples and 
derivatisations, up on both Aqueous and Non-Aqueous gradients. Following GC-MS 
analysis, the raw data were transformed to mzXML format, chromatograms were aligned 
and metabolic features were picked by XCMS. Then the data were normalized to TIC prior 
to applying signal threshold removal of 5. 
Data reproducibility is reported as Relative Standard Deviation percentage (%RSD) with 
30% acceptance tolerance was reported for metabolomics studies using GC-MS [281]. 
Method reproducibility was achieved by identifying a total of 2706 of features present in 
100% of samples for both NAQ (1295) and AQ (1431) phase, then those features measured 
when a minimum of 70% sample cut off was applied. The %RSD results are shown in table 
3.1.  
Table 3.1 Measured metabolite features in the AQ and NAQ GC-MS method in experiment 
5. Showing the number of metabolite peaks identified and their relative variability in 100%, 85%, 
71% and 57% of 7 sample replicates. a percentage of samples a peak is detected in, b coefficient of 
variance of peak intensity between samples. 
 RAW RAW  
 GC AQ GC NAQ  
%RSD 100%a 85%a 71%a 57%a 100%a 85%a 71%a 57%a  
< 5b 66 74 86 91 103 117 99 102  
5-10b 82 83 104 138 111 108 131 153  
10-15b 101 106 114 239 167 199 347 309  
15-30b 274 289 369 316 1009 1081 2061 2221  
> 30b 894 981 1077 1142 1884 1931 1980 2168  
Total 1417 1533 1750 1926 3247 3436 4618 4953 
 
Non-aqueous: 80ul of sample derivatised 2:1-1 uL Injection volume -49mins Medium gradient. 







From the results, it can be concluded that reproducibility of LC-MS (reported in Chapter 
2) is better than GC-MS. The variability in GC-MS analysis could be owed to the 
derivatization process. As mentioned before in GC-MS, the samples need to be derivatized 
before being injected into the column which will add more sample preparation stages 
including procedures of drying under nitrogen and transfers, therefore the removal of this 
pre-analytical steps will reduce the sample variability and processing time. GC-MS 
chromatography exhibits less matrix effects than LC/MS, this could be that during the 
derivatisation step, any residue following the extraction can be precipitated. From the 
result, it can also be deduced that GC-MS can provide reliable chromatographic 
fingerprinting approach for brain tissue with approximately 3K features detected in all the 
samples (100%).This result would also suggest brain extract contains a lot of compounds 
that are made volatile after derivatization. 
• Data normalization 
The most important part in the processing step is feature detection and selection. Here, a 
feature is an ion defined by a certain range of mass and RT. This step is usually called 
“peak detection and picking” in mass spectrometry literature where different signal 
detection methods are used to find a peak from a real signal in the presence of noise. To 
define a peak, it is required to meet certain criteria such as peak shape quality or reasonable 
signal-to-noise ratios. Different commercial and free tools exist for this purpose. In this 
study we mainly relied on XCMS[282]  which is developed in R. 
Normalization of the processed GC/LC-MS data is considered before application of any 
statistical analysis method to the data to minimize undesired bias [283] and avoid 
misleading results. The bias can be introduced from differences in the analytical 
procedures, in sample collection, biomolecule extraction, or from column separation 
nonlinearity and instrument variability [284] . Thus, normalization is used to address and 
ameliorate these issues. Raw data normalization using S/N TIC has improved %RSD as 
reported in Table 3.2.  
In the raw brain data, the next step in determining the method’s performance was to 
identify the number of metabolite features following GC separation and to assess the 
precision of these peaks. At this point features were counted as in “featuring” in all 





3.1), allowing for some noise or low abundant metabolites with high variation. The number 
of metabolite features measured in both AQ and NAQ phase were a total of 4664 peaks 
(signal/noise > 5). When the minimum cut off of peaks of 57% applied, 6879 metabolite 
features where identified. 
 
In 100% of samples, metabolite features were reproducible with 13.5% and 41.5% of 
features have RSD of <15% and <30% in AQ and NAQ phase respectively. To improve 
reproducibility data was normalised to total ion count (TIC), with the normalization 
improving the reproducibly with 19.3% and 50.6% of features have RSD of <15% and 
<30% in AQ and NAQ phase respectively. The S/N>5 followed by TIC normalization 
applied has improved the reproducibility of the peaks measured. 
 
Table 3.2 Measured metabolite features in the GC AQ and NAQ phase method in experiment 5. 
Showing the number of metabolite peaks identified and their relative variability in 100%, 85%, 
71% and 57% of 7 sample replicates after transformation based on TIC normalization after S/N of 
5. a percentage of samples a peak is detected in, b coefficient of variance of peak intensity between 
samples. 
 TIC TIC 
 
 GC AQ GC NAQ  
%RSD 100%a 85%a 71%a 57%a 100%a 85%a 71%a 57%a 
< 5b 97 110 123 101 148 169 176 193 
5-10b 108 109 129 146 177 159 206 243 
10-15b 163 142 209 293 205 252 479 406 
15-30b 384 395 413 389 1080 1198 2121 2244 
> 30b 665 777 876 997 1637 1658 1636 1867 
Total 1417 1533 1750 1926 3247 3436 4618 4953 
 
3.3.4 GC-MS Analysis Condition 
In this study, electron impact ionization energy was set to 70 eV so that the MS spectra 
could be compared with a GCMS library acquired at the same voltage. To get a better 
separation, different temperature programmes were tested and the ideal GC condition was 
described in 1.2.5. An example of temperature adjustment to remove dead volume in GC-






Figure 3.12 Showing (A)Atypical chromatogram of NAQ phase of 60 mins (B) NAQ 
chromatogram after dead volume removal (47 min). X axis represent the retention time in minutes 
and Y axis represent the intensity. 
 
3.3.5 Metabolites Annotation 
In GC-MS, a list of 60 compounds from both NAQ and AQ run were identified (Appendix 
B) using NIST and IEM libraries with a similarity index over 90%. These include: amino 
acids, amines, alcohols, sugars, organic acids, sterols, purines, and fatty acids. GC-MS 
applies electron ionization mode with 70 eV which can provide a standard spectrum for 
each compound, so it can compare samples with the database directly. This increases the 
efficiency in helping to identify unknowns. This is an advantage of GC-MS over LC-MS 
as in the latter fragmentation is less reproducible between instruments and identification is 
considered to be harder. GC-MS gives more information on the chemical composition. 
Therefore, using GC-MS to fingerprint of brain tissue to gain information about the 
chemical composition was successful. Many new metabolites were detected by GC-MS 
that could not be detected by LC-MS. These include fatty acids, amines, sugars, alcohols, 











In this study, a simple step derivatization procedure was applied for GC-MS analysis of 
the AQ and NAQ phase of rat brain samples. The GC-MS metabolomics protocol 
developed in this study achieved analytical reproducibility including data treatment and 
extracted features that were representative of the raw data. Modification of derivatisation 
procedures to simple steps provided a wide coverage of various volatile molecules and 
reported 60 metabolites of those identified in both AQ and NAQ phases(Appendix B-Table 
3.1). 
 
It can be concluded that this is a powerful metabolomics platform that can be used for our 
future brain studies. However, this still needs to be validated for application using complex 
samples. Therefore, the next chapter will test the applicability of the LC-MS (in Chapter 
2) and GC-MS (in this chapter) brain IVDE method by analysing brain and plasma samples 
(as a proof of concept) of control and AD groups in volunteers. Another point to be 
addressed in the next chapter is managing and developing a standard data treatment 





















CHAPTER4: Multimodal metabolomics 
combining UPLC-qToF-MS and GC-MS data in 

















AD is also known to have a long prodromal phase to the disease in which pathology 
accumulates without the presence of symptoms, making the discovery of a panel of 
biomarkers that can identify individuals in this phase of the disease highly relevant. A 
number of biomarker candidates have been frequently reported in the literature are the 
measurements of protein markers, amyloid beta, total tau and phosphorylated tau in 
cerebrospinal fluid (CSF) [118, 120, 285-287]. These are considered as lead marker 
candidates for AD. Moreover, brain imaging such as magnetic resonance imaging (MRI) 
[102, 288]and positron emission tomography (PET) [289, 290] with observations on 
specific brain region volume have also been suggested. However, the risk and difficulty in 
CSF samples collection along with high cost and difficulty in data interpretation of brain 
imaging suggests a growing need for more accessible biomarkers enable to recognize 
patients particularly at preclinical stage. Therefore, it is hoped by extending our coverage 
of the metabolome to include metabolites previously unstudied in AD will aid for this 
diagnosis approach. 
 
Metabolomics is the unbiased analysis of the composition of small molecule metabolites 
in a given biological tissue or bio-fluid under a specific set of environmental conditions 
[291, 292]. In recent years the development of new methods has seen metabolomics 
progress from a novel analytical technique towards a mainstay of the biological toolbox. 
However, before this transformation can be completed a number of technical challenges 
remain to be overcome, foremost among these is maximizing coverage of the metabolome 
[263, 293]. A number of previous studies have done this by utilizing multiple 
complimentary techniques including liquid chromatography – mass spectrometry (LC-
MS), nuclear magnetic resonance spectroscopy (NMR) and gas chromatography – mass 
spectrometry (GC-MS) [246, 248, 249, 294] enabling metabolic profiling to be performed 
in various biofluids such as blood [182, 193, 207, 295-297], urine [207, 298] and saliva 
[205, 206], demonstrating the easy accessibility of samples and the importance of this 
approach for the search of potential biomarkers. Another biofluid explored is CSF which 
is believed to reflect pathology of AD [179, 180, 182, 183]. Few studies presented 





scarcity of human brain tissue whereas, many studies alternatively used transgenic AD 
mice model [220, 221, 252, 253]. However, these strategies require individual sample 
preparation techniques which significantly increases the volume of sample and potentially 
variation and analysis time. Therefore, it is hoped by extending our coverage of the 
metabolome to include metabolites previously unstudied in AD will aid for this diagnosis 
approach. 
 
The large and complex dataset generated using metabolomics studies is challenging and 
data processing and pre-processing procedure needed to simplify these data. In LC-MS 
based metabolomics the raw data are produced in 3-D format and data pre-processing step 
need to be applied to reduce data dimension to 2-D format. Our laboratory has previously 
developed a metabolomics workflow using Markerlynx [68], and Chapter 2 dataset 
processed was based on the established data pre-processing procedures. However, 
Markerlynx works only for Waters instruments and processes relatively small data sets, 
thus new data pre-processing techniques were necessary. XCMS was used to process data 
in this chapter as it has emerged as a powerful metabolomics data processing method. It is 
available from the R software (free-access programme), and it is highly adaptable to almost 
all types of LC-MS and GC-MS data sets with the help of format conversion tools [299, 
300] 
Following data pre-processing, large number of metabolic features will be generated that 
are difficult to manage and visualize. This raises the need for employing multivariate 
analysis and modelling (see introduction section 1.5.3 for more details). Models can either 
be non-supervised method, e.g. principal component analysis (PCA), where outliers and 
overall data distribution will be assessed, or supervised, such as partial least-squares (PLS), 
partial least-squares discriminate analysis (PLS-DA) and orthogonal partial least-squares 
discriminate analysis (OPLS-DA), where grouping of samples is possible to select their 
descriptive metabolic features or variables [301, 302]. 
 
To this end we developed a strategy that enables 6 analytical assays (4 LC-MS and 2 GC-
MS) to be applied to a single in-vial dual extraction utilising as little as 3mg of brain tissue 
[303] or 20µl of plasma [256]. The method was designed to analyse samples in the future 





The robustness and utility of this strategy was assessed by combining all the data and 
applying the method to 7 rat cerebellum samples and a pilot experiment of plasma samples 
of 20 Alzheimer’s patients versus 20 healthy age matched controls split into stable and 
declining individuals to allow us to assess the ability of the platform to detect both large 
and subtle metabolic differences.   
 
4.2. Materials and Methods 
4.2.1. Chemicals and Reagents 
All solvents including acetonitrile, ammonium formate, formic acid, methanol, methyl 
tertiary butyl ether (MTBE), toluene and water were all LC-MS grade, GC-MS reagents, 
internal standards and serum used to prepare quality control samples were purchased from 
Sigma-Aldrich except for acetonitrile which was purchased from VWR international. 
Three internal standards were added for LC-MS analysis, L-serine13C3
15N (95%) and L-
valine13C5
15N (95%) for hydrophilic liquid interaction chromatography (HILIC), 
Tripentadecanoylglycerol for reversed phase (RP) and one internal standard for GCMS 
analysis, Succinic D4 acid for GC Aqueous. Sample derivatisation for GC-MS analysis 
was performed using N,O-Bis(trimethylsilyl)trifluoro-acetamide (BSTFA) with 1% 
trimethylchlorosilane (TMCS) purchased from Sigma-Aldrich.  
 
4.2.2. Biological Material 
Brain tissue samples were obtained from rat cerebellums which were harvested in the 
Biomedical services unit, King’s College London as per Schedule 1 of the Animal 
(scientific procedures) Act of 1986. All animal procedures were approved by local animal 
welfare and the Ethics Review Body (King’s College London). Plasma samples from 40 
individuals, 20 Alzheimer’s patients and 20 healthy controls were collected in Kupio 
(Finland) for the Addneuromed cohort were selected for analysis.   [304]. Patient groups 
were balanced for age and gender, with mini-mental state examination score (MMSE) 
balanced between genders within each group (Table 4.1). MMSE was used as the primary 





Living (ADCS-ADL) being used as a secondary cognitive measure specifically for AD 
patients. 
 
Table 4.1. Characteristics of study cohort.  
 Controls Alzheimer’s 
Gendera 10/10 10/10 
Age 74.8 +/- 5.0 75.3 +/- 6.1 
MMSE 28.5 +/- 1.4 22.5 +/- 4.6 
APOE4b 4 11 
ADCS-ADLc n/a 48.2 (+/- 16.4) 
a male/female, b number of APOE4(genetic risk factor for AD) positive patients, c Alzheimer’s 
disease Cooperative Study scale for Activities of Daily Living. 
 
4.2.3. Plasma and brain samples derivatisation and Quality Control samples (QC) 
Preparation  
The in vial dual extractions (IVDE) were performed as previously described for plasma 
[256] and brain tissue [303]. Following LC-MS analysis, the remaining aqueous and non-
aqueous phases were split into separate vials and dried down under a stream of nitrogen at 
37oC. Samples were then re-suspended in a 1:1 solution of acetonitrile and the derivatising 
agents (BSTFA) with 1% TMCS, and were incubated at 37oC for 1 hour. After incubation 
samples were again dried down under nitrogen and were subsequently re-suspended in 
25µl of toluene for analysis. A graphical description of the analytical workflow used in 
this study is shown in Figure 4.1below. QC samples (Quality control) were prepared by 
using commercially available serum samples. Samples were analyzed in a randomized 









Figure 4.1 Analytical workflow from sample preparation to multiplatform analysis using LC-MS 
and GC-MS and onto multimodal and multivariate analysis. 
 
4.2.4. Data Acquisition  
The HILIC and reversed phase LC-MS analysis was performed on a Waters ultra-
performance liquid chromatography (UPLC) system coupled to a quadrupole time-of-
flight (Q-TOF) mass spectrometer (Waters, Milford, MA, USA) as described 
previously[256, 303].  GC-MS analysis was carried out on a Shimadzu QP-2010 with an 
AOC-20S auto sampler and AOC-20i auto injector (Shimadzu, Kyoto, Japan).  The 
aqueous phase was analyzed in split less mode with 4µl of sample injected on a BP5MS 
column (length 30m, thickness 0.25mm, diameter 0.25mm). The carrier gas (helium) 
pressure was 79.5Kpa, with a total flow of 125ml/min, a column flow of 1.18ml/min, a 
linear velocity of 40cm/sec and a purge flow of 6ml/min. The gradient temperature started 
at 80oC and was held for 5 minutes followed by a linear increase of 10oC per minute to 
200oC, where the rate of increase was slowed to 2oC per minute to a final temperature of 
225oC where it was held for 4 minutes.  Analysis of 4µl non-aqueous phase was performed 
in the split less mode on the same column. The carrier gas (helium) pressure was set to 
86.2Kpa with a total flow of 122.8ml/min a column flow of 1.16ml/min, a linear velocity 
of 40cm/sec and a purge flow of 6ml/min. The gradient temperature started at 100oC and 
was held for 5 minutes followed by a linear increase of 15oC per minute to 250oC, where 





was held for 4 minutes. Mass spectral analysis of both phases was performed using electron 
impact ionisation between 50 and 600 m/z with an ion source temperature of 200oC, an 
interface temperature of 280oC with a scan speed of 833 and an event time of 0.7 seconds.  
 
4.2.5. Data Processing  
Initially all raw data files were converted into an mzXML format, LC-MS files were 
converted using msConvert (ProteoWizard), whilst GC-MS files were converted using 
GCMS Solutions® (Shimadzu). Converted data files were analyzed using XCMS [282]  
performed in the open source software package R, picking was performed using a 
”massifquant” method for the GCMS data allows isotope trace feature detection and a 
‘'centwave’’ method for LCMS data, allows the deconvolution of closely eluting or slightly 
overlapping peaks. Metabolite features were defined as any peak with an average intensity 
5 times higher in the analytical samples than is measured for this peak in the extraction 
blanks. Measured metabolite features from all assays were combined into a single 
multimodal dataset that was analyzed using a range of multivariate tests including principle 
component analysis (PCA) and orthogonal projections to latent structures – discriminant 
analysis (OPLS-DA) and hierarchical clustering analysis (HCA) performed in SIMCA 
14.0 (Umetrics, Umeå, Sweden). The data in all models was logarithmically transformed 
(base10) and pareto scaled. The performance of the generated models was assessed based 
on the cumulative correlation coefficients (R2X[cum]) and predictive performance based 
on seven-fold cross validation (Q2[cum]), with the significance of the model assessed 
based on the ANOVA of the cross-validated residuals (CV-ANOVA). Feature selection to 
create curated models was performed by iteratively removing variables using the variable 
influence to projections plot to achieve the fitted model with the optimal R2 and Q2 values 
[305].  
 
The Curated PLS-DA models were produced using the variable importance to projection 
(VIP) scores, where the VIP is mean centred score of the contribution of a variable to the 
observed class separation. Metabolite features with a VIP less than 1 were iteratively 





predictive ability of the generated OPLS models were validated by using permutation test 
[306]. The results showed that none of the permuted Q2 values is higher than the one in the 
original model which confirms the reliability of the produced models. Comparison of 
model performance of each individual method was performed, then followed by looking 
at how all of the methods performed together. 
 
4.3. Results and Discussion 
The total run time of this method was four hours which is unusually long in metabolomics, 
where methods need to be high-throughput. The present method was designed to acquire 
as much information as possible from one sample and the instrument time and cost of 
analysis were increased to achieve this end. The quality of the generated data was assessed 
by looking at the compositional similarity of QC samples based on all metabolite features 
using PCA (Figure 4.2). QCs clustered apart from QC1 which was the first injection into 
the run (highlighted in a box), the other QCs clustered once the columns were equilibrated, 
hence showing a clustering lower than biological variance suggesting across run 
reproducibility and stability. In a PCA analysis of just the QC samples it could be seen that 
the analytical drift across the run accounted for 17.2% of the overall variance observed in 
the QC. Reproducibility of the Aqueous phase internal standard was calculated in the raw 
data from plasma in both samples and QCs (Table 2). The %RSD was reported at less than 
15 % across both samples and QCs, which is recommended in bio analytical method 
validation, which ultimately shows the values obtained have acceptable reproducibility. 
No shift in retention time over the runs was observed. There was limited overlap between 
the analytical methods used with no identified metabolites in common, this limited overlap 
demonstrates the importance of using complimentary separation techniques to obtain a new 







Figure 4.2 PCA score plot of plasma samples generated from the combined dataset from all 6 
analytical methods combined.  Plot showing controls, Alzheimer’ and quality control samples, first 
QC is enclosed in a square.  
 
Table 4.2: Reproducibility of internal standard in the GCMS aqueous phase. 
 %RSD of IS in QCs %RSD of IS in Samples 
Plasma 3.22% 14.11% 
QC =Quality Control samples, %RSD=% Relative Standard Deviation, IS: Internal Standard. 
 
The selectivity and reproducibility of the method was assessed in both brain tissue (Table 
4.3) and plasma (Table 4.4) by determining the number of peaks measured and their 
relative variance.  In the raw brain data, the peaks detected in the 4 LC-MS methods were 
a total of 9459 peaks (signal/noise > 5), and reproducible with 61.8% of the metabolite 
features with coefficients of variance (CV) of less than 15% and 84.0% with CV’s below 
30% (Table 4.3). The data generated by GC-MS was also shown to be measuring 11248 
(signal/noise > 5) metabolite features, however the reproducibility of the data is poor with 
only 1.5% of metabolite features showing CV’s of less than 15% and 12.3% below 30% 
CV’s. To improve the reproducibility, the data was normalized to total ion count (TIC), 
with this normalization significantly improving the reproducibility with 34.4% of total 
peaks now with CV’s of less than 15% and 68.7 below 30%, however normalization 
appeared to have a limited effect on the LC-MS data. The initial selectivity and 





the pilot experiment. As with the data generated from brain tissue the LC-MS data was 
shown to be measuring a total of 9551 metabolite features as well as highly reproducible 
with 36.9% of peaks showing CV’s of less than 15%, and 61.8% below 30% CV’s, whilst 
9.8% of the 7715 of the GC-MS metabolite features showing CV’s lower than 15% and 
only 17.3% with CV’s below 30%. The data when normalized to TIC, produced a modest 
increase in the reproducibility of the RP data from 33.3% and 74.0% to 50.7% and 75.2% 
and HILIC data from 41% and 60.5% to 50.5% and 71% with CV’s below 15% and 30% 
respectively. Normalization of the GC-MS data also improved reproducibility from 16.5% 
to 30.9% to CV’s below 15% and 30%. Inspection of the non-aqueous phase data which 
shows the least number of features with CV’s <30% compared to LC-MS and GC-MS 
aqueous method. However, during method development the non-aqueous phase achieved 
CV’s in line with the brain experiments shown in Table 3. The aqueous phase showed 







Table 4.3. Reproducibility of RAW and TIC normalized data generated by each analytical method from brain tissue samples. Variability of metabolite 
features measured in 7 independent IVDE’s from rat cerebellum.  
 HILIC Pos HILIC Neg RP Pos RP Neg GC Aqueous GC-non aqueous 
 RAW
a       TICb RAWa       TICb RAWa       TICb RAWa       TICb RAWa       TICb RAWa       TICb 
<5%c 676 658 299 388 168 184 196 94 2 247 5 399 
5-10%c 724 733 613 492 443 407 303 411 11 495 9 512 
10-15%c 853 838 555 483 389 336 267 249 87 1147 64 1069 
15-30%c 711 724 762 804 746 801 241 248 594 2119 611 1745 
>30%c 309 320 524 586 653 671 27 32 5398 2084 4467 1431 
Total 3273 2753 2399 1034 6092 5156 
a peak numbers for raw data b peak numbers for TIC normalized data c coefficient of variance of peak intensity between runs. GC; gas chromatography, 
HILIC; hydrophilic liquid interaction chromatography, Neg; negative, Pos; positive, RP; reversed phase. 
 
Table 4.4: Reproducibility of RAW and TIC normalized data generated by each analytical method from plasma samples. Variability of metabolite features 
measured in 8 pooled QC samples.  
 HILIC Pos HILIC Neg RP Pos RP Neg GC Aqueous GC-non-aqueous 
 RAWa       TICb RAWa       TICb RAWa       TICb RAWa       TICb RAWa       TICb RAWa       TICb 
<5%c 592 668 102 336 78 175 56 241 18 87 3 17 
5-10%c 684 794 458 473 203 398 236 272 95 254 6 29 
10-15%c 349 447 256 284 261 369 230 253 609 809 27 58 
15-30%c 668 748 488 472 1029 837 213 196 522 925 72 212 
>30%c 1167 803 1180 919 996 788 305 78 2048 1217 4315 4107 
Total 3460 2484 2567 1040 3292 4423 
a Peak numbers for raw data b peak numbers for TIC normalized data c coefficient of variance of peak intensity between runs. GC; gas chromatography, 





Having shown the method was reproducible the next stage in assessing its performance 
was to determine its ability to detect differences in a small pilot between biological classes 
using multimodal multivariate data analysis. Curated models were generated using both 
raw and TIC normalized data from all the 6 platforms combined into a single dataset to 
identify the metabolite features with the greatest predictive performance for 
discriminating diagnostic classes. The optimal model calculated between control and AD 
samples from the combination of all LC-MS and GC-MS raw data was based on 314 
metabolite features, and showed a significant class separation (R2X = 0.489, R2Y = 0.903, 
Q2 = 0.794, CV-ANOVA = 1.418×10-11). However, in the same comparison a better 
separation was achieved by using the TIC normalized LC-MS and GC-MS data, with the 
final curated model based of 426 features (Figure 4.3A) (R2X = 0.585, R2Y = 0.933, Q2 
= 0.869, CV-ANOVA = 2.72×10-14). Of the 426 metabolite features on which this model 
is based 95 were measured in HILIC positive, 84 were measured in HILIC negative, 63 
came from RP positive, 72 from RP negative, with GC aqueous accounting for 69 and 
GC Non-aqueous for 43 of the features. In both the OPLS-DA (Figure 4.3A) and PCA 
(Figure 4.3B) analysis there is a visible separation between controls and AD, but also 
between the control samples themselves, the stable (control A) and declining control (B) 
samples. To investigate this further we performed hierarchical clustering analysis (HCA) 
(Figure 4.3C) to assess the compositional similarity of individual samples from the three 
sample groups. This analysis showed that the ‘declining’ control samples clustered in the 
same primary clade as the AD samples suggesting that they were more compositionally 
similar to the AD samples than they were to the ‘stable’ controls. Whilst these samples 
were diagnosed clinically as controls and showed no difference in cognitive ability at 
baseline, at a 12 month follow up these individuals had exhibited a significant decline in 
cognitive function (0.83 MMSE points, p = 0.019). When metabolite features were 
considered individually it could be seen that the ‘declining’ controls had a similar 
abundance to that which is observed in the AD samples or is intermediary between the 








Figure 4.3 Multivariate analysis of all data using OPLS-DA and PCA scores plots and HCA 
dendrogram. A) PCA analysis (R2X = 0.561, Q2 = 0.498) based on the 426 metabolite features 
identified in curated OPLS-DA model, B) curated OPLS-DA model of healthy controls vs. AD 
patients (R2X = 0.585, R2Y = 0.933, Q2 = 0.869, CV-ANOVA = 2.72×10-14), C) HCA based on 
the PCA model to analyze compositional similarity of individual samples. In figure 4.3A and 4 
.3B, blue circle refer to AD (Alzheimer’s disease) samples and red circle refer to Control samples. 
 
Having shown the ability of this method to discriminate controls from AD, the next step 
was to determine if the method could detect more subtle differences by looking for gender 
specific differences in metabolite composition. A curated 4 class OPLS-DA was 
generated model based on 808 metabolite features (R2X = 0.639, R2Y = 0.643, Q2 = 
0.473, CV-ANOVA = 1.73×10-7), the primary separation in the first component was 
between controls and AD samples (Figure 4.4A) of both genders. Whilst no difference is 
seen in the control samples, there does appear to be a modest separation between the male 
and female AD patients. HCA was performed to assess this difference further (Figure 
4.4C). This analysis confirmed that male and female AD patients are compositionally 
distinct both from each other and from controls, with female patients being more different 
to controls than males. This finding is potentially unsurprising owing to women’s greater 








Figure 4.4 Gender specific analysis of all data that passed QC using a range of multivariate 
analysis approaches shown using A) PCA B) OPLS-DA and scores plots and C) HCA 
dendrogram.  
 
Having observed that this method could discriminate between defined biological classes 
we wanted to determine whether metabolite composition could be directly correlated with 
a range of relevant clinical measures. Determining the association between metabolite 
composition and clinical outcomes was done using OPLS analysis with MMSE, age and 
ADCS-ADL set as Y variables. Using SIMCA’s inner relations plot it can be seen that 
metabolite composition correlates with MMSE (Figure 4.5A) (R2 = 0.893), age (Figure 
4.5B) (R2 = 0.636) and ADCS-ADL (Figure 4.5C) (R2 =0.634). This direct correlation of 
metabolite composition to clinical outcomes further demonstrated biological relevance of 






Figure 4.5 Inner relations plots of OPLS models demonstrating significant correlations between 
metabolite composition and a range of clinical outcomes. A) MMSE (R2 = 0.893), B) age (R2 = 
0.636), and C) ADCS-ADL (R2 = 0.634) 
 
Metabolite annotation was performed by searching the m/z of measured metabolite 
features in a range of publicly accessible metabolite databases including the human 
metabolome database (HMDB), METLIN and LipidMap, by matching the fragmentation 
pattern of the peak being annotated to the fragmentation pattern shown for metabolites 
within the databases. In addition, some standards are available for these compounds 
allowing fragmentation spectra of these metabolites to be identified and easily confirmed.  
 
 Of the metabolite features that were important for driving the separation between the two 
groups of controls we annotated the excitatory neurotransmitter glutamate (Figure 4.6) 
which has previously been linked to the pathology and progression of Alzheimer’s disease 






Figure 4.6 Boxplots showing examples of features discriminating between all three diagnostic 
groups. The feature name is the mode of chromatography followed by the ionization mode, then 
the feature mass and retention time in minutes. AD; Alzheimer’s disease, HILIC; hydrophilic 
liquid interaction chromatography, QC; quality control. 
 
In this small pilot, metabolic shifts potentially associated with subtle differences in 
biological phenotypes were observed. Hence, this multimodal method was able to 
discriminate ‘stable’, ‘declining’ controls and AD patients using a PCA, however 
promising this result, the number of samples does not warrant metabolite identification 
and validation using larger scale study is needed. 
 
4.4 Conclusions 
The study presented here in chapter 4 illustrates the utility of combining metabolomics 
data to measure large numbers of metabolite features from small sample volumes with 
multivariate statistics, to detect metabolic differences. Applying multimodal data to 
discriminate AD patients from healthy controls, also showed correlation of metabolite 
composition to clinical outcomes including mini-mental state examination (MMSE), age 
and Alzheimer’s disease cooperative study scale – Ability of Daily Living (ADCS-ADL). 
In the next chapter, the metabolomics multimodal data protocol performed in this chapter 
combined with developed LC and GCMS methods (Chapter 2 and 3) will be applied to 












CHAPTER 5: Brain metabolomics identifies 













Extracellular accumulation of amyloid-β (Aβ) plaques and intracellular accumulation of 
neurofibrillary tangles are the pathological hallmarks of AD. A growing body of evidence 
suggests that metabolic perturbations in various pathways may mediate the occurrence of 
Alzheimer pathology as well as the onset of cognitive impairment in patients [314]. The 
application of large- scale unbiased metabolomics techniques to study the role of 
metabolism in Alzheimer pathogenesis may facilitate a more complete understanding of 
Alzheimer pathology and mechanisms triggering symptom expression. Several 
metabolomic studies have previously examined the relationship between metabolism and 
AD pathology. While studies on serum, plasma, and cerebrospinal fluid have identified 
several metabolic pathways involving bile acids, sphingolipids, antioxidants, 
phospholipids, and amino acids that appear to be associated with disease [68, 181, 190, 
193, 315, 316], it is likely that metabolomic studies on human brain tissue samples may 
provide direct insights into the molecular basis of Alzheimer pathogenesis. A handful of 
studies have performed metabolomics on brain tissue samples from both transgenic 
animal models and humans. Salek et al. found alterations in neurotransmitters, amino 
acids and antioxidants to be strongly associated with AD [2]. Graham et al.  used 
metabolomics to analyze human brain neocortex samples (15 controls versus 15 AD) and 
were able to differentiate controls and AD samples [210]. Inoue et al. analyzed the parietal 
and frontal lobes of healthy controls and Alzheimer patients (10 versus10) and identified 
increased brain polyamine metabolism in AD brains [239]. 
 
In AD, there is a regional specificity in the vulnerability of various brain regions to 
pathology, with some regions exhibiting greater amyloid pathology whilst others are 
dominated by neurofibrillary tangles [317, 318]. However, previous studies have not 
examined changes in brain metabolite profiles in relation to the regional distribution of 
disease pathology. Equally important, few studies have addressed the relationships 
between brain metabolite signatures and the manifestation of clinical symptoms of AD in 
response to pathology. It is now well recognized that substantial levels of Alzheimer 
pathology can occur in the brains of cognitively normal individuals [319]. In the 





individuals as “asymptomatic” (ASM) [320], i.e., subject with significant AD 
neuropathology at death but without evidence for cognitive impairment during life, as 
assessed by longitudinal cognitive assessments. 
 
In this study, we applied untargeted metabolomics to brain tissue collected through the 
autopsy sample of the BLSA in three groups of individuals (AD; N = 14, control; N = 14 
and ASM; N = 15) and studied differences in brain metabolite levels within regions both 
vulnerable and resistant to AD pathology. We thus examined the middle frontal gyrus 
(MFG; vulnerable to Aβ deposition), inferior temporal gyrus (ITG; vulnerable to tau 
deposition), and the cerebellum (CB), which is relatively spared of classical AD 
pathology [321]. 
 
The relationships between metabolic shifts and specific features of Alzheimer pathology 
and disease outcome were assessed by applying untargeted metabolomics utilizing LC-
MS and GC-MS method presented in chapter 2 and 3 to maximize the metabolite 
coverage obtained. 
 
5.2 Materials and methods 
5.2.1 Sample information 
The ethics approval was obtained from the Institutional Review Board of the University 
of Maryland Baltimore County (03-AG-0325). The BLSA is a prospective, ongoing 
cohort study of community dwelling volunteer participants in Baltimore that originated 
in 1958. As such, it is among the largest and longest running longitudinal studies of aging 
in the United States [322, 323]. In general, at the time of entry into the study, participants 
had no physical or cognitive impairment. Detailed examinations, including 
neuropsychological assessments and neurological, laboratory, and radiological 
evaluations, were conducted every 2 years. Since 2003, participants older than 80 years 
have received yearly assessments. Written informed consent was obtained at each visit, 
and the study was approved by the local Institutional Review Board and the National 





diagnosis conferences relying on information from neuropsychological tests as well as 
clinical data as described previously[324]. Diagnoses of dementia and AD were based on  
the NINCDS-ADRDA criteria [6]. 
 
Table 5.1 Clinical Characteristics of study participantsa. 
 CN ASM AD 
Samples (Region)b 40 (11/15/14) 39 (9/15/15) 44 (15/15/14) 
Genderc 7/33 12/27 23/21 
Age 81 +/- 10.7 85.5 +/- 8.4 77.6 +/- 9.9*** 
MMSEd 27.8 +/- 2.4 29.0 +/- 0.9* 23.0 +/- 6.9** 
 a values are reported as the mean +/- standard deviation, and range, b total number of samples 
analysed per diagnostic class and the number of these samples split between three brain regions 
CB/MFG/ITG, c gender distribution (female/male),. dMMSE: Mini-mental state examination, , 
Significance relative to controls * <0.05,**p<0.01,***p<0.001. ASM, asymptomatic; CN, 
control; AD , Alzheimer. 
 
5.2.2 Chemicals and reagents 
All solvents and reagents, water, methanol, acetonitrile, ammonium formate, formic acid, 
and methyl tertiary butyl ether (MTBE), were LC-MS grade purchased from Sigma-
Aldrich. Two internal standards for LC-MS analysis were added, L-serine 13C3 15N (95%) 
and L-valine 13C5 15N (95%), purchased from Sigma-Aldrich Sample derivatization for 
GC-MS analysis was performed using N,O-Bis (trimethylsilyl) trifluoro-acetamide 
(BSTFA) with 1% trimethylchlorosilane (TMCS) purchased from Sigma-Aldrich. 
 
5.2.3 Sample preparation 
The in-vial dual extractions were performed as previously described[303]. After LC-MS 
analysis, the remaining aqueous and non-aqueous phases were split into separate vials 
and dried down under a stream of nitrogen at 37˚C. Samples were then resuspended in a 
1:1 solution of acetonitrile and the derivatizing agents N,O-
Bis(Trimethylsilyl)trifluoroacetamide and 1% Trimethyl- chlorosilane, and were 
incubated at 37˚C for 1 h. After incubation, samples were again dried down under 






5.2.4 Metabolite acquisition 
Samples were analysed using HILIC-LC/MS, AQ and NAQ GC/MS. Analysis settings 
are described in detail in chapter 2, section 2.2.7 (HILIC-LC/MS) and chapter 3, section 
3.2.5.  
 
5.2.5 Data processing 
Initially, all raw data files were converted into.mzXML format, LC-MS files were 
converted using msConvert (ProteoWizard) whilst GC-MS files were converted using 
GCMS Solutions (Shimadzu). Converted data files were analysed using XCMS and 
performed in the open source software package R, with peak picking performed on all 
MS assays using a “centwave” method, which allows the deconvolution of closely eluting 
or slightly overlapping peaks. After peak picking, metabolite features were defined as 
peaks with an average intensity 5 times higher in analytical samples than is measured in 
the extraction blanks. Metabolite features were analysed using a range of multivariate 
tests, with all the data logarithmically transformed (base10) and scaled to unit variance 
(UV), including principal component analysis (PCA) and partial least square discriminant 
analysis (PLS-DA) performed in SIMCA 13.0.4 (Umetrics, Umeå, Sweden). Model 
performance was assessed based on the cumulative correlation coefficients (R2X[cum]) 
and predictive performance based on 7-fold cross validation (Q2[cum]), with the 
significance of the model assessed based on the ANOVA of the cross-validated residuals 
(CV-ANOVA). Feature selection to create curated models was performed by iteratively 
removing metabolite features that had a score of less than 1 in the variable importance to 
projections plot to achieve the fitted model with the optimal R2 and Q2 values. All 
metabolite annotations were made by matching metabolite fragmentation patterns to those 








Figure 5.1 Data processing workflow. TIC: Total ion count, S/N: Signal to noise, PCA: Principal 
Componenet Analysis, PLS-DA: Partial least square discriminant analysis, VIP: Varible 






To compare the fatty acids among three groups (CN, ASM, and AD), we used 
nonparametric Kruskal–Wallis test for testing the null hypothesis that all three groups are 
equal and Mann–Whitney U test for pairwise comparisons. To control for type 1 errors 
in the p-values calculated using the Mann-Whitney U test, two false discovery rate 
strategies were employed. The first was to determine which p-values passed a Bonferroni 
corrected significance threshold and the second was to subject the p-values to a 
Benjamini-Hochberg procedure performed in “R.”. Pearson’s correlation coefficient 
applied to calculate the correlation of the abundance of unsaturated fatty acids and 
measures of amyloid-β and tau pathology. To evaluate the effect of fatty acids on 
longitudinal cognitive performance, we created domain-specific composite scores. We 
standardized each of the cognitive measures (using their baseline mean and standard 
deviation) and averaged the corresponding Z scores to form the composite score. Trail 
making tests A and B were first log transformed and then standardized. The following 
five cognitive domains were created: memory is the composite score of California Verbal 
Learning Test (CVLT), CVLT long delay free recall and learning and immediate free 
recall, attention is the composite score of Trail making test A and WAIS-R Digits 
Forward, executive function is the composite score of Trail making test B and WAIS-R 
Digits Backward, language is the composite score of letter fluency and semantic fluency, 
and visuospatial ability is the composite score of clock drawing and card rotation tests. 
 
We then used separate linear mixed models with each cognitive domain as the outcome 
variable. The main predictor time (or time of follow up) was anchored at the last visit, 
and all the previous longitudinal follow-up visits were negative relative to the last visit. 
This kind of recentering of the time variable allows us to test the effect of the levels of 
each fatty acid on the cognitive performance at last visit and cognitive rates of change 
simultaneously in a single model. The predictors included fatty acid levels, sex, age at 
last visit, time, and interactions of time with fatty acid levels, sex, and age at last visit. 







 5.3.1 LC-MS  and GC-MS  analysis 
The brain IVDE method described in Chapter 2(HILIC) and 3(GC-MS AQ and NAQ) 
were used to analyse the brain samples. The clinical characteristics of the three diagnostic 
groups analysed are summarised in Table 5.1. The three groups are not balanced for either 
age or gender, with the Alzheimer’s group having significantly more female participants 
and lower mean age relative to both controls and asymptomatic patients. In this study, a 
total of 4,897 metabolite features were measured, 3,482 by LC-MS and 1,415 by GC-MS. 
Of these measured metabolite features, 126 were successfully annotated, representing 100 
structurally distinct metabolites (Appendix C-Table 5.1).  
 
5.3.2 Method assessment and Data quality test (PCA) 
Following sample analysis, data from the 124 brain samples and the 22 QC underwent 
PCA analysis in SIMCA 14 to assess intra batch reproducibility. The %RSD of the three 
IS used were reported at less than 30 % across both samples and QCs, which is 
recommended in bioanalytical method validation, this ultimately shows the values 
obtained have acceptable reproducibility. In QC samples, %RSD was more reproducible 
with less than 15% variation (Table 5.2). 
 






%RSD across all 
sample 
run(n=124) 
% RSD in QC 
raw signal 
intensity 
RT(min) / % 
RSD of RT 
 
Histidine HILIC (Positive) 17.38 7.38 12.17/0.2 
Valine HILIC (Positive) 14.58 4.58 14.80/0.2 
Serine HILIC (Positive) 23.96 9.96 17.18/0.3 
Histidine HILIC (Negative) 13.09 3.79 12.17/0.2 
Valine HILIC (Negative) 10.47 3.01 14.80/0.1 
Serine HILIC (Negative) 19.95 8.91 17.09/0.2 
HILIC=Hydrophilic Interaction Liquid Chromatography, QC =Quality Control samples, RT=Retention 





 5.3.3 Partial least square discriminant analysis of HILIC-LC-MS and GC-MS 
data. 
Multivariate models were constructed based on all 4,897 metabolite features to assess the 
effects of both brain region and pathological diagnosis on metabolite composition. In 
curated PLS-DA models, it can be seen that both brain region (Figure 5.2A: R2X = 0.639, 
R2Y = 0.622, Q2 = 0.608, cross validated ANOVA [CV-ANOVA] = 5.65 × 10−33) and 
pathological diagnosis (Figure 5.2B: R2X = 0.499, R2Y = 0.439, Q2 = 0.404, CV-ANOVA 
= 4.72 × 10−21) are significantly associated with metabolite composition. The PLS-DA 
scores plots (Figure 5.2A) show that all three of the brain regions possess unique 
metabolite compositions, whilst the MFG and the ITG are compositionally distinct, 
shown by a modest separation in the second component (t[2]), and are more similar to 
each other than they are with the CB (Figure 5.2A), which is highly compositionally 
distinct, as shown by a clear separation in the first component (t[1]). As with the brain 
regions, PLS-DA analysis showed that the three diagnostic groups possessed unique 
chemical compositions, with less difference observed between control and ASM, shown 
by the modest separation in the second component, with the AD groups the most distinct 
with the greatest separation in the first component. 
 
 
 Figure 5.2 Scores plots from curated PLS-DA models comparing the metabolite composition of 
brain regions and diagnostic groups. A) Comparison of metabolite composition of cerebellum 
(CB), inferior temporal gyrus (ITG) and medial frontal gyrus (MFG) (R2X = 0.639, R2Y = 0.622, 
Q2 = 0.608, CV-ANOVA = 5.65×10-33) B) Comparison of metabolite composition of diagnostic 
groups, control, asymptomatic and demented (R2X = 0.499, R2Y = 0.439, Q2 = 0.404, CV-







Figure 5.3 Scores plots from curated PLS-DA models comparing the metabolite composition of 
diagnostic groups in individual brain regions. A) Comparison of metabolite composition of 
diagnostic groups, control, asymptomatic and Alzheimer’s  in cerebellum samples (R2X = 0.527, 
R2Y = 0.539, Q2 = 0.424, CV-ANOVA = 5.04×10-4), B) Comparison of metabolite composition 
of diagnostic groups, control, asymptomatic and demented in medial frontal gyrus samples (R2X 
= 0.592, R2Y = 0.563, Q2 = 0.424, CV-ANOVA = 3.28×10-7), C) Comparison of metabolite 
composition of diagnostic groups, control, asymptomatic and demented in inferior temporal gyrus 
samples (R2X = 0.650, R2Y = 0.563, Q2 = 0.490, CV-ANOVA = 1.62×10-5). 
 
Having shown that AD pathology is significantly associated with brain metabolite levels, 
we then examined specific metabolites and metabolic pathways driving the observed 
shifts. The metabolite features that were used to generate the optimal curated PLS-DA 
models in all three diagnostic groups were taken forward for further analyses of their 
relationships to AD pathology and disease status. The optimal curated PLS-DA model 
was comprised (Figure 5.2B) of 876 metabolite features putatively representing 160 
metabolites as associated with diagnostic status, with 32 of these metabolites annotated 
(Table 5.3).  
 
Having shown that metabolite composition differs significantly between diagnostic 





replicated in each brain regions individually. It can be seen in Figure 5.3 that the pattern 
observed was replicated in each of the three brain regions. 
 Table 5.3 Annotated metabolites identified as being important compositional differences between 
the three diagnostic groups. 
 CN VS ASM CN VS AD 
 p-value FC p-value FC 
Cholesterol 7.5×10-3 0.74 6.8×10-8*+ 0.53 
Linoleic Acid 7.3×10-3 0.74 8.8×10-8*+ 0.52 
Cholestenol 1.0×10-1 1.17 1.0×10-7*+ 1.44 
Docosahexanoic acid 1.7×10-1 1.14 1.7×10-7*+ 1.45 
Carbamic acid 1.9×10-1 1.15 2.0×10-7*+ 1.53 
Methylheptadecadiynoic acid 2.4×10-2 0.79 2.8×10-7*+ 0.59 
Oleic acid 5.5×10-2 0.73 3.3×10-7*+ 0.34 
Palmitic acid 1.9×10-2 0.73 4.8×10-7*+ 0.44 
Hexanedioic acid 2.7×10-1 1.11 6.4×10-7*+ 1.42 
Dimethylglycine 2.9×10-2 0.89 1.0×10-6*+ 0.74 
Guanidobutanoate 1.9×10-1 0.94 3.7×10-6*+ 0.75 
Ascorbate 1.5×10-1 1.20 1.9×10-5*+ 1.54 
Aminobutanal 6.7×10-2 0.94 9.1×10-5*+ 0.86 
Gluconic acid 1.4×10-2 1.31 1.0×10-4*+ 1.51 
Cysteine 4.7×10-1 1.06 1.0×10-4*+ 1.33 
Aspartate 6.2×10-2 1.17 1.5×10-4*+ 0.84 
L-DOPA 9.2×10-2 1.11 1.8×10-4*+ 1.23 
Fumaric acid 4.4×10-2 0.91 1.9×10-4*+ 0.85 
Linolenic acid 7.5×10-2 0.90 2.5×10-4*+ 0.84 
Indoleacetic acid 1.4×10-1 0.93 2.6×10-4*+ 0.82 
Eicosapentaenoic acid 1.6×10-3 0.25 4.4×10-4* 0.16 
Allantoin 6.9×10-3 1.19 4.6×10-4* 1.30 
Hypoxanthine 4.7×10-1 0.98 5.4×10-4* 0.88 
Coumaric acid 5.9×10-2 1.16 7.6×10-4* 1.28 
Adenine 9.2×10-2 1.10 8.0×10-4* 1.18 
Oxoarginine 9.0×10-1 0.99 8.6×10-4* 0.77 





Arginine 5.7×10-2 1.24 1.1×10-3* 1.38 
GABA 3.6×10-1 1.07 4.4×10-3 1.18 
Myo-Inositol 5.7×10-1 1.09 6.6×10-3 0.70 
Methylstearate 5.4×10-1 0.85 2.6×10-2 0.56 
Octadecanal 1.6×10-1 2.41 5.6×10-1 0.68 
DOPA: dihydroxy-phenylalanine, GABA: gamma-aminobutyrate. * passes FDR using  
Benjamini-Hochberg correction (0.05 threshold), + significant pass Bonferroni correction. ASM, 
asymptomatic; CN, control; AD , Alzheimer. 
 
5.3.4 Feature selection and structural elucidation  
These annotated metabolites were subsequently mapped onto known metabolic pathways 
using the Kyoto Encyclopedia of Genes and Genomes’ pathway mapping tool [325]. This 
approach identified 113 metabolic pathways that contained at least one of the 31 
metabolites. Of these 113 metabolic pathways, poly-unsaturated fatty acid (PUFA) 
metabolism was identified for more detailed analysis, as the metabolites in this pathway 
showed the strongest association with diagnostic status. 
 
In GC-MS, Six PUFA were identified using NIST and IEM libraries with a similarity 
index over 90%. These are linoleic acid, linolenic acid, eicosapentanoic acid (EPA), oleic 
acid, arachidonic acid (AA) and Decosahexanoic acid(DHA). Calculated degree of 
similarity (similarity index). This is 100 when the spectra are perfectly identical.  GC-MS 
applies electron ionization mode with 70 eV which can provide a standard spectrum for 
each compound, so it can compare samples with the database directly. This increases the 
efficiency and help to identify unknowns. This is an advantage of GC-MS over LC-MS 
as in the latter fragmentation is not as reproducible between instruments and identification 
is difficult. 
 
We were able to run three PUFA standards, AA, EPA and DHA . Figure 5.4 ,5.5 & 5.6 
represent the spectra obtained by similarity search results of the three Standards. This was 
matched with results of identified PUFA and validate the identification results for PUFA 
peaks in brain samples (also the the six identifies PUFA were the highest similarity index 







Figure 5.4 Spectrum of DHA analysed by GC-MS. The top spectrum shows the target spectrum 




Figure 5.5 Spectrum of EPA analysed by GC-MS. The top spectrum shows the target spectrum 









Figure 5.6 Spectrum of AA analysed by GC-MS.  The top spectrum shows the target spectrum of 
AA that is the subject of the search. The bottom spectrum shows the spectrum registered in the 
library. 
 
PUFA abundance in human brain regions 
Table 5.4 and Figure 5.7 summarize results of analyses comparing brain tissue (PUFA) 
levels between the three groups. The overall pattern of results showed that brain tissue 
levels of the PUFAs, linoleic acid, linolenic acid, EPA, oleic acid, and (AA) were reduced 
in the ITG and MFG regions in AD relative to the control group. The AD group showed 
higher tissue levels of DHA in the ITG and MFG regions relative to controls. Within the 
CB, EPA levels also appeared to be lower in AD with oleic acid levels showing a similar 
trend relative to controls. Cerebellar DHA levels in AD were also higher relative to 
controls. Within the MFG, decrements in the levels of oleic acid, linoleic acid, linolenic 
acid, and arachidonic followed the pattern control> ASM >AD. Increments in DHA levels 
in the MFG followed the pattern AD>ASM >control. Six PUFA’s, oleic acid, linoleic 
acid, linolenic acid, DHA, and EPA were shown to be highly associated with disease. 
Except for DHA all of the measured PUFA’s were reduced in abundance with disease with 
only DHA increased in abundance (Table 5.4).  These trends showed that whilst each of 





however the shifts in the ITG appear to occur at an earlier stage of disease with the shifts 
in these metabolites equal to greater in asymptomatic patients relative to controls than is 
observed in Alzheimer’s patients (Figure 5.7), whilst in the CB and MFG Alzheimer’s 













Table 5.4  Relative changes in abundance of 6 poly-unsaturated fatty-acids between all three diagnostic groups in individual brain regions. 
P: P-value calculated using mann-whitney U-test. b fold change relative to controls, c fold change relative to asymptomatic, * passes FDR using 
Benjamini-Hochberg correction (0.05 threshold), + significant pass Bonferroni correction. CB; Cerebellum, ITG; Inferior Temporal Gyrus, MFG; 





 CN Vs ASM CN Vs AD ASM Vs AD 
 CB ITG MFG CB ITG MFG CB ITG MFG 






Pa FCb Pa FCc Pa FCc Pa 
FC
c 
Linoleic acid (ω-6) 7.6×10-1 1.08 6.5×10-2 0.66 7.7×10-2 0.61 3.5×10-4* 0.42 9.0×10-3 0.57 2.3×10-1 1.34 2.4×10-1 0.86 1.0×10-5*+ 0.77 2.7×10-5*+ 0.47 
Oleic acid (ω-9) 1.1×10-1 1.67 1.0×10-1 0.50 4.7×10-3 0.30 7.2×10-4* 0.26 1.0×10-2 0.43 2.9×10-1 1.64 1.6×10-1 0.77 5.1×10-5*+ 0.61 3.7×10-6*+ 0.27 
Docosahexanoic 
acid (ω-3) 
8.9×10-7*+ 0.34 4.5×10-2 1.24 
3.1×10-
8*+ 
3.67 2.0×10-3 1.43 2.1×10-2 1.30 1.6×10-1 0.91 2.9×10-3 1.49 3.3×10-6*+ 1.06 1.4×10-3 1.26 
Arachidonic acid 
(ω-6) 
6.1×10-1 0.90 1.1×10-1 0.87 8.4×10-1 0.96 1.6×10-3 0.78 3.0×10-2 0.83 4.1×10-1 1.07 8.3×10-1 1.02 2.8×10-2 0.78 9.0×10-6*+ 0.76 
Linolenic acid(ω-3) 
3.3×10-1 0.83 6.9×10-2 0.88 7.9×10-1 1.04 5.9×10-4* 0.81 1.9×10-2 0.86 3.1×10-1 1.06 8.3×10-1 1.02 4.6×10-2 0.81 4.8×10-6*+ 0.80 
Eicosapentaenoic 
acid (ω-3) 






   Figure 5.7  Boxplots showing the effect of disease status on the abundance of six PUFAs in the CB, ITG, and MFG. Dysregulation of six PUFAs shown                                                                                             
   by boxplots of three disease statuses separated by brain region.  A) arachidonic acid (AA), B) oleic acid (OLA), C) eicosapentaenoic acid (EPA), D)  





5.3.5 Correlation analysis of selected PUFA  
As well as associating with disease status, levels of all six PUFA’s in the MFG and ITG 
were shown to correlate significantly with both measures of neurofibrillary pathology 
estimated by Braak score and amyloid plaque burden assessed by the CERAD score 
(Table 5.6).  
Table 5.5 Correlation analysis of the abundance of unsaturated fatty acids and measures of 
amyloid-β and tau pathology. 
  Braak CERAD 




Eicosapentaenoic acid -0.310 0.0959 -0.3540 0.0550 
Linoleic -0.129 0.4974 -0.1933 0.3060 
Arachidonic acid -0.111 0.5590 -0.1848 0.0328 
Oleic acid -0.280 0.1334 -0.2744 0.1423 
Docosahexanoic acid 0.411 0.0239 0.3376 0.0680 




Eicosapentaenoic acid -0.332 0.0415 -0.3577 0.0275 
Linoleic -0.382 0.0179 -0.3492 0.0317 
Arachidonic acid -0.376 0.0199 -0.3641 0.0246 
Oleic acid -0.335 0.0399 -0.3448 0.0340 
Docosahexanoic acid 0.310 0.0579 0.3227 0.0481 





Eicosapentaenoic acid -0.613 <0.0001 -0.5251 0.0006 
Linoleic -0.572 0.0001 -0.5819 0.0001 
Arachidonic acid -0.564 0.0002 -0.5527 0.0003 
Oleic acid -0.640 <0.0001 -0.6363 <0.0001 
Docosahexanoic acid 0.602 <0.0001 -0.6919 <0.0001 
Linolenic acid -0.634 <0.0001 -0.6673 <0.0001 
Relationships between global measures of amyloid and tau pathologies and the regional 
abundances of 6 unsaturated fatty acids, values highlighted in bold are significant at p<0.05. 






Assessments of brain tissue levels of these PUFA’s in relation to domain-specific 
measures of cognitive performance showed consistent patterns across domains and 
several significant cross sectional and longitudinal associations across the three brain 
regions were found (Appendix C-Tables 5.2-5.6). In general, the pattern of these 
associations showed that lower tissue levels of linoleic acid, linolenic acid, EPA, oleic 
acid, and AA were related to worse cognitive performance, whereas higher brain DHA 
levels were associated with poorer cognitive performance. The strongest associations 
with cognitive performance were between abundance of these fatty acids in the MFG and 
the final premortem memory, attention and executive function scores (Figure 5.10), as 
well as longitudinal trajectories in memory and language performance. The strongest 
association observed in the ITG between levels of these fatty acids was with longitudinal 
trajectory of visuospatial performance (Figure 5.9). 
 
 Figure 5.8 Forest plot showing the relationship of the abundance of six PUFA’s in the CB and 
five measures of cognition. A) association between fatty acid abundance of PUFA levels and 
longitudinal cognitive performance B) associations between fatty acid abundance cognitive 
performance at the last visit prior to death. AA: arachidonic acid, DHA: docosahexaenoic acid, 
EPA: eicosapentaenoic acid, LA: linoleic acid, LNA: linolenic acid, OLA: oleic acid. This figure 






Figure 5.9 Forest plot showing the relationship of the abundance of six PUFA’s in the ITG and 
five measures of cognition. A) association between fatty acid abundance of PUFA levels and 
longitudinal cognitive performance B) Associations between fatty acid abundance cognitive 
performance at the last visit prior to death. AA: arachidonic acid, DHA: docosahexaenoic acid, 
EPA: eicosapentaenoic acid, LA: linoleic acid, LNA: linolenic acid, OLA: oleic acid. This figure 
was produced by Dr.Yang Li and his permission was obtained to present. 
 
 
 Figure 5.10 Fore`st plot showing the relationship of the abundance of six PUFA’s in the MFG 
and five measures of cognition. A) association between fatty acid abundance of PUFA levels and 
longitudinal cognitive performance B) associations between fatty acid abundance cognitive 
performance at the last visit prior to death. AA: arachidonic acid, DHA: docosahexaenoic acid, 
EPA: eicosapentaenoic acid, LA: linoleic acid, LNA: linolenic acid, OLA: oleic acid. This figure 







The metabolic basis of vulnerability to AD pathology and the subsequent expression of 
symptoms of AD are poorly understood. In this study, we applied mass spectrometry-
based metabolomics to human brain tissue samples from a well-characterized longitudinal 
cohort, i.e., the BLSA, to address this issue. Our results suggest that perturbations in brain 
UFA metabolism are closely related to AD pathogenesis. To the best of our knowledge, 
this report is the first to measure brain tissue levels of PUFAs to demonstrate a 
relationship with both severity of AD pathology and the expression of AD symptoms. 
Including brain tissue samples from “ASM” individuals who represent an intermediate 
group in the gradation of neuropathology from controls to AD patients in the absence of 
cognitive impairment during life allowed us to relate measures of brain UFAs to 
incremental levels of AD pathology and symptom expression.  
 
Importantly, by measuring PUFA levels in brain regions both vulnerable to distinct 
pathological features of AD, i.e., MFG (amyloid deposition) and ITG (tau accumulation) 
as well as in a region relatively resistant to AD pathology, i.e., CB, we were able to ask 
whether the observed alterations in these metabolites were related to AD-defining 
pathological processes. We can categorize our results broadly as follows: 
 
i. In the CB, the observed shifts in the abundance of the six UFAs measured do not follow 
a consistent trend (Figure 5.7) as observed in both the ITG and MFG, which are 
vulnerable to tau and amyloid pathology, respectively. Consistent shifts in the abundance 
of the UFAs are observed in the ITG, with the greatest difference between control and 
ASM participants. Consistent shifts are also observed in the MFG, with the ASM group 
being intermediate (Control>ASM >AD). 
 
ii. There is an extensive body of literature exploring the potential mechanisms of 
Alzheimer pathology[326-328]  with a number of metabolomic studies having examined 
associations with AD[190, 193, 256] , however few have studied these differences in 





differences between three diagnostic groups, i.e., healthy controls, AD, and ASM, i.e., 
individuals with significant levels of Alzheimer pathology, but with no cognitive 
`1impairment during life (Figure 5.2). The overall pattern of metabolite shifts observed in 
the brain was mirrored in each of the individual brain regions (Figure 5.3), with the 
metabolism of PUFA’s discriminating between the clinical groups in all brain regions. 
 
iii. Whilst the CB was included in this study as a brain region showing low levels of 
Alzheimer pathology, we did observe significant alterations in the levels of the six PUFA’s 
in this region relative to controls, suggesting that both Alzheimer pathology and other non-
AD-related processes may contribute to or result from the metabolic differences observed 
in this brain region [235]. 
 
Previous studies have examined the abundance of PUFA’s in the brain of AD patients. 
Nasaruddin et al. [329] reported that the abundance of 20 fatty acids was increased in 
Brodmann’ 7 region of late stage AD patients. Four of these species, i.e., oleic, linoleic, 
linolenic, and AA were shown to be reduced in our present study, whereas levels of DHA 
were consistent. Cunnane et al.  measured fatty acids in both plasma and brain tissue 
samples and reported lower levels of esterified DHA in the AD group specifically in 
phosphatidylserine in the middle frontal and superior temporal cortices [330]. It must be 
noted that DHA containing phospholipids are structurally and functionally distinct 
metabolites to the free fatty acids reported in this study. 
 
The PUFAs can broadly be split into two classes, the omega-3 and omega-6 fatty acids. 
Alpha linolenic acid (omega-3) and linoleic acid (omega-6) are both “parental” essential 
fatty acids, both of which are converted into long chain PUFAs, AA from linoleic acid 
and DHA and EPA from linolenic acid. Amtul et al. [331]  performed an in vitro study to 
deter- mine the effect of the omega-6 fatty acids linoleic acid and AA, and the omega-9 
fatty acid oleic acid on the pathology of AD. Linoleic, oleic acid and AA were all shown 
to induce the polymerisation of both tau and Aβ , with AA also shown to induce Aβ42 
formation reducing the observed ratio of Aβ40/Aβ42.  Whilst this information and 





significant body of literature supporting the idea that oleic acid is protective against AD 
[332, 333]. Amtul et al. demonstrated that in in vitro models, oleic acid supplementation 
reduced secreted Aβ levels and validated these findings in a transgenic mouse model fed 
an oleic acid- rich diet [332]. The potential benefits of oleic acid supplementation in 
humans are highlighted by olive oil, which is rich in oleic acid and thought to be 
protective against age-related cognitive decline and onset of AD [332, 334, 335] , In a 
clinical trial, Martinez-Lapiscina et al. showed that patients randomised to an olive oil-
rich diet had better cognitive function compared to those on a control diet [336]. 
 
Dietary supplementation with the omega-3 fatty acids DHA and EPA has also been shown 
to improve cognitive performance in several animal studies of AD [337-340]. Previous 
human studies have also reported promising effects on cognition in individuals receiving 
either DHA, EPA, or a combination of the two [341-343]. The mechanisms by which 
DHA supplementation may impact AD may be by modulating a beta deposition in the 
brain[344] . The potentially protective effects of EPA in the brain may be mediated 
through competitive inhibition of the action of lipoxygenases (LOX) (Figure 5.11), 
cyclooxygenases (COX), and cytochrome P450 (CYP450) against its omega-6 
homologue arachidonic acid (AA) [345-348]. The breakdown of AA by COX and 5-LOX 
produces prostaglandin E2 and leukotriene B4 [347], which, respectively, are both highly 
proinflammatory [348, 54], whilst the breakdown of EPA by these enzymes to produce 
prostaglandin E3 and leukotriene B5 is less efficient [347] and whilst they are also 







 Figure 5.11 Overview of omega-3 and omega-6 PUFA metabolism showing the potential 
association between the measured PUFA’s. Metabolites highlighted in red have been shown to 
pathogenic with metabolites highlighted in green shown to be protective of disease. COX: 
cyclooxygenase, CYP450: cytochrome P450, DHA: docosahexanoic acid, EPA: eicosapentaenoic 
acid, LCD: lineoyl-CoA desaturase, LOX: lipoxygenase, PLA2: phospholipase A2. 
 
PUFAs are also precursors of the eicosanoids, which are a large class of highly potent 
regulatory lipid hormones (Figure 5.11), possessing a wide range of biological functions. 
Studies have shown that DHA and EPA containing phosphatidylcholines (PCs) are 
reduced in abundance in the blood of patients with AD [68, 349, 350]. It has been 
reported that COX, LOX, and CYP450, i.e., enzymes that break down EPA and the other 
five PUFAs measured, have all been shown to be up-regulated in patients with AD [351, 
352], potentially explaining the decrease in the observed PUFA species. Breakdown of 
EPA and other PUFAs by COX leads to the production of prostaglandins with LOX 
breakdown leading to the production of leukotrienes, and breakdown by CYP450 
producing epoxyeicosatrienoic acid, all of which have been associated with pathology in 
a range of diseases including AD [353-355]. The breakdown of DHA by these three 
enzymes produces resolvins, maresins, and protectins, which have been shown to be 







In this chapter, we identified significant differences in the abundance of six PUFAs in 
three brain regions with gradations in these metabolites being related to both severity of 
neuropathology at death as well as domain-specific cognitive performance during life. 
This suggests that dysregulation of PUFA’s metabolism plays a role in AD pathology and 
that these results provide further evidence for the metabolic basis of AD pathogenesis. 































Chapter 6: Comprehensive lipidomics analysis of 
brain reveals changes in sphingolipid metabolism 
in the inferior temporal gyrus (ITG) of patients 
















6.1 Introduction  
As described in the introduction (Chapter 1), AD is accompanied with brain atrophy as a 
result of synaptic loss and neuronal death, and microscopically in the brain by the 
extracellular deposition of Aβ plaques, which arise as result of enzymatic cleavage of 
APP by β- and γ- secretase in sequential order; and the occurrence of NF tangles inside 
neurons, consisting of hyper-phosphorylated tau proteins formed in paired helical 
filaments [361-363]. Early pathological changes in the AD brain occur first in the 
hippocampus and cortex and then extend to the medial temporal lobe which is involved 
in the deficits in memory, hence as the disease progresses cognitive deficits begin to 
show. Other parts of the brain, like the cerebellum and midbrain, are also affected due to 
metabolic changes.  
  
Metabolomics data regarding AD has shown abnormal concentrations of many lipids in 
various tissues, mainly CSF and plasma, suggesting evidence of irregular lipid 
metabolism [68, 182, 364, 365]. This could be related to AD’s main genetic determinant 
APOE4, a lipoprotein that regulates lipid homeostasis by mediating lipid transport from 
one tissue or cell type to another and a major cholesterol carrier that supports lipid 
transport and injury repair in the brain [366, 367]. Many studies have identified 
irregularities in lipids concentration among AD as well as preclinical groups, suggesting 
their role in AD progression [82, 213] .  
A rapidly growing body of literature is highlighting the importance of lipids in cell 
signalling and pathophysiological processes including phospholipids, sphingolipids 
(SPHL) and glycerides. Considering these findings, a comprehensive LC-MS lipidomics 
method of brain tissue was applied in this study based on an untargeted approach 
(described in Chapter 2). To our knowledge, no studies have analysed lipids directly in 
human brain and linked them to the progression of classic hallmarks of AD pathology. 
This is surprising considering that AD is a disease that primarily affects the brain, which 
is known to have the second highest concentration of lipids only behind rich adipose 






 In this chapter, we present a comprehensive lipidomics analysis to identify metabolic 
changes associated with both Aβ and tau pathologies in the inferior temporal gyrus 
(vulnerable to tau deposition) and medial frontal gyrus (vulnerable to Aβ deposition) with 
the cerebellum as a low pathology control. Samples included three diagnostic groups, 
healthy controls, Alzheimer’s patients and a third group of subjects that exhibit high 
levels of tau and amyloid pathology but were cognitively normal (called Asymptomatic 
patients) and that can be assumed to be in the early stages of AD. 
 
All samples were analysed using the RP-LC-MS method described in chapter 2. We then 
carried out the analysis of correlation with pathology parameters (Braak staging (tau) and 
CERAD scoring (Aβ)) and cognition parameters. Our results show a significant increase 
in sphingolipid (SPHL) species in Asymptomatic group (ASM) brain in the Inferior 
temporal gyrus (ITG) region, these also revealed association with tau tangles.  
 
6.2 Materials and Methods 
6.2.1 Samples used for the analysis 
All samples (n=124) were obtained from the Baltimore Longitudinal Study of Aging 
(BLSA), Baltimore, USA. At post-mortem 43 patients were stratified as healthy controls 
(CN), Alzheimer’s patients(AD), and asymptomatic (ASM), patients with significant 
Alzheimer’s pathology without exhibiting cognitive decline during life. Samples of three 
brain regions, cerebellum(CB) as pathology control region, inferior temporal gyrus (ITG) 
with high tau pathology and medial frontal gyrus (MFG) with high Aβ pathology were 
collected from all patients. The clinical characteristics (age, MMSE, PMI) of participants 










Table 6.1 Demographic Characteristics of study participants. a value is reported as the mean 
+/- standard deviation, and range, b values are reported as the mean +/- standard deviation c 
values are reported as the mean +/- standard deviation, and range. MMSE: Mini-mental state 
examination, PMI: post mortem interval, *p<0.05, ** p<0.01***<0.001. ASM, asymptomatic; 
CN, control; AD , Alzheimer. 
 CN ASM AD 
Participants 
(f/m) 
14 (4/10) 15 (5/10) 14 (7/7) 
Age at death 
(Years)a 
82.6 +/-11.0 (64.2-9.2) 89.2 +/- 7.9 (71.9-96.4) 87.9 +/- 8.9 (62.9-98.7) 
MMSEb 27.8 +/- 2.4 29.0 +/- 0.9* 23.0 +/- 6.9** 
Boston 
Naming 
54.4 +/- 4.3 55.2 +/- 3.3 46.7 +/- 6.5*** 
Benton 
Retention 
7.1 +/- 4.6 7.3 +/- 3.0 14.2 +/- 8.47*** 
PMI (Hours) 
c 
16.9 +/- 6.4 (7.0-28.0) 14.8 +/- 8.1 (2.0-33.0) 14.7+/- 6.0 (3.0-23.0) 
 
 
6.2.2 Chemicals and reagents 
Solvents including water, MTBE and methanol were LC-MS grade purchased from 
Sigma-Aldrich (Poole, UK). Ammonium formate and the two internal standards, Cer 
(41:1) and SM (35:1) and commercially available serum samples were also purchased 
from Sigma-Aldrich.  
 
6.2.3 Sample preparation  
Human brain tissues were acquired from the BLSA. For all 124 biopsies, identical 
lipidomics procedures for sample preparation and LC-MS/MS analysis were executed. 
Sample preparation prior to analysis followed brain IVD extraction procedure as 
described in Chapter 2, Section 2.2.5. Samples were then analysed in a randomized order. 
Quality control (QC) samples were composed of a pool of commercially available serum 
samples (n=22) being extracted and analysed every 6 samples. Details of the analytical 






Figure 6.1 Lipidomics Data processing workflow. RP: Reversed phase, TIC: Total ion count, S/N: 
Signal to noise, PCA: Principal Componenet Analysis, PLS-DA: Partial least square discriminant 








Samples were analysed using RP-LC/MS. Analysis was performed using Waters Aquity 
coupled to Waters Xevo QTOF (Waters,Milford, USA). Analysis was completed in both 
positive and negative ionization mode with LC and MS settings designed for each phase 
are described in detail in chapter 2, section 2.2.6.  
 
6.2.5 Data collection and Pre-processing  
All data was collected by Waters Xevo QTOF which used MSe technique, two collision 
energies applied that grant data collection at two levels. The first level obtained data using 
5 V of collision energy, the second level obtained data at higher collision energy of 50 V. 
This can assist in structural elucidation and to simultaneously collect accurate mass of 
parent ion and fragmentation data. 
 
Following LC-MS analysis of samples, the MS raw data were transformed into mzXML 
format using msConvert (ProteoWizard). XCMS software package in R was then used to 
analyse the converted mzXML data files, underwent preprocessing steps of peak picking 
and alignment processed, using a ‘centwave’ method which enables the deconvolution of 
closely eluting or slightly overlapping peaks. Following peak picking, metabolite features 
were defined as peaks with an average intensity five times higher in analytical samples 
than in the extraction blanks.  
 
6.2.6 Data Processing 
Metabolite features were analysed using a multivariate data analysis, including principle 
component analysis (PCA), Partial least square – discriminant analysis (PLS-DA) and 
Orthogonal partial least square – discriminant analysis (OPLS-DA). All were performed 
in SIMCA 13.0.4 (Umetrics, Umeå, Sweden). The performance of the model was 
evaluated using the cumulative correlation coefficients (R2X[cum]) and predictive 
performance based on seven-fold cross validation (Q2[cum]. Feature selection to create 





of <1 to achieve the fitted model with the optimal R2 and Q2 values. The optimal Curated 
PLS-DA model has total of 323 features. Statistical analysis on features of interest was 
performed using one-way ANOVA with multiple comparison testing performed using 
Benjamini and Hochberg applied to TIC normalised data in SPSS software. Spearman’s 
correlation analysis was applied to investigate the correlation with clinical of pathology 
parameters: Braak staging and Cerad score. All correlation analysis was also conducted 
in SPSS 22 (IBM: Armonk, United States). The potential disease pathology indicators 
selection was based on those features exhibiting high magnitude of variation in the s-plot 
with value (p[1]) >0.15  and statistical significance.  
 
6.3 Results  
6.3.1  Brain lipidomics analysis 
The lipidomics brain IVDE method described in Chapter 2 was used to analyse the brain 
samples. A final list of 3023 metabolite features (m/z at retention time) were obtained 
after data pre-processing and alignment using XCMS divided in to 2014 features from 
RP positive ionization mode and 1009 features from negative ionization mode. 
 
6.3.2 Method assessment and data quality  
Following sample analysis, XCMS data underwent PCA analysis in SIMCA 14 to 
overview data and check for outliers. The %RSD of both IS used were reported at less 
than 30 % across samples and QCs, shows the values obtained have acceptable 
reproducibility. In Table 6.2, %RSD in QC samples was lower with <15% variation. IS 
high reproducibility would indicate analytical stability since it is important to ensure the 
reproducibility of the whole run and allow for instrument calibration, this is to asses any 












%RSD across all 
sample run 
(n=124) 




% RSD of RT 
Cer (17:1/24:1) RP (Positive) 18.73 7.8 17.17/0.2 
Cer (17:1/24:1) RP (Negative) 18.51 8.2 22.01/0.2 
SM (18:1/17:0) RP (Positive) 24.66 12.7 11.45/0.4 
RP=Reversed Phase, Cer=Ceramide, SM= Sphingomyelines, %RSD=% Relative Standard 
Deviation, RT=Retention time, QC =Quality Control samples. 
 
6.3.3 Partial Least Square Discriminant Analysis (PLS-DA) of lipidomics data 
PLS-DA models were constructed based on 3023 metabolite features to assess the effect 
of both brain regions and pathological diagnosis on metabolite composition. In curated 
PLS-DA models both pathological diagnosis (Figure 6.2B - R2X = 0.469, R2Y = 0.443, 
Q2 = 0.422, CV-ANOVA = 4.63х10-19) and brain region (Figure 6.2A - R2X = 0.594, 
R2Y = 0.582, Q2 = 0.529, CV-ANOVA = 3.54х10-23) have a significant effect on 
metabolite composition. From the scores plot (Figure 6.2A) it can be observed that ITG 
and MFG regions are more similar to each other although they are metabolically 
compositionally distinct, with CB showing to be highly distinct. The same is observed 
when comparing the three diagnostic groups, asymptomatic and control groups appear to 
be more like each other than the group representing Alzheimer’s patients. It can be seen 
(Figure 6.3) that the pattern observed was replicated in each of the three brain regions 
with the effect size appearing comparable in the ITG and MFG and slightly weaker model 






Figure 6.2 Curated PLS-DA scores plots models comparing the metabolite composition of brain 
regions and diagnostic groups. (A) Comparisons of metabolite composition of cerebellum (CB), 
inferior temporal gyrus (ITG) and medial frontal gyrus (MFG) R2X = 0.594, R2Y = 0.582, Q2 = 
0.529, CV-ANOVA = 3.54х10-23). (B) Comparison of metabolite composition of diagnostic 
groups, control(CN), asymptomatic (ASM) and Alzheimer’s (AD) (R2X = 0.469, R2Y = 0.443, 














Figure 6.3 Curated PLS-DA scores plots comparing the metabolite composition of diagnostic 
groups in individual brain regions. (A) Comparisons of metabolite composition of diagnostic 
groups, control, asymptomatic and Alzheimer’s in cerebellum samples (R2X = 0.516, R2Y = 
0.527, Q2 = 0.412, CV-ANOVA = 7.03×10-6). (B) Comparisons of metabolite composition of 
diagnostic groups, control, asymptomatic and Alzheimer’s in inferior temporal gyrus samples 
(R2X = 0.589, R2Y = 0.561, Q2 = 0.471, CV-ANOVA = 2.17×10-5). (C) Comparisons of 
metabolite composition of diagnostic groups, control, asymptomatic and Alzheimer’s in medial 
frontal gyrus samples (R2X = 0.553, R2Y = 0.561, Q2 = 0.410, CV-ANOVA = 4.23×10-5).  
 
The metabolic features used to create the optimal curated PLS-DA models of all three 
diagnostic classes (Figure 6.2B) were taken forward as being the most interesting to 
pathology. The optimal PLS-DA model obtained comprised of 323 features that 





6.3.4 Orthogonal partial least square discriminant analysis of lipidomics data 
OPLS-DA models were created using 323 features obtained from the optimal PLS-DA 
model, as a further data mining approach. The samples were grouped by class (CN or 
ASM or AD) with first model composed of all three diagnostic groups within the same 
model (Figure 6.4A). It can be seen that the AD group is different from the controls 
groups (CN and ASM). Based on this OPLS-DA model of the two controls groups and 
AD group was performed (Figure 6.4B- refers to as three-way model). The three-way 
model OPLS-DA returned an R2 and Q2 value of 0.873 and 0.425 respectively (Figure 
6.4B). The model was considered an acceptable predictive model. From the OPLS-DA 
model an S-plot was produced (Figure 6.4C), in order to obtain the features that varied 
the most between diagnosis groups. The features with p[1] of >0.10 and p(corr)[1] of  > 
0.20 were selected (Table 6.4C). The model produced 42 features that underwent further 
investigation and annotation. 
 
 
Figure 6.4 The figure depicts pareto scaled OPLS-DA model of Lipidimics data (n=323). (A) 
Three groups showing clear separation between AD and Controls (ASM and CN). (B) OPLS-
DA for three-way model by combining ASM and CN as one group and AD as second group with 
model validation value R2= 0.873   Q2= 0.425. (C) S-Plot with features exhibiting great 
magnitude of variation (p [1] of >0.10 and p(corr) [1] of > 0.20) are in red colour. These features 









Table 6.3 Features obtained from the data S-plot analysis. 










































889.7 28.6 748.51 19.15 
858.6 17.31 916.63 21.44 
860.8 18.3 764.50 18.19 
866.7 17.5 778.56 21.81 
617.7 16.08 804.54 18.62 
632.8 19.37 788.52 18.68 
645.8 18.83 646.59 23.05 
604.8 17.58 742.53 19.32 
684.6 16.38 849.61 21.84 
686.8 16.67 742.52 19.32 
661.7 17.76 838.52 18.28 
671.8 17.95 851.65 21.96 
644.7 19.64 862.63 22.67 
548.8 13.65 819.52 20.05 
585.8 13.41 464.30 5.77 
520.8 11.60 788.52 18.68 
597.7 10.82 832.49 16.04 
711.7 18.22   
730.6 16.42   
787.8 16.55   
704.8 10.52   
630.8 12.17   
646.8 16.86   
 
6.3.4 Lipid feature selection  
Out of the 42 features detected in the s-plot (Table 6.3), we were able to confirm the 
structural elucidation of 15 features (see Table 6.4 below), with sphingolipids (SPHLs) 
making up for over half of the annotated metabolites, and a massive body of literature 
also linked SPHLs to AD pathology. To this end, SPHLs were identified for more detailed 









Table 6.4 List of annotated lipids displaying p-value and fold change and listed by lipid family. 
 CN Vs ASM CN Vs AD ASM Vs AD 
 p-value FCb p-value FCb p-value FCc 
Cer(18:1/16:0) 8.4×10-2 1.34 3.0×10-2 0.61 1.8×10-2 0.82 
Cer(18:1/18:0) 6.8×10-3* 0.74 2.3×10-1 0.52 4.0×10-2 0.16 
Cer(18:1/22:0) 6.3×10-2 1.11 8.0×10-1 1.44 2.4×10-2 1.30 
Cer(18:1/24:0) 7.8×10-3* 1.14 8.5×10-1 1.31 5.4×10-3 0.78 
Cer(18:1/24:1) 6.3×10-3* 1.15 7.5×10-1 1.53 8.7×10-3 1.26 
Cer(18:1/26:1) 6.4×10-3* 1.06 7.5×10-1 0.59 9.7×10-2 1.11 
SM (18:1/16:0) 4.6×10-1 0.73 3.4×10-1 0.34 8.8×10-1 1.21 
SM (18:1/22:0) 2.8×10-2 0.63 8.2×10-1 0.44 3.2×10-2 0.91 
DG (13:0/21:0) 7.5×10-1 1.11 6.7×10-3 1.42 2.1×10-2 0.80 
DG (17:0/20:3) 1.0×10-2* 0.89 7.3×10-2 1.31 1.1×10-2 0.93 
PC (22:4/20:4) 8.1×10-1 0.94 1.1×10-2 1.38 1.6×10-2 1.05 
PC (18:1/22:0) 6.4×10-1 1.20 3.3×10-2 0.46 1.5×10-1 1.31 
PE (20:5/19:0) 6.4×10-1 1.04 1.2×10-1 0.88 4.4×10-2 0.85 
PA (33:0) 2.8×10-1 1.19 8.9×10-3 1.90 1.6×10-2 1.58 
TG (55:8) 2.1×10-1 0.59 4.1×10-1 0.94 1.5×10-1 1.22 
Cer=ceramides, SM=Sphingomyelin, PC=Phosphatidylcholine, DG=Diacylglycerol, 
TAG=Triacylglycerol, PE=Phosphatidylethanolamine, PA=Phosphatidicacid, *pass Benjamin 
and Hochberge correction (q=<0.05). ASM, asymptomatic; CN, control; AD , Alzheimer. 
 
6.3.5 Structural elucidation and identification: Sphingolipids.  
In total 184 metabolites were annotated out of the features detected in this lipidomics 
study (Appendix D-Table 6.1). Following the selection of highly correlated features using 
multivariate modeling, these features underwent putative identification using database 
and MSe technology on the Waters Xevo instrument by checking for fragments for 
structural identification. A set of rules were also applied to filter the search results as 
described in Chapter 2 (Section 2.3.4). Table 6.5 displays the fragments of each molecule 
as observed on MSe data. Moreover, in this lipidomics study, two internal standards were 





process to elucidate side chain cleavages and retention time order of related structures. 
Figure 6.1 & 6.2 (Appendix D) represent the MS spectra (both channel 1 and channel 2) 
of the two Standards.  
 
Cers were identified as [M+H2O-H]
 + as sphinganine molecules. Initial observations 
showed a fragment ion in each m/z at 264 Da which represents the sphinganine head 
group of (18:1), this m/z is unique and does not match with other molecules. The 
unsaturated fatty acid 24:1 has m/z 630.88 with 2 less Da due to the double bond and loss 
of Hydrogen. SM was identified as [M+H] +. The fragment ion of m/z 184.07 Da is known 
to refer to the Choline head group that is distinctive to 2 lipids classes which are 
phosphatidylcholines (PC) and SM. However, when matching the results from open 
access data base and the retention time of our in-house database, no PC molecule were 
associated with the detected m/z, providing support that the 2 features with 184.07 
(choline head group) are SM.   
  
Table 6.5 Identification based on the observed ions, collision induced dissociation fragmentation 
of lipids, and retention time (product ion m/z 264.2 and 184.07 for ceramides and Sphingomyelins 
species corresponds to sphingosine base chain and choline head group respectively.) 
Identified as Observed ion Fragments RT (min) 
Cer (d18:1/16:0)/Cer16:0 [M+H2O-H] + 520.83 & 264.24 11.60 
Cer (d18:1/18:0)/Cer18:0 [M+ H2O -H] + 548.85 & 264.24 13.65 
Cer (d18:1/18:1)/Cer18:1 [M+ H2O -H] + 546.85 & 264.24 12.33 
Cer (d18:1/20:0)/Cer20:0 [M+H2O-H] + 576.81 & 264.24 14.84 
Cer (d18:1/22:0)/Cer22:0 [M+H2O-H] + 604.87 & 264.24 17.58 
Cer (d18:1/24:0)/Cer24:0 [M+H2O-H] + 632.89 & 264.24 19.37 
Cer (d18:1/24:1)/Cer24:1 [M+H2O-H] + 630.88 & 264.24 17.96 
Cer (d18:1/26:1)/Cer26:1 [M+H2O-H] + 644.78 & 264.24 19.64 
SM (d18:1/16:0)/SM16:0 [M+H] + 704.83& 184.24 10.52 





6.3.6 Sphingolipids abundance in the three human brain regions. 
In this study we analysed sphingolipids in human brain of CN, ASM and AD groups from 
three brain regions which are ITG, MFG and CB. Lipids sphingomyelines (SM 
(18:1/16:0) and SM (18:1/22:0) will be referred to as (SM 16:0, SM22:0) and ceramides 
will be referred to as (Cer16:0, Cer18:0, Cer22:0, Cer24:0, Cer24:1 and Cer26:1) 
throughout the rest of the chapter. 
 
Mann Whitney test value was used to show mean significant difference of identified 
SPHL species between groups in individual brain regions. SPHLs showed a similar trend 
increasing in ASM and AD compared to CN in ITG region. The same trends were 
observed in the MFG region, however, in MFG region no significant change were 
observed in SPHLs abundance between groups, except SM 24:0 which show significant 
increase in AD compared to CN. Based on these observations, SPHL abundance in ITG 
brain region (Table 6.6 and Figure 6.7)  was processed using one-way ANOVA with 
Benjamini and Hochberg correction to control the false discovery rate (FDR). All p-
values were represented as q values after correction. Lipids with q<0.05 were selected for 
correlation analysis.     
 
Table 6.6 Sphingolipids passed multiple comparison correction (n=5) in ITG brain region. 
ITG Region Overall q-Value CN vs ASM CN vs AD ASM vs AD 
Cer22:0 0.011* 0.013 0.883 0.065 
Cer24:0 0.002* 0.002 0.725 0.019 
Cer26:1 0.006* 0.017 0.999 0.016 
SM 16:0 0.032* 0.019 0.027 0.902 
SM 22:0 0.043* 0.017 0.049 0.787 
* Pass ANOVA Kruskal Wallis test with Benjamini and Hochberg multiple corrections, values 








Figure 6.5 Boxplots showing the effect of disease status on the abundance of five sphingolipid in 
the Inferior Temporal Gyrus(ITG). *pass ANOVA Kruskal-Wallis with Benjamin and Hochberg 
multiple correction (*<0.05 threshold). 
 
6.3.7 Correlation analysis of selected sphingolipids in brain’s ITG region 
From the gathered data, significant changes were observed in the brain’s ITG region, with 
our findings showing elevated ceramides and sphingomyelins levels in this region. The 
results of ANOVA Kruskal wallis test with Benjamini and Hochberge multiple correction 
revealed that the abundance of very long chain Cer24:0 and Cer26:1 level show 
significant increase in ASM vs CN (q= 0.002 and 0.017) and in ASM vs AD (q= 0.019 
and 0.016) (Table 6.6). On the other hand, SM16:0 and SM22:0 levels were significantly 







Spearman’s correlation analysis of the 3 Cers and 2 SMs that passed multiple corrections 
were performed using the three diagnostic groups (Table 6.7). It is important to note that 
ASM is a group with no cognitive decline but with AD pathology (Aβ and tau). Cer levels 
in the ITG region were shown to be correlated with tau tangles (Table 6.7). and no 
correlation was observed with any of the cognitive tests. CB is considered as spared 
region of the brain, believed not to show changes in pathology and also correlation 
analysis in this region revealed no correlation with neither pathology nor cognition 
parameters.  
 
Table 6.7 Correlation analysis of sphingolipid abundance and measures of Aβ and tau pathology 
in ITG region. 
Relationships between global measures of amyloid and tau pathologies and the abundances of 
five Sphingolipids, values highlighted in bold are significant at p<0.05. CERAD; Consortium to 




Introduction and study overview 
Many studies have suggested sphingolipids role in AD pathology. However, role of SPHL 
metabolism in disease aetiology and mechanism of AD pathology is yet to be understood. 
In this study, we applied mass spectrometry-based metabolomics to human brain tissue 
from the longitudinal cohort i.e. BLSA to explore this mechanism in three brain regions. 
As mentioned previously, ASM group represents the early stage of AD pathology, with 
this group having Alzheimer’s neuropathology without exhibiting cognitive decline 
during life. Up on observing changes between groups in different brain regions, it can be 
noticed that changes in SPHL levels occur mainly in the ITG brain region (Appendix D 
Figure 6.1). Therefore, it was decided to focus on the trends Cers and SM in ITG region. 
 Braak CERAD 
 R2 p-value R2 p-value 
Cer 22:0 0.209 0.183 0.053 0.741 
Cer 24:0 0.405 0.008 0.244 0.120 
Cer 26:1 -0.168 0.288 -0.110 0.488 
SM 16:0 0.518 0.0001 0.297 0.056 





Interestingly, ITG has high tau pathology and it is described to contribute to early disease 
pathology where functions as memory, understanding and language are controlled. Five 
lipids passed multiple corrections, comprised of two SM (SM16:0 and 22:0) both with 
the omega-9 fatty acid oleic (18:1) chain and 3 Cers (Cer22:0, 24:0 and 26:1). Correlation 
analysis revealed association of SPHL metabolism with tau tangles. Our data observed an 
increase in Cers and SM species level in ASM and AD compared to CN groups in the 
ITG region of brain. The alteration in both early and late AD stage suggested that these 
species might have a role in disease pathology and shift in cognition. SPHL are class of 
lipids composed of a backbone of sphingoid base, including but not limited to ceramides 
(Cers) sphingomyelins (SMs) and sulfatides. They regulate diverse cellular processes 
such as a apoptosis, cell senescence, cell cycle and cellular differentiation [368].  
 
Many studies have revealed elevated levels of SPHL in human AD brain [213, 369]. Han 
et al. 2002 performed MS lipidomics analysis of Cers in white and grey matter in post-
mortem brain tissue of AD subjects at early clinical stage (very mild dementia) This 
showed a remarkable increase in Cers level in very mild samples compared to age 
matched controls in white matter. They also found no change in Cers at all stages of AD 
in the MFG region [210]. Bandaru, Troncoso et al 2009 [370] have also reported no 
change in Cers in MFG grey matter except for Cer24:0, this molecule showed significant 
increase in AD versus CN, these findings are in agreement with what we observed in this 
study, with only Cer24:0 in the MFG region showing to be  significant and increased in 
AD (q=0.024) and ASM (q=0.047) groups brain compared to CN. The same group 
reported that Cers production can be due to sulfatide degradation (another class of 
sphingolipids) as sulfatide depletion was reported in AD brain [213]. Also, investigated 
Cer and SM levels in AD plasma providing new insight into the AD sphingolipidome and 
the potential use of metabolite signatures as potential biomarkers [190]. 
 
In the case of SM levels previous studies in AD brain have reported both increases and 
decreases. One 2012 study stated significantly elevated CSF SM levels in patients with 
prodromal AD and no change between those with mild and moderate AD compared to 
controls [371]. The authors of this study hypothesized that the observed increase in SM 





can be obtained from Cer via catabolic pathway leading to elevated SM abundance. 
Another assumption is this increase in SM can be owed to neuronal death and brain 
atrophy, this explanation is commonly used with lipid levels since SM exist in membranes 
and form the myelin sheet in the nerve cells maintaining it is structure. 
 
Following the metabolic pathway of SPHL synthesis, it was also reported that the 
dramatic increases seen in Cers content could be related to abnormal de novo ceramide 
synthesis from sphinganine and fatty acyl CoA by the action of ceramide synthase or the 
hydrolysis of SM by activation of sphingomyelinase (SMase), enzyme that facilitates the 
SM conversion to ceramide. SMase found to present in several forms (Neutral and 
Acidic). Acidic SMase was reported to be high in AD brains [372]  suggesting lower SM 
levels in the AD brain.  
 
Contrary to this hypothesis our results observed an elevation of two SM species (SM 16:0 
and SM 22:0) in ASM and AD brains. This is in line with other publications which 
reported elevated SM levels in AD brains compared to age matched controls [370, 373]. 
Yet again, two studies described a significant decrease in SM levels in AD brain, so it 
might be the case that particular fatty acid chains are changing and not all the lipid family 
as a whole [372, 374].  
 
It has been proven that membrane associated oxidative stress occurs in association with 
lipid alterations and Aβ accumulation in AD brain. Aβ has been reported to be involved 
in the pathogenesis of AD, owing to its association with levels of oxidative stress in the 
brain [375]. Furthermore, both AD brain tissue and neurons treated with Aβ show 
excessive oxidative stress, and constant increase in Cer and membrane cholesterol 
abundance, suggesting irregularities in SPHL and cholesterol metabolism in AD brain 
[369], including elevated Cer and cholesterol levels in patients with mild symptoms. In 
our work although we did find specific Cers to be elevated, cholesterol in its free form 







Considering these observations, it could be suggested that changes Cers would occur 
early during AD pathogenesis. In 2004 a study by Lee et al showed that treating cultural 
cells with Aβ lead to Cers accumulation. Also, it was reported that Cers production can 
affect Aβ production [376] and APP process [377] causing neuronal dysfunction and cell 
death in AD. Another study suggested that increased Cers concentration result in 
activation of the enzymes acetyltransferases 1 and 2, BACE1 protein acetylation and 
therefore protecting protein degradation. This would mean a leading role for Cers in Aβ 
production [378]. It was also reported that immunization with Aβ caused reduction in Aβ 
plaque but did not improve cognition due to CNS inflammatory response observed at 
phase II trial  [379]. With these findings in mind, Aβ effect on increasing Cers level would 
trigger inflammatory effects and this would induce ROS and lead to cognitive dysfunction 
as a result of cell and neuronal death.  
 
However, this would not be the case in the very early stage, since Cers levels in the ASM 
group were the highest and these volunteers had not experienced cognitive decline 
symptoms, unless sustained Cers inflammation could lead to cognitive decline. Yet again, 
Cers in our study were higher in the ITG, at early and late AD stage, in an area which is 
susceptible to tau and correlated to tau measures. 
 
To corroborate this assumption, we performed correlation analysis for the five SPHL that 
passed multiple correction with AD pathology represented as Braak staging (tau tangle) 
and Cerad score (Aβ accumulation). According to our results (Table 6.7), the correlation 
analysis of SPHL species with pathology parameters, showed strong correlation of 3 
SPHL with tau tangles in the ITG. It was reported that progression of tau pathology 
through the brain correlated with decline in cognitive function [380]. None of the SPHL 
correlated with either Braak or CERAD scores in the MFG region, confirming that the 
observed increases were associated to tau accumulation in the ITG region. 
 
Tau pathology in AD is credited to dead neurons releasing of tau aggregates. This axonal 
protein’s role is to regulate microtubules stability and it mainly accumulates in areas of 
the brain that are essential for learning and memory such as the ITG [381]. A number of 
recent studies used various AD models have manifested the active release and inter-





increased Aβ production, since secreted extracellular tau (eTau) leads to neurons 
hyperactivity and this is a possible process by which eTau regulates Aβ production 
suggesting that stopping tau spread and progression could prevent Aβ deposition, 
cognitive decline and thus apoptosis [384]. 
 
This theory is proposing that controlling the release of tau would assist the transneuronal 
expansion of misfolding. Therefore, elucidating the mechanism of tau transfer and spread 
early in disease is crucial.  Braak and Braak et al 1991, hypothesized that tau pathology 
proceed Aβ plaque formation and that tau load correlated better with severity and 
progression of the disease compared to  Aβ plaque [385]. This is a theory that is gaining 
a lot of support recently, especially in the ADNI imaging studies, where results have 
shown that tau was a better predictor of AD progression [386]. 
 
Our results show Three SPHL to correlate with tau at early stage of AD in the region 
vulnerable to tau (ITG) (Figure 6.7), suggesting that these SPHL levels increase with 
disease progression with no correlation seen to cognitive tests. It has been suggested that 
this could be due to the absence of severe inflammation at this stage and oxidative stress 
which plays a role in changes in the tau structure to promote its aggregation and lipids 
peroxidation [387]. We would hypothesize that tau induces Cers production but not to the 
degree of causing neuronal death and affecting mental functions.  
 
Considering tau as hallmark in AD and Cers as inflammatory species that contribute to 
cell apoptosis, studying the mechanism by which tau would promote the elevation in Cers 
is crucially important, especially since this mechanism is believed to take place at the 
very early stages of disease. 
 
Several studies indicated that Cer and sphingosine mediate apoptosis, growth arrest, and 
senescence, while their phosphorylated derivatives promote proliferative and 
antiapoptotic activities.  It has been suggested that Cers involved in hyper 
phosphorylation of tau via activation of protein kinases [388] , such as GSK-3β, MAPK 
and Cdk5, activated on cellular membranes and thus dysregulation of lipid metabolism 
may affect the activity of these kinases that are involved in stress signalling cascade hence 





regulate the clearance of tau aggregates by stimulating the autophagy pathway [391, 392]. 
Thus, the importance of exploring the mechanisms by which tau aggregates, is secreted 
leading to propagating the tau pathology are still unknown. Maccioni et al. 2010 
suggested that tau hyper phosphorylation may be a convergent point of toxicity in the AD 
brain stressing the importance of tau in targeting therapeutic in AD [393].  
 
It was also reported that neuronal survival could be antagonized with very small shifts in 
ceramide metabolism [363] . Moreover, shift in SPHL metabolism toward accumulation 
of Cer with the reduction of anti-apoptotic signalling, has been suggested as a function of 
the disease progression [394].Interestingly, there  have been a great emphasize that defect 
in autophagy (defined as “a vesicle and lysosome-mediated degradative pathway that is 
essential for protein homeostasis and cell health” are likely to contribute to AD 
neurodegenerative mechanism [395]. 
   
Studies have also related long chain Cer, to tau phosphorylation vis  the regulation of 
phosphoprotein phosphatase 2A (PP2A) signalling and activity [396, 397].  PP2A is a key 
tau phosphatase, found to be low in AD brain. Activation of PP2A is believed to reduce 
tau phosphorylation level. Cers are the only endogenous small lipid molecules along with 
metal cation and polyamines that were shown to regulate PPA2 activity[398] either by 
blocking I2 inhibitor binding [399] or inhibiting demethylation of PP2A mediated by 
lithium effects on ceramide [400] . According to this mechanism Cers will increase PP2A 
activity leading to reduction in tau phosphorylation and therefore inflammation and 
neuronal dysfunction. This could explain the lack of cognitive decline with high Cers 
level in ASM group and it is correlation to tau, however this would represent a protective 
role to ceramides and the evidence is somehow more robust in the inflammatory role. 
Together with this ceramide do remain increased once AD is diagnosed in our study. 
 
Recent research has postulated that its “glial cells and not neurons that cause regional 
shift in human brain aging, with glial-specific genes predicting age with greater precision 
than neuron-specific genes”. This emphasizes the importance of understanding neuron-
glial interaction in aging [401]. Satoi et al reported abnormal expression of cers in the 





link between tau pathology and the activation of microglial activation has been reported 
in brain regions of  mice over-expressing  human tau deposits [403, 404] .  A study by 
Patil et al. 2007 reported the involvement of free fatty acid palmitic acid (PA) in 
increasing cer release by astroglial cells. This increase in cer levels upon PA treatment of 
astroglia did not cause cellular stress in astroglia or affect the astroglial cell viability 
compared with controls [405] . With the aim of investigating fatty acid metabolism in 
different brain region, the same group [406] examined PA effect in the cortex (AD 
affected region) and cerebellum (as control region), high fatty acid metabolism was 
observed in cortical astroglia compared to cerebellar  astroglia which would indicate 
region vulnerability in AD. 
 
Considering fatty acids metabolism in AD. We have reported dysregulation in unsaturated 
fatty acids metabolism in chapter 5 [407] with region specificity effect on AD pathology 
and cognition using the same samples employed to conduct this lipidomics study. PA was 
reported as one of the 32 annotated metabolites that highly associated with disease 
pathology (see Table 5.3 in Chapter 5). It can be noticed that PA trends in MFG region is 
similar to CB. However, a distinct significant decrease in PA was seen in the ASM and 
AD compared to CN in ITG region (q=0.0001 and q=0.01). This suggests abnormal 
metabolism of PA particularly in ASM groups in ITG region where SPHL metabolism 
deregulations were also observed (See Appendix D Figure 6.2). The other fatty acids 
related to our SPHLs were oleic, arachidonic, linoleic, linolenic, eicosapentanoic and all 
were decreased (Control>ASM>AD) in ITG region. 
 
Changes in SPHL abundance as earliest incidents of AD development were investigated 
by number of studies in biofluids. A study in our research group [365] has reported 
increased Cer levels in plasma AD at younger age suggesting a role of Cers in the very 
early stage of disease. Moreover, another study correlated higher plasma SM levels with 
slower cognitive decline among AD patients, illustrating SM as potential sensitive blood 
based biomarker for disease progression[408] . Recent study by Varma et al. 2018, 
identified SPHL as relevant biomarker for early detection of AD, showing connection 
with disease progression and pathology over the preclinical and prodromal stages of AD 
in both brain and blood, and suggested that amending the disturbance in this class of lipids 






 Imaging techniques such as MRI and PET scan are used in AD to observe brain regions 
volume and to trace labelled molecules allowing imaging of Aβ and tau. A recent study 
conducted by researchers in Washington University using PET brain scans of individuals 
with mild AD symptoms and those cognitively normal, suggested that tau protein build 
up in the brain as “better marker of AD symptoms” than the long-studied Aβ build up. 
This was seen mainly in the temporal lobe where tau deposition occurs, with this data 
supporting AD hypothesis that tau pathology follows functional changes in brain that 
leads to the onset of early symptoms and somehow shifting the theory that Aβ  is the main 
target for AD therapies [386]. 
 
6.5 Conclusions 
The work presented in this chapter suggested SPHL species, as indicators associated with 
disease pathology and progression. The changes in these species were observed in ITG 
brain region with correlation to tau. These observations would suggest that tau pathology 











































Study strengths and limitations   
The main strengths of the study applied in chapter 5 and 6 are the well-characterized 
longitudinal BLSA cohort with serial cognitive assessments and detailed 
neuropathological examination at death. Inclusion of the “ASM” group of individuals 
allows us to relate the observed shifts in metabolism with both severity of pathology and 
the expression of AD symptoms. Inclusion of distinct brain regions representing areas 
both vulnerable and resistant to AD pathology is another key strength of this study. 
We applied four distinct metabolomic assays utilizing a range of complementary 
instruments and chromatographic techniques that together provided a wide coverage of 
the brain metabolome. The main limitation of this study is the relatively small sample size. 
There are few cohorts with extensive longitudinal cognitive assessments during life and 
detailed neuropathological assessments at death as the BLSA. Our findings therefore merit 
confirmation in larger studies. Another limitation of this study is one shared by all 
untargeted metabolomics approaches, which is the difficulty in assigning metabolite 
identities to metabolite features within the data set. With the advent of large publicly 
available metabolite databases, it is hoped that larger numbers of metabolites will be 
identified in future studies using these methods. 
 
Chapters conclusions 
AD is a major global burden in terms of the economic cost of care and the psychological 
effect on patients and their families. Finding a diagnosis that does not rely on AD 
symptoms is a major challenge in AD. Recent approaches depend on expert’s opinion by 
testing patient’s cognition and assessing their physical ability. This adds variability when 
diagnosing different types of dementia. Other challenge is the difficulty in following AD 
progression, with patient’s category usually divided into moderate to severe dementia, 
just considering a battery of cognitive tests and their performance. 
Taking all this together, investigating molecular markers that can provide meaningful 
trends to follow disease progression, cognitive decline and provide accurate measures to 





This thesis applied MS based metabolomics to look at molecular markers in the AD brain 
and possibly to provide a map of brain metabolism with pathology. With the current 
literature indicating that AD pathology appears 20 years earlier prior to AD symptoms, 
the stage where symptoms have not developed is very important for early intervention In 
our investigations we were lucky to have participants with AD pathology (tau and AB) 
and in absence of cognitive decline (referred to as ASYM-Asymptomatic). 
Furthermore, the need to design clinical trials with objective outcomes to halt disease 
progression also emphasizes the urgent need to find molecular markers of interest to help 
predict disease prior to symptoms of cognitive decline. The brain is the first organ affected 
by AD and changes in this organ will give insight into molecular shifts at different disease 
stages. 
Many markers have been reported on the literature including genes and proteins, these 
show inconsistencies particularly when it comes to finding marker to diagnose AD from 
different disease state forms and at early stage. In this work, our aim was to look at 
molecular changes in brain and to expand the knowledge of brain metabolism by 
investigating small molecular markers and their role in relation to AD pathology and 
progression.  
A number of investigations were undertaken and the results were presented and discussed 
in the following thesis chapters. 
 
In chapter 2, an untargeted metabolomics method was developed aimed at investigating 
brain small molecules using LC-Q-Tof-MS. The method development consisted of 
several validation procedures designed to examine reproducibility and metabolites 
coverage with different sample volumes. In chapter 3, GC-MS was used to develop 
untargeted metabolomics method aimed at obtaining a wider and more diverse coverage 
of brain metabolites.  
In chapter 4, using multimodal data obtained in the previous chapters, it was possible to 
discriminate Alzheimer’s disease (AD) patients from healthy controls, it also showed the 
method has potential to resolve subtle biological differences and to correlate metabolite 





In Chapter 5, the untargeted screening method developed in chapter 2 (LC-MS) and 
chapter 3 (GC-MS), along with proposed data processing approach in chapter 4. This was 
applied to a total of 124 tissues from human brain. The results showed six PUFA to be 
strongly associated with Alzheimer’s disease. Of these, 5 were decreased with disease, 
with only docosahexanoic acid increasing in abundance, with the greatest shifts observed 
in the ITG of ASM patients.  The ITG has been implicated in driving early stages AD, so 
with the largest shifts in PUFA metabolism occurring in this brain region of ASM 
patients, suggested that these shifts maybe triggering symptom onset of Alzheimer’s 
disease. 
 
 In chapter 6, we continued with processing the Lipidomics (RP-LC-MS) data. The results 
showed disturbance in sphingolipids species including 2SM (SM(16:0) and (22:0)) and 
3Cer ( Cer(22:0), (24:0) and (26:1))  with some of these species reported in the literature 
already. All were significantly higher in the ASM and AD group compared to controls in 
ITG only. Cers more significantly changed between groups whereas SMs significantly 
correlated with Braak. The results of this chapter suggest that tau pathology could be 
linked to SPHLs metabolism at very early stages in Alzheimer’s disease.  
 
Future Work 
Future work would be to incorporate brain region from a greater number of participants. 
Another interesting aspect could be to analyze UFA concentration in brain regions along 
with corresponding plasma or serum. This would allow the observation of metabolites 
variation across the blood brain barrier, further increasing the understanding of UFA in 
AD brain as considering using of biofluids is important for markers to be applied 
successfully in clinical scenario. Extending the finding of FA in Chapter 5, quantitation 
of eicosanoids in relation to FA would be interesting approach. 
Another possible future investigation would be to compare FA and SPHLs concentration 
from AD cases with a range of alternative types of dementia, brain tumor, epilepsy and 
stroke. This result will be useful to investigate how these metabolites change when 





targets in AD and help to improve understanding of disease leading to novel therapeutic 
treatment.  
Another aspect would be to investigate if trends in UFA and SPHLs observed in AD are 
primary or secondary response to the disease. It should also be necessary to see if there 
are any correlations between these metabolites and major lipoproteins linked to AD in the 
literature. 
To briefly summarize, the project performed in this thesis identified many metabolites of 
interest in AD brain, including UFA and SPHLs. Further validation to these results can 
provide leads to future research and improve the understanding of underlying 
mechanisms in AD. Therefore, replication in larger samples will provide more clear 
outcomes and reduce variability of small sample sizes. 
Further important future work would be to develop AD-Metabolomics data repository or 
database which primarily involve sharing metabolomics data in brain. This will help for 
example to produce a validated map of human brain lipids that would help to study the 
brain lipidome effect of AD, involve mapping different brain regions and establish 
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Table 2.1 Metabolites annotated from the HILIC method. Annotations were made by matching 
fragmentation of analyte peaks to fragmentations in publicly accessible databases. Displaying the 
molecular formula, molecular weight in Da, retention time (RT) in minutes and intensity in 
positive and negative ionisation modes in arbitrary units for all metabolites. – represents 







    Positive Negative 
Acetylalanine C5H9NO3 131.0582 15.56 6.2 - 
Acetylaspartate C6H9NO5 175.0480 7.66 6.4 56.2 
Acetylaspartylglutamate C11H16N2O8 304.0906 8.38 7.2 28.6 
Acetylcarnitine C9H17NO4 203.1157 14.08 27.0 0.4 
Acetylneuraminate C11H19NO9 309.1059 23.88 0.4 - 
Acetylserine C5H9NO4 147.0531 8.31 - 22.3 
Adenosine C10H13N5O4 267.0967 12.92 33.3 - 
Adenosine monophosphate C10H14N5O7P 347.0630 15.60 6.2 - 
Adrenaline C9H13NO3 183.0895 6.74 2.9 - 
Alanine C3H7NO2 89.0476 16.61 184.5 39.2 
Aminobutyrate C4H9NO2 103.0633 16.25 - 84.5 
Arachidonoyl glycidol C23H36O3 360.2664 5.01 7.8 - 
Arginine C6H14N4O2 174.1116 26.47 40.9 7.4 
Ascorbate C6H8O6 176.0320 10.72 4.2 69.1 
Asparagine C4H8N2O3 132.0534 17.01 - 1.4 
Aspartate C4H7NO4 133.0375 7.81 109.2 33.6 
Butyrlcarnitine C11H21NO4 231.1470 12.11 1.7 - 
Carnitine C7H15NO3 161.1051 17.06 135.5 - 
Carnosine C9H14N4O3 226.1065 28.8 2.1 - 
Citrate C6H8O7 192.0270 10.7 - 1.2 
Citrulline C6H13N3O3 175.0956 17.17 2.7 2.2 
Coumarate C9H8O3 164.0473 14.40 26.7 - 
Creatine C4H9N3O2 131.0694 16.62 576.9 20.5 
Creatinine C4H7N3O 113.0589 16.61 15.6 1.0 





Cysteine C3H7NO2S 121.0197 15.30 2.8 - 
Cytidine C9H13N3O5 243.0855 17.33 2.1 1.2 
Deoxyfluorouridine C9H11FN2O5 246.0651 12.20 - 6.2 
Dimethylarginine C8H18N4O2 202.1429 24.45 1.4 - 
Dimethylglycine C4H9NO2 103.0633 17.21 24.9 - 
Fumarate C4H4O4 116.0109 7.78 - 0.8 
Gluconate C6H12O7 196.0583 15.64 - 43.1 
Glutamate C5H9NO4 147.0531 16.17 79.1 61.6 
Glutamine C5H10N2O3 146.0691 16.78 27.9 95.2 
Glutamyl-glutamate C10H14N2O7 274.0801 15.61 8.2 - 
Glutamyl-leucine C11H19N2O5 259.1293 15.48 2.8 - 
Glutathione C10H17N3O6S 307.0838 15.06 22.8 - 
Glycine C2H5NO2 75.0320 17.13 2.2 1.3 
Glycolate C2H4O3 76.0160 6.51 - 4.5 
Guanidinobutanoate C5H11N3O2 145.0851 15.73 8.4 - 
Guanine C5H5N5O 151.0494 11.90 13.5 7.9 
Guanosine C10H13N5O5 283.0916 11.87 2.3 18.4 
Hexose-deoxy sugar C6H12O5 164.0679 14.39 - 5.2 
Hexose-Phosphate C6H13O9P 260.0297 14.94 - 17.4 
Histidine C6H9N3O2 155.0694 25.13 14.6 6.1 
Hydroxyphenylglycine C8H9NO3 167.0582 16.61 - 0.7 
Hydroxyproline C5H9NO3 131.0582 16.17 - 1.6 
Hypoxanthine C5H4N4O 136.0385 9.45 489.9 108.7 
Indoleacetate C10H9NO2 175.0633 9.17 5.0 - 
Inosine C10H12N4O5 268.0807 10.03 45.7 388.8 
Kynurenine C10H12N2O3 208.0847 12.19 0.9 - 
Lactate C3H6O3 90.0316 7.57 - 6.1 
leucine/Isoleucine C6H13NO2 131.0946 12.69 20.3 1.6 
Lysine C6H14N2O2 146.1055 26.62 4.7 16.3 
Lysophosphatidylserine C24H48NO9P 326.3033 6.89 4.9 - 
Malate C4H6O5 134.0215 8.66 - 9.5 
Malonate C3H4O4 104.0109 7.27 0.4 - 
Methionine C5H11NO2S 149.0510 13.43 7.3 1.2 





Methylaspartate C5H9NO4 147.0531 8.39 48.4 20.3 
Methylbutyroylcarnitine C12H23NO4 245.1627 11.8 0.3 - 
Methylfuranone C6H8O2 98.0368 15.66 - 223.4 
Methylhistidine C7H11N3O2 169.0851 25.54 2.2 - 
Methylsulfolene C5H8O2S 132.0245 13.44 16.9 - 
Methylthioadenosine C11H15N5O3S 297.0895 10.61 1.3 - 
Methylthiophene C5H6S 98.0190 7.80 1.2 - 
myo-inositol C6H12O6 180.0633 15.83 5.3 5.0 
Nicotinamide C6H6N2O 122.0480 9.57 104.8 - 
Nicotinate C6H5NO2 123.0320 9.14 - 0.6 
Ornithine C5H12N2O2 132.0898 26.39 0.5 14.4 
Oxoproline C5H7NO3 129.0425 16.77 217.42 30.2 
Pantothenate C9H17NO5 219.1106 6.74 10.1 2.2 
Pentose sugar C5H10O5 150.0528 13.55 - 10.7 
Phenylalanine C9H11NO2 165.0789 12.03 9.2 0.4 
Phosphatidylcholine C40H80NO8P 733.5621 9.08 63.6 - 
Phosphenolpyruvate C3H5O6P 167.9823 12.09 - 0.4 
Phosphocreatine C4H10N3O5P 211.0358 15.05 4.1 - 
Pipecolate C6H11NO2 129.0789 14.76 1.7 - 
Proline C5H9NO2 115.0633 14.99 30.2 0.3 
Propionylcarnitine C10H19NO4 217.1314 12.92 1.3 - 
Putrescine C4H12N2 88.1000 34.8 - 0.8 
Riboflavin C17H20N4O6 376.1382 7.9 5.5 - 
Serine C3H7NO3 105.0425 17.06 4.2 1.9 
Spermidine C7H19N3 145.1578 30.46 1.1 - 
Taurine C2H7NO3S 125.0146 15.00 119.9 286.3 
Thiouracil C4H4N2OS 128.0044 8.4 - 0.9 
Threonine/Homoserine C4H9NO3 119.0582 16.37 6.9 - 
Thymidine C10H14N2O5 242.0902 8.2 - 1.6 
Thymine C5H6N2O2 126.0429 9.30 0.6 25.6 
Tocopherol C29H50O2 430.3810 20.89 5.1 - 
Tryptophan C11H12N2O2 204.0898 12.74 4.2 1 
Tyrosine C9H11NO3 181.0738 14.39 8.8 14.9 





Urate C5H4N4O3 168.0283 11.19 2.3 3.8 
Uridine C9H12N2O6 244.0695 9.18 1.7 12.1 
Valine C5H11NO2 117.0789 14.66 4.6 0.9 
Xanthine C5H4N4O2 152.0334 8.88 78.1 51.7 
Xanthosine C10H12N4O6 284.0756 11.85 - 2.8 
Xanthurenate C10H7NO4 205.0375 11.20 1.4 - 
 
Table 2.2  Metabolites annotated from the reversed phase method. Annotations were made by 
matching fragmentation of analyte peaks to fragmentations in publicly accessible databases. 
Displaying the molecular formula, molecular weight in Da, retention time (RT) in minutes and 
intensity in positive and negative ionisation modes in arbitrary units for all metabolites. – 








    Positive Negative 
Eicosatetraenoic acid C20H32O2 304.2395 18.20 7.4 - 
Docosahexaenoic acid C22H32O2 328.2400 5.02 - 16.8 
Oxo-nonadecanoic acid C19H36O3 312.2661 20.81 14.1 - 
Glucopyranosyl-
octacosaneteraol 
C34H68O9 620.4783 18.45 0.4 - 
Glucopyranosyl-
triacontanetanetriol 
C36H70O9 646.4954 20.90 2.0 - 
Octadecatrienal C18H30O 262.2281 19.43 0.8  
Hexadecynyl acetate C18H32O2 280.2388 4.61 - 1.7 
Hydroxycholestanol C27H48O2 404.363 15.06 - 3.7 
DG(40:5) C43H74O5 670.5535 20.79 1.8 - 
DG(34:2) C37H68O5 592.5103 27.07 0.7 - 
DG(42:3) C45H82O5 702.6099 17.58 3.9 - 
DG(37:2) C40H74O5 634.5490 27.14 1.2 - 
SM(d36:0) C41H85N2O6P 732.6091 13.20 0.7 - 
SM(d41:1) C46H93N2O6P 800.6832 18.55 1.9 - 
SM(d42:1) C47H95N2O6P 814.6965 24.13 3.9 - 
SM(d42:2) C47H93N2O6P 812.6822 20.20 18.9 - 





TG(52:7) C55H92O6 848. 6842 28.10 6.2 - 
TG(49:3) C52H94O6 814.6965 19.44 3.5 - 
TG(48:3) C51H92O6 800.6823 17.70 1.4 - 
TG(50:3) C53H96O6 828.7112 19.97 1.1 - 
TG(54:7) C57H96O6 876.7199 30.36 3.1 - 
TG(54:6) C57H98O6 878.7420 30.43 1.1 - 




C40H75O8P 714.5224 23.40 6.2 - 
PI(36:3) C45H81O13P 860.5627 21.29 - 6.93 
PI(32:0) C41H79O13P 811.5319 20.97 - 19.00 
PI(38:2) C47H87O13P 891.5596 19.08 - 34.13 
PA(33:0) C36H71O8P 662.4854 15.97 1.4 - 
PA(36:1) C39H75O8P 524.4359 26.03 32.8 - 
PA(O-38:2) C41H79O7P 714.5610 23.33 7.2 - 
PA(35:1) C38H75O7P 674.5328 20.86 1.7 - 
PA(0-39:0) C42H85O7P 732.6091 14.89 0.9 - 
Didocasanoyl-
glycerosulfocholine 
C51H101O8PS 904.6917 15.92 3.2 - 
GlcCer(36:1) C42H81NO8 727.5962 24.19 5.5 - 
GlcCer(d40:1) C48H93NO8 811.6851 23.04 16.7 - 
GlcCer(d40:2) C46H87NO8 781.6351 23.60 - 4.3 
Cerebroside D C43H81NO9 755.6033 17.50 1.5 - 
TermetomycesphinA C41H77NO10 743.5492 18.71 - 2.9 
Cholestanediol C27H48O2 404.3636 14.84 - 1.4 
PC(31:2) C39H74NO8P 715.5134 18.85 2.4 - 
PC(36:2) C44H84NO7P 770.7432 18.36 1.5 - 
PC(33:2) C41H78NO8P 743.5492 20.21 1.7 12.1 
PC(32:3) C42H74NO8P 751.5152 18.77 - 57.7 
PC(33:1) C41H80NO8P 745.5574 21.30 - 0.3 
PC(37:6) C45H78NO8P 791.5417 19.61 - 1.9 
PC(32:2) C40H76NO8P 729.5322 15.98 13.7 - 





PC(38:9) C46H74NO8P 799.5298 19.11 - 45.4 
PC(35:6) C43H74NO8P 763.5146 18.70 2.3 22.4 
PC(35:3) C43H80NO8P 769.5688 20.70 41.5 - 
PC(35:6) C43H74NO8P 763.5146 17.63 2.1 - 
PC(35:3) C43H80NO8P 769.5??? 25.57 1.5 - 
PC(36:3) C44H82NO8P 783.5663 15.49 15.7 - 
PC(44:1) C52H103NO8P 900.7242 24.05 19.9 - 
PC(P-38:6) C46H80NO7P 789.5609 18.20 1.0 - 
PC(44:0) C52H105NO8P 902.7421 28.94 18.6 - 
PC(45:0) C53H107NO8P 916.6589 27.84 11.5 - 
PG(38:3) C44H81O10P 801.0817 17.50 14.8 - 
PG(36:2) C42H79O10P 775.0444 17.53 1.4 - 
PG(0-42:0) C48H97O9P 848.6842 19.75 2.7 - 
PE(40:6) C45H78NO8P 791.5417 19.61 - 31.3 
PE(33:1) C38H74NO8P 703.5118 16.54 24.6 - 
PE(35:2) C40H80NO8P 729.5307 25.83 4.9 - 
PE(38:3) C43H80NO8P 769.5688 25.96 24.2 - 
PE(33:2) C38H72NO8P 701.4996 18.18  36.9 
PE(34:2) C39H74NO8P 715.5134 18.85 - 12.4 
PE(36:4) C41H76NO8P 739.5154 12.76 0.1 - 
PE(36:2) C41H78NO8P 743.5492 14.70 2.4 - 
PE(36:5) C41H72NO8P 737.9865 21.03 2.5 - 
PE(36:1) C41H76NO8P 745.5574 20.23 - 0.3 
PE(38:6) C43H74NO8P 763.5116 18.70 12.2 - 
PE(38:4) C43H78NO8P 768.0551 23.40 7.4 - 
PE(46:1) C51H100NO8P 885.7367 22.07 7.6 - 
PE(O-36:0) C41H86NO6P 719.6105 12.32 0.1 - 
PE(O-40:0) C45H92NO7P 789.6791 16.03 1.0 - 
PE(44:8) C49H82NO8P 844.5151 19.64 3.2 - 
LPC(20:4) C28H50NO7P 543.3353 1.80 3.1 - 
LPC(24:1) C32H64NO7P 605.4384 6.13 2.1 - 
LPE(22:0) C27H56NO7P 537.7098 15.76 - 10.1 
LPE(24:1) C29H58NO7P 563.7471 16.41 - 7.2 





PS(37:3) C43H78NO10P 799.5298 10.64 - 1.5 
PS(36:1) C42H80NO10P 789.5609 13.75 0.8 - 
PS(36:0) C42H82NO10P 791.5800 14.77 0.4 - 
PS(36:5) C42H72NO10P 781.9955 12.70 1.1 - 
PS(0-34:0) C40H80NO9P 749.5511 14.55 0.3 - 
Cer(36:1) C36H67NO3 565.5435 17.49 - 8.6 
Cer(38:1) C38H67NO3 593.5725 19.16 - 3.7 
Cer(40:1) C40H67NO3 621.6163 20.60 - 1.9 
Cer(42:1) C42H67NO3 649.6446 20.83 - 1.2 
Cer(d44:2) C44H85NO3 675.6477 24.30 5.6 - 
Cer(d40:1) C40H80NO6P 701.5575 15.13 3.8 - 
PC aa C38:0 C46H92NO8P 817.6561 26.70 3.2 - 
PC aa C40:1 C48H94NO8P 843.6717 20.24 6.6 6.4 
PC aa C40:6 C48H84NO8P 833.5935 18.78 1.5 68.1 
PC aa C38:6 C44H76NO8P 805.5622 15.60 16.8 - 






Table 2.1  List of metabolites identified by GC-MS aqueous, and non-aqueous, based on 
Similarity Index search of  90 and over(AQ and NAQ) 
Extraction 
Phase 











7.882 Octadecenoic acid 
8.384 Oleic acid 
8.679 Gamma-Linolenic acid 
9.193 Hexadecanoic acid (Palmitic acid) 
10.288 Hexanedioic acid 
10.810 Linoleic acid 
11.277 Methylheptadecadiynoic acid 
11.474 Methylstearate 
12.592 Arachidonic acid 
14.581 Benzesulfonamide 
16.225 Carbamic acid 
16.358 Cholestenol 
16.743 Cholesterol 
16.933 Docosahexanoic acid 
17.531 Eicosapentaenoic acid 
17.717 Cyclobarbital 





21.906 Propanedioic acid-, diethyl ester 
23.466 Ergosta-5,22-dien-3-ol, 24-methyl 




29.353 Eicosanoic acid, trimethylsilyl ester 








(trifluoroacetyl)-,tris(tert butyldimethylsilyl) ether 
31.520 6,26-Pentatriacontadien-2-one 
31.928 Methionine, N-neopentyloxycarbonyl-, tetradecyl ester 
32.211 
1,4-Cyclohexadiene-1-propanoic acid, 3-(dichloromethyl)-
3-methyl-6-oxo-, ethyl ester 
32.519 Cyclobarbital 
32.667 Cholesterol trimethylsilyl ether 
34.173 3.alpha-(Trimethylsiloxy)cholest-5-ene 
34.371 3-Hydroxy-11-ketocholanic acid 
37.130 Card-20(22)-enolide 
37.326 3-Cyclopentylpropionic acid, phenyl ester 
43.292 Undecanoic acid,11-chloro-trimethylsilyl ester 
43.53 Succinic acid, dodec-9-yn-1-yl undecyl ester 
44.12 Cyclobarbital 








Propanoic acid, 2-oxo-3-(trimethylsilyl)-, trimethylsilyl 
ester 
11.015 Glycerol, tris(trimethylsilyl) ether 
12.858 
Propanedioic acid, methyl-bis(tert-butyldimethylsilyl) 
ester 
13.967 Ribitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl) 





Isopropylmalic acid, O-(tert-butyldimethylsilyl)-, bis(tert-
butyldimethylsilyl) ester 
16.685 Myristic acid, 2,3-bis(trimethylsiloxy)propyl ester 
17.227 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- 
18.317 Levoglucosan, tris(trimethylsilyl)- 
18.866 D-Xylose, tetrakis(trimethylsilyl)- 
20.36 Galactofuranose 








Malonic acid, 2-trifluoroacetamido-2-trimethylsiloxy-, 
di(trimethylsilyl)- 
25.587 Piperazine, 1-n-propyl-4-[3-phenpropyl]- 
29.413 Cholesta-3,5-diene 
32.35 Heptanoic acid, 6-oxo-trimethylsilyl ester 


























Table 5.1 Summary of the association of all annotated metabolites with disease pathology. 
 CN Vs ASM CN Vs AD ASM Vs AD 
 p-valuea FCb p-valuea FCb p-valuea FCc 
Acetylaspartate 4.7×10-2 0.93 9.1×10-3 0.91 6.5×10-1 0.98 
Acetylaspartylglutamate 8.4×10-1 0.99 9.1×10-2 0.90 1.5×10-1 0.91 
Acetylcarnitine 5.0×10-2 1.21 1.1×10-2 1.28 5.5×10-1 1.06 
Adenine 9.2×10-2 1.10 8.0×10-4 1.18 1.4×10-1 1.08 
Adenosine 1.2×10-1 1.23 9.5×10-1 0.99 1.0×10-1 0.81 
Adenosylmethionine 9.1×10-1 0.98 4.4×10-3 0.68 2.1×10-3 0.69 
Alanine 7.4×10-1 1.02 1.6×10-2 0.87 2.5×10-2 0.85 
Allantoin 7.0×10-3 1.19 4.7×10-4 1.30 2.0×10-1 1.09 
Aminobutanal 6.8×10-2 0.94 9.2×10-5 0.86 6.9×10-2 0.92 
AMP 6.0×10-1 0.90 3.3×10-2 1.50 9.4×10-3 1.66 
Arachidonic acid 9.5×10-2 0.88 2.9×10-5 0.75 1.4×10-2 0.84 
Arginine 5.7×10-2 1.24 1.1×10-3 1.38 2.9×10-1 1.12 
Ascorbate 1.6×10-1 1.20 1.9×10-5 1.54 6.2×10-3 1.29 
Asparagine 2.4×10-1 1.17 3.0×10-2 1.29 4.3×10-1 1.10 
Aspartate 6.3×10-2 0.91 1.5×10-4 0.84 1.0×10-1 0.92 
Benzesulfonamide 6.7×10-2 0.76 4.6×10-7 0.40 6.7×10-4 0.52 
Butyrylcarnitine 1.9×10-1 1.17 1.2×10-2 1.40 1.4×10-1 1.19 
Carbamic acid 1.9×10-1 1.15 2.0×10-7 1.53 4.0×10-4 1.32 
Carnitine 7.5×10-1 0.98 7.2×10-1 1.02 5.6×10-1 1.04 
Carnosine 2.9×10-1 0.91 2.0×10-1 1.21 6.6×10-2 1.33 
Cholestenol 1.1×10-1 1.17 1.0×10-7 1.44 3.0×10-3 1.24 
Cholesterol 7.6×10-3 0.74 6.9×10-8 0.53 1.1×10-2 0.72 
Citrulline 1.7×10-1 1.25 7.4×10-1 0.96 1.2×10-1 0.77 
Coumaric acid 9.8×10-2 1.16 1.1×10-3 1.28 2.3×10-1 1.10 
Creatine 1.6×10-1 0.95 3.2×10-2 0.92 4.5×10-1 0.97 
Creatinine 5.1×10-1 0.98 3.5×10-1 0.98 8.7×10-1 1.00 
Csytathionine 6.3×10-1 1.09 7.3×10-1 1.06 9.0×10-1 0.98 





Cytidine 2.8×10-1 1.14 8.5×10-3 1.28 2.2×10-1 1.13 
Cytosine 8.4×10-1 0.98 7.4×10-1 1.03 6.4×10-1 1.06 
Dehydroascorbic acid 8.6×10-1 0.94 1.9×10-2 2.14 1.4×10-2 2.28 
Deoxyflurouridine 5.3×10-1 1.08 1.0×10-3 1.45 2.1×10-2 1.34 
Deoxy-Ribose 6.1×10-1 0.94 3.6×10-1 0.90 6.7×10-1 0.95 
Dimethylglycine 2.9×10-2 0.89 1.1×10-6 0.74 2.3×10-4 0.84 
Docosahexanoic acid 1.8×10-1 1.14 1.7×10-7 1.45 1.6×10-3 1.27 
Dopamine 1.4×10-1 0.91 4.7×10-3 0.82 2.3×10-1 0.90 
Eicosapentaenoic acid 1.6×10-3 0.25 4.4×10-4 0.16 1.8×10-1 0.63 
Fumaric acid 4.5×10-2 0.91 1.9×10-4 0.85 1.6×10-1 0.93 
GABA 3.6×10-1 1.07 4.4×10-3 1.18 8.7×10-2 1.11 
Galactofuranose 5.7×10-1 1.06 6.8×10-2 1.17 2.3×10-1 1.11 
Gluconic acid 1.5×10-2 1.31 1.0×10-4 1.51 1.6×10-1 1.15 
Glucose 5.1×10-1 0.95 3.3×10-1 1.07 1.4×10-1 1.13 
Glutamate 9.5×10-1 1.00 1.0×10-1 0.96 1.9×10-1 0.96 
Glutamine 7.1×10-1 1.02 8.3×10-1 0.99 5.4×10-1 0.97 
Glutathione 8.3×10-1 1.02 1.3×10-1 1.13 3.4×10-1 1.10 
Glycine 3.8×10-1 1.07 2.6×10-1 0.93 8.8×10-2 0.87 
Guanidobutanoate 2.0×10-1 0.94 3.7×10-6 0.75 5.9×10-5 0.80 
Guanine 4.5×10-2 0.83 1.0×10-3 0.75 3.2×10-1 0.91 
Guanosine 7.5×10-2 0.83 5.0×10-3 0.76 4.4×10-1 0.92 
Hexanedioic acid 2.8×10-1 1.11 6.4×10-7 1.42 5.3×10-4 1.28 
Histidine 9.1×10-1 0.99 7.6×10-3 0.71 7.8×10-3 0.72 
Homocysteine 8.0×10-1 0.97 2.0×10-1 1.14 1.6×10-1 1.17 
Hydroxyanthranillate 5.4×10-1 0.95 3.6×10-1 0.92 7.4×10-1 0.97 
Hydroxyguanine 8.3×10-2 3.06 2.1×10-1 1.05 9.0×10-2 0.34 
Hypoxanthine 4.7×10-1 0.98 5.5×10-4 0.88 4.1×10-3 0.91 
Indoleacetic acid 1.4×10-1 0.93 2.6×10-4 0.82 4.8×10-2 0.89 
Inosine 2.8×10-1 0.93 8.9×10-1 0.99 3.1×10-1 1.07 
Kynurenic acid 7.3×10-1 0.96 3.2×10-1 0.87 5.2×10-1 0.91 
Lactic acid 9.1×10-1 1.00 7.1×10-1 0.99 8.2×10-1 0.99 
L-DOPA 9.3×10-2 1.11 1.9×10-4 1.23 6.1×10-2 1.10 
Leucine/Isoleucine 4.5×10-1 1.05 3.4×10-2 1.14 1.7×10-1 1.09 





Linolenic acid 7.5×10-2 0.90 2.6×10-4 0.84 1.6×10-1 0.93 
Lysine 1.9×10-1 1.20 3.1×10-2 1.41 2.9×10-1 1.18 
Malate 9.8×10-1 1.00 1.8×10-1 0.91 2.7×10-1 0.91 
Methionine 4.2×10-1 1.09 2.1×10-1 1.14 6.1×10-1 1.05 
Methyl-aspartic acid 8.2×10-1 0.99 4.6×10-2 0.88 7.5×10-2 0.89 
Methylheptadecadiynoate 2.5×10-2 0.79 2.8×10-7 0.59 1.2×10-2 0.75 
Methylstearate 5.4×10-1 0.85 2.6×10-2 0.56 2.0×10-1 0.66 
Myo-Inositol 5.8×10-1 1.09 6.6×10-3 0.70 9.7×10-3 0.65 
Nicotinamide 6.9×10-1 0.98 6.8×10-1 0.98 9.6×10-1 1.00 
Nicotinic acid 2.5×10-1 1.13 1.7×10-2 0.80 1.7×10-3 0.71 
Nitrotyrosine 9.6×10-3 1.25 1.6×10-3 1.33 4.9×10-1 1.06 
Noradrenaline 2.9×10-1 1.16 9.8×10-3 1.35 1.9×10-1 1.16 
Octadecanal 1.6×10-1 2.41 5.6×10-1 0.68 5.5×10-2 0.28 
Oleic acid 5.5×10-2 0.73 3.3×10-7 0.34 3.9×10-4 0.46 
Ornithine 8.5×10-2 1.18 2.1×10-3 1.29 3.1×10-1 1.09 
Oxoarginine 9.0×10-1 0.99 8.6×10-4 0.77 2.3×10-2 0.78 
Oxoglutarate 9.3×10-1 0.99 5.5×10-2 1.10 1.1×10-1 1.11 
Palmitic acid 2.0×10-2 0.73 4.9×10-7 0.44 1.9×10-3 0.61 
Pantothenate 3.3×10-1 0.88 3.3×10-2 0.75 1.1×10-1 0.85 
Phenylalanine 2.1×10-1 1.09 5.5×10-2 1.14 4.3×10-1 1.05 
Phosphocholine 3.5×10-1 1.06 9.5×10-3 1.14 2.6×10-1 1.07 
Phosphocreatine 3.7×10-1 0.87 1.1×10-1 0.77 4.4×10-1 0.88 
Proline 2.6×10-1 1.06 8.5×10-1 1.01 3.4×10-1 0.95 
Propionylcarnitine 1.3×10-1 1.29 2.7×10-2 1.37 6.5×10-1 1.07 
Serine 6.9×10-1 1.04 6.7×10-1 0.96 4.3×10-1 0.92 
Spermidine 8.4×10-1 0.95 1.8×10-1 0.72 2.1×10-1 0.76 
Succinate 6.6×10-1 0.96 7.0×10-2 1.13 3.4×10-2 1.18 
Taurine 5.0×10-1 0.96 9.3×10-1 1.01 4.7×10-1 1.04 
Threonine 3.4×10-1 1.07 8.9×10-2 1.11 5.6×10-1 1.04 
Tryptophan 1.5×10-1 1.16 1.2×10-1 1.19 7.8×10-1 1.03 
Tyrosine 2.6×10-2 1.22 2.7×10-3 1.30 4.4×10-1 1.07 
Uracil 8.5×10-1 1.01 1.8×10-3 1.22 1.8×10-3 1.21 
Uric acid 5.9×10-1 1.06 4.5×10-2 0.80 2.0×10-2 0.76 





Valine 4.1×10-2 1.21 5.6×10-3 1.25 7.6×10-1 1.03 
Xanthine 3.2×10-1 1.04 1.2×10-1 0.95 2.0×10-2 0.92 
Xanthosine 9.7×10-1 1.00 7.5×10-1 1.02 7.3×10-1 1.03 
a p-value calculated using mann-whitney U-test. b fold change relative to controls, c fold change relative to 
asymptomatic. AMP; adenosine-monophosphate, Asymp; asymptomatic, Cont; control, Dem; demented,  
GABA; gamma-aminobutanoate, L-DOPA; L-dihydroxy-phenylalanine. 
 
 
Table 5.2 Correlation of the abundance of 6 unsaturated fatty acids with measures of both cross 











  Last Score* Longitudinal decline+ 
  Estimate p-value Estimate p-value 
CB 
Eicosapentaenoic acid 0.185 0.551 0.020 0.490 
Linoleic acid 0.042 0.867 0.019 0.394 
Arachidonic acid 0.275 0.264 0.039 0.093 
Oleic acid 0.489 0.032 0.047 0.029 
Docosahexanoic acid -0.607 0.022 -0.052 0.035 
Linolenic acid 0.305 0.209 0.023 0.290 
ITG 
Eicosapentaenoic acid 0.073 0.731 0.000 0.988 
Linoleic acid 0.238 0.231 0.010 0.599 
Arachidonic acid 0.236 0.244 0.011 0.585 
Oleic acid 0.182 0.373 0.006 0.751 
Docosahexanoic acid -0.131 0.528 0.003 0.866 
Linolenic acid 0.282 0.188 0.014 0.515 
MFG 
Eicosapentaenoic acid 0.109 0.620 0.027 0.206 
Linoleic acid 0.344 0.121 0.039 0.075 
Arachidonic acid 0.283 0.200 0.034 0.116 
Oleic acid 0.350 0.121 0.039 0.080 
Docosahexanoic acid -0.347 0.148 -0.038 0.105 





Table 5.3 Correlation of the abundance of 6 unsaturated fatty acids with measures of both cross 











  Last Score* Longitudinal decline+ 
  Estimate p-value Estimate p-value 
CB 
Eicosapentaenoic acid 0.068 0.804 0.015 0.583 
Linoleic acid 0.176 0.404 0.008 0.644 
Arachidonic acid 0.154 0.472 0.017 0.347 
Oleic acid 0.194 0.346 0.018 0.273 
Docosahexanoic acid -0.053 0.817 -0.020 0.272 
Linolenic acid 0.294 0.154 0.020 0.225 
ITG 
Eicosapentaenoic acid 0.253 0.178 -0.002 0.907 
Linoleic acid 0.371 0.050 0.026 0.127 
Arachidonic acid 0.348 0.067 0.025 0.156 
Oleic acid 0.341 0.077 0.023 0.207 
Docosahexanoic acid -0.384 0.044 -0.017 0.354 
Linolenic acid 0.329 0.074 0.023 0.217 
MFG 
Eicosapentaenoic acid 0.105 0.605 0.054 0.032 
Linoleic acid 0.230 0.253 0.047 0.015 
Arachidonic acid 0.173 0.383 0.043 0.026 
Oleic acid 0.236 0.215 0.047 0.012 
Docosahexanoic acid -0.125 0.499 -0.033 0.074 






Table 5.4 Correlation of the abundance of 6 unsaturated fatty acids with measures of both cross 










  Last Score* Longitudinal decline+ 
  Estimate p-value Estimate p-value 
CB 
Eicosapentaenoic acid 0.152 0.650 -0.027 0.382 
Linoleic acid 0.222 0.234 0.016 0.384 
Arachidonic acid 0.220 0.244 0.016 0.392 
Oleic acid 0.306 0.058 0.031 0.003 
Docosahexanoic acid -0.065 0.755 -0.011 0.555 
Linolenic acid 0.356 0.031 0.026 0.003 
ITG 
Eicosapentaenoic acid 0.277 0.093 0.013 0.502 
Linoleic acid 0.230 0.173 0.013 0.455 
Arachidonic acid 0.202 0.236 0.013 0.494 
Oleic acid 0.189 0.269 0.011 0.549 
Docosahexanoic acid -0.256 0.123 -0.009 0.631 
Linolenic acid 0.284 0.102 0.014 0.475 
MFG 
Eicosapentaenoic acid 0.233 0.184 0.011 0.640 
Linoleic acid 0.385 0.027 0.030 0.117 
Arachidonic acid 0.347 0.042 0.028 0.138 
Oleic acid 0.352 0.042 0.032 0.096 
Docosahexanoic acid -0.345 0.064 -0.034 0.087 





Table 3.5 Correlation of the abundance of 6 unsaturated fatty acids with measures of both cross 











  Last Score* Longitudinal decline+ 
  Estimate p-value Estimate p-value 
CB 
Eicosapentaenoic acid -0.007 0.984 0.005 0.765 
Linoleic acid 0.119 0.552 0.008 0.396 
Arachidonic acid 0.193 0.336 0.011 0.288 
Oleic acid 0.349 0.068 0.016 0.126 
Docosahexanoic acid -0.258 0.227 -0.009 0.476 
Linolenic acid 0.376 0.053 0.008 0.383 
ITG 
Eicosapentaenoic acid 0.244 0.160 -0.004 0.764 
Linoleic acid 0.273 0.123 0.003 0.768 
Arachidonic acid 0.248 0.165 0.002 0.855 
Oleic acid 0.262 0.145 0.004 0.742 
Docosahexanoic acid -0.357 0.038 -0.006 0.620 
Linolenic acid 0.379 0.037 0.011 0.400 
MFG 
Eicosapentaenoic acid 0.270 0.134 0.005 0.775 
Linoleic acid 0.525 0.002 0.008 0.545 
Arachidonic acid 0.484 0.005 0.009 0.468 
Oleic acid 0.518 0.003 0.009 0.477 
Docosahexanoic acid -0.575 0.002 -0.007 0.654 





Table 5.6 Correlation of the abundance of 6 unsaturated fatty acids with measures of both cross 





  Last Score* Longitudinal decline+ 
  Estimate p-value Estimate p-value 
CB 
Eicosapentaenoic acid 0.383 0.166 0.055 0.013 
Linoleic acid 0.296 0.091 0.025 0.218 
Arachidonic acid 0.349 0.020 0.033 0.015 
Oleic acid 0.422 0.004 0.042 0.002 
Docosahexanoic acid -0.182 0.366 -0.025 0.248 
Linolenic acid 0.329 0.033 0.035 0.004 
ITG 
Eicosapentaenoic acid 0.038 0.815 0.030 0.079 
Linoleic acid 0.160 0.317 0.029 0.034 
Arachidonic acid 0.131 0.417 0.028 0.056 
Oleic acid 0.128 0.434 0.032 0.027 
Docosahexanoic acid -0.218 0.173 -0.033 0.014 
Linolenic acid 0.266 0.113 0.042 0.008 
MFG 
Eicosapentaenoic acid 0.258 0.118 0.025 0.186 
Linoleic acid 0.330 0.043 0.025 0.094 
Arachidonic acid 0.305 0.059 0.026 0.084 
Oleic acid 0.303 0.065 0.028 0.065 
Docosahexanoic acid -0.235 0.176 -0.031 0.074 








 Table 6.1 show annotated metababolites of lipidomics study between groups. 
 Control Vs ASM Control Vs AD ASM Vs AD 
 p-value FCb p-value FCb p-value FCc 
LPE(18:0) 4.56E-01 1.08 5.92E-02 1.24 2.76E-01 1.15 
LPC(16:1) 7.47E-01 0.97 3.85E-01 1.13 3.23E-01 1.16 
LPC(16:0) 9.68E-01 1.00 9.66E-02 1.14 1.26E-01 1.14 
LPE(20:0) 9.76E-01 1.00 4.27E-01 1.11 4.52E-01 1.10 
LPC(18:3) 5.91E-01 1.07 5.27E-02 1.30 1.56E-01 1.21 
Cer(d34:1) 6.51E-02 1.57 2.25E-01 1.16 1.71E-01 0.74 
LPC(18:1) 8.21E-01 0.98 2.17E-01 1.11 2.31E-01 1.13 
LPC(18:0) 9.66E-01 1.00 1.52E-01 1.14 1.42E-01 1.14 
Cer(36:2) 1.38E-01 1.48 7.96E-01 1.03 1.66E-01 0.70 
Cer(36:1) 5.77E-02 1.52 1.93E-02 1.24 3.04E-01 0.82 
Cer(38:1) 5.02E-02 1.23 2.26E-01 1.12 4.40E-01 0.92 
DG(34:0) 7.56E-01 1.02 5.44E-01 0.97 3.87E-01 0.95 
Cer(40:1) 3.02E-02 1.31 9.95E-01 1.00 1.51E-02 0.76 
DG(35:3) 2.55E-01 1.07 4.41E-01 0.96 3.33E-02 0.90 
DG(36:4) 7.44E-01 0.96 1.41E-02 1.33 6.92E-03 1.38 
Cer(42:1) 4.48E-03 2.16 6.38E-01 1.09 7.78E-03 0.51 
Cer(42:1) 4.54E-03 1.70 7.38E-01 1.05 3.98E-03 0.62 
DG(37:0) 5.43E-01 1.04 2.23E-01 0.92 5.50E-02 0.88 
Cer(43:2) 5.35E-03 1.87 6.63E-01 1.06 9.61E-03 0.57 
PA(O-33:1) 3.44E-02 1.64 5.86E-01 1.10 7.05E-02 0.67 
DG(38:0) 8.92E-01 1.02 7.47E-01 1.05 8.89E-01 1.02 
Cer(44:2) 1.53E-03 1.89 7.35E-01 1.05 2.70E-03 0.55 
DG(40:8) 5.95E-01 0.93 5.40E-03 1.49 1.11E-03 1.61 
PA(33:0) 2.22E-01 1.23 6.14E-04 1.97 1.64E-02 1.59 
DG(40:6) 3.01E-01 1.22 9.63E-04 1.87 1.53E-02 1.53 





SM(32:2) 5.45E-01 1.10 4.59E-03 1.69 1.62E-02 1.54 
PE(P-34:1) 1.00E-01 1.34 3.66E-01 1.11 2.54E-01 0.83 
SM(34:1) 2.83E-01 1.14 2.32E-01 1.10 7.46E-01 0.97 
DG(44:12) 7.99E-01 1.04 1.34E-03 1.76 2.00E-03 1.69 
PE(36:2) 4.75E-01 1.12 6.43E-01 1.07 7.40E-01 0.95 
SM(36:2) 5.70E-01 0.96 8.82E-01 1.01 5.04E-01 1.05 
PC(P33:1) 1.01E-01 1.34 5.99E-01 1.07 1.81E-01 0.80 
SM(36:1) 8.64E-02 0.87 3.76E-01 1.07 4.80E-03 1.22 
PA(O-39:0) 4.93E-01 1.12 8.00E-01 1.04 6.16E-01 0.93 
PE(P-38:6) 3.36E-01 1.12 8.11E-01 1.02 4.35E-01 0.91 
PS(0-34:0) 5.00E-02 0.68 6.53E-01 1.09 2.19E-02 1.59 
PC(33:1) 4.69E-01 1.10 9.91E-01 1.00 4.76E-01 0.91 
PE(P-38:4) 8.41E-01 0.98 6.61E-01 0.97 8.61E-01 0.99 
PC(34:2) 7.16E-01 0.98 1.27E-01 0.93 4.26E-01 0.95 
SM(38:1) 6.35E-01 0.94 1.22E-01 0.84 3.02E-01 0.89 
PC(35:0) 1.86E-01 0.97 9.89E-01 1.00 1.54E-01 1.03 
PCae(36:5) 4.96E-01 0.95 6.36E-01 1.03 2.64E-01 1.08 
PC aa(36:4) 1.15E-01 1.19 7.18E-01 0.96 5.12E-02 0.80 
PC(35:3) 3.40E-01 1.10 8.85E-01 1.01 4.01E-01 0.92 
PC(26:1) 1.39E-01 0.89 7.87E-02 0.89 9.67E-01 1.00 
PE(P-40:7) 1.94E-01 1.27 6.96E-01 1.06 2.91E-01 0.83 
PC(34:4) 3.46E-02 0.88 3.69E-01 0.96 1.72E-01 1.09 
PE(P-40:5) 9.48E-01 0.99 4.35E-01 1.15 3.89E-01 1.17 
PC aa(36:5) 5.44E-01 1.04 1.36E-01 0.90 2.77E-02 0.86 
SM(38:1) 5.55E-01 1.04 1.62E-01 0.90 3.80E-02 0.87 
PC(36:4) 3.17E-01 0.91 7.86E-01 0.97 4.98E-01 1.08 
PC(36:3) 1.15E-01 0.81 9.60E-01 0.99 8.76E-02 1.23 
PC(36:2) 9.07E-01 0.99 1.97E-01 0.90 2.44E-01 0.91 
Glucer(d40:0) 7.72E-01 1.02 3.04E-01 0.96 2.19E-01 0.94 
SM(40:1) 2.32E-01 1.41 7.36E-01 1.04 2.77E-01 0.74 
PC(37:1) 1.15E-01 1.06 9.91E-01 1.00 1.06E-01 0.95 
Glucer(d39:1) 7.06E-01 1.10 3.38E-01 1.10 1.00E+00 1.00 
PC ae(38:6) 7.72E-01 0.98 3.07E-01 0.94 5.53E-01 0.96 





PG(38:3) 1.15E-01 1.46 3.75E-01 1.14 2.75E-01 0.78 
GlcCer(d40:1) 5.70E-02 0.89 2.79E-01 1.05 4.93E-03 1.19 
Pcaa(38:6) 1.34E-01 1.43 3.38E-01 1.20 4.23E-01 0.84 
SM(40:2) 4.12E-01 1.18 4.77E-01 0.90 1.71E-01 0.76 
SM(40:1) 6.97E-02 0.90 3.37E-01 0.96 2.45E-01 1.06 
PC(37:0) 1.49E-01 0.92 1.00E-01 0.92 9.70E-01 1.00 
PC(38:4) 5.06E-01 1.17 6.79E-01 1.09 7.50E-01 0.93 
PC(38:3) 4.50E-02 2.14 3.46E-01 1.32 1.54E-01 0.62 
SM(42:2) 6.37E-02 1.40 3.90E-01 1.13 1.97E-01 0.81 
PC(37:6) 8.50E-02 1.36 4.17E-01 1.12 2.39E-01 0.82 
SM(42:1) 8.36E-02 1.55 4.69E-01 1.12 1.69E-01 0.72 
SM(43:2) 1.02E-01 1.45 3.59E-01 1.15 2.74E-01 0.79 
Pcae(40:1) 8.28E-01 1.04 4.60E-01 1.12 6.05E-01 1.08 
PC aa(40:6) 1.95E-02 0.86 6.14E-01 1.03 7.65E-03 1.20 
SM(42:1) 3.48E-01 0.86 2.95E-02 1.48 7.80E-03 1.73 
PC(30:4) 5.72E-01 0.96 2.16E-01 0.92 5.15E-01 0.96 
SM(42:0) 5.55E-01 0.96 1.95E-01 0.91 4.99E-01 0.95 
SM(44:2) 1.71E-01 1.38 2.48E-01 1.23 6.08E-01 0.89 
PC aa(40:1) 1.51E-01 0.88 7.51E-02 1.14 2.82E-03 1.29 
PS(36:2) 2.07E-01 1.29 4.48E-01 1.13 4.78E-01 0.87 
TG(50:0) 9.66E-02 1.37 9.63E-02 1.22 4.83E-01 0.89 
PC ae(42:3) 2.50E-01 0.91 2.12E-01 1.12 3.19E-02 1.24 
PC(42:9) 1.00E-01 0.81 9.53E-01 0.99 8.84E-02 1.22 
TG(52:5) 5.10E-01 1.13 2.80E-01 0.87 1.73E-01 0.77 
PC(42:7) 2.12E-01 1.21 1.55E-02 1.37 3.23E-01 1.14 
Glc cer(40:1) 2.65E-02 0.77 7.31E-01 1.04 1.20E-02 1.34 
PC(42:4) 8.77E-02 0.84 5.16E-01 1.07 2.82E-02 1.28 
TG(51:0) 3.00E-01 2.26 6.69E-02 0.66 1.86E-01 0.29 
PC(44:5) 9.62E-01 1.01 9.03E-01 1.01 9.48E-01 1.01 
TG(52:0) 4.78E-01 1.09 4.72E-02 1.16 5.56E-01 1.07 
TG(52:0) 6.38E-01 1.05 4.94E-02 1.16 3.58E-01 1.10 
PC(44:1) 2.38E-01 1.33 5.42E-01 1.11 4.18E-01 0.84 







4.26E-01 1.09 7.18E-02 0.89 8.40E-02 0.82 
Tetradecanedioic 
acid 
5.71E-01 0.95 7.08E-01 1.03 4.20E-01 1.08 
Octadecadenoic 
acid 
7.52E-01 0.96 5.19E-01 1.08 4.29E-01 1.13 
hydroxycalciol 3.27E-01 1.17 2.65E-01 1.17 9.91E-01 1.00 
LPE alkenyl 18:1 7.63E-01 1.04 1.19E-01 1.19 2.46E-01 1.15 
LPE(18:1) 7.12E-01 1.03 7.79E-02 1.15 2.52E-01 1.11 
LPC(15:0) 8.53E-01 0.99 3.73E-01 1.06 3.05E-01 1.08 
Lyso PE(20:4) 9.29E-01 0.99 4.04E-01 1.07 4.44E-01 1.08 
LPE(20:1) 9.77E-01 1.00 7.78E-01 0.98 8.35E-01 0.98 
LPE(20:0) 7.74E-01 0.98 4.11E-01 1.07 2.63E-01 1.10 
Cer(36:1) 1.18E-01 1.36 3.67E-02 1.21 5.09E-01 0.89 
Cer(38:1) 2.82E-01 1.18 9.64E-01 1.00 2.44E-01 0.84 
Cer(42:2) 1.09E-02 1.48 9.52E-01 1.01 1.54E-02 0.68 
PA(34:1) 7.65E-02 1.44 1.02E-01 1.26 4.85E-01 0.88 
Cer(41:0) 3.21E-02 1.34 4.68E-01 0.94 1.22E-02 0.70 
Cer(42:1) 1.47E-02 1.52 4.97E-01 0.92 6.86E-03 0.60 
PA(36:1) 2.46E-01 1.17 9.73E-02 1.13 8.05E-01 0.97 
PE(34:2) 9.06E-01 1.01 5.78E-01 1.04 6.64E-01 1.03 
PE(34:1) 5.87E-01 0.97 4.66E-01 0.96 8.82E-01 0.99 
PE(34:0) 7.44E-01 0.97 6.54E-01 1.03 4.51E-01 1.06 
PE(35:3) 7.05E-01 1.05 5.16E-01 1.07 8.34E-01 1.02 
PC(32:1) 7.00E-01 1.03 2.24E-01 0.93 1.45E-01 0.91 
PC(33:2) 2.66E-01 1.07 3.01E-01 1.06 8.14E-01 0.99 
PE(36:2) 6.41E-01 1.03 2.26E-02 0.91 2.79E-02 0.88 
PE(36:1) 7.76E-01 1.01 7.85E-01 0.99 5.79E-01 0.97 
PE ae(38:6) 7.37E-01 0.98 9.59E-01 1.00 6.94E-01 1.03 
PS(32:6) 1.29E-01 1.39 3.16E-01 1.22 4.63E-01 0.88 
PE(38:4) 5.78E-01 0.96 2.12E-01 0.92 5.97E-01 0.96 
PC(34:1) 3.14E-01 1.05 2.27E-01 0.95 6.92E-02 0.91 
PC(35:3) 4.53E-01 1.10 8.60E-01 1.02 5.59E-01 0.93 





PE(39:6) 8.49E-01 1.01 7.40E-01 1.01 9.02E-01 1.00 
PS(36:7) 2.83E-01 0.92 3.26E-01 1.07 3.74E-02 1.16 
PE(39:5) 6.16E-01 0.96 8.21E-01 1.02 4.57E-01 1.06 
PE(39:5) 8.61E-01 0.99 7.23E-02 0.86 7.98E-02 0.87 
PC(36:4) 6.68E-01 0.97 4.66E-01 0.96 8.20E-01 0.99 
PE(40:6) 7.70E-01 1.02 3.33E-01 0.94 2.66E-01 0.92 
PG(36:6) 8.54E-01 0.98 8.75E-01 1.02 7.29E-01 1.05 
PE(42:9) 8.85E-01 0.99 1.03E-01 0.86 1.46E-01 0.87 
PE(40:3) 4.39E-01 0.94 1.43E-01 0.88 3.96E-01 0.94 
PS(38:3) 3.54E-01 0.90 5.84E-01 0.95 6.25E-01 1.05 
PS(37:1) 7.29E-01 1.03 3.29E-02 0.88 4.53E-02 0.85 
PS(37:0) 9.36E-01 1.00 5.66E-01 0.97 6.35E-01 0.98 
PA(44:5) 9.16E-01 0.99 5.78E-01 0.97 6.66E-01 0.98 
PS(38:6) 9.30E-01 1.01 8.61E-01 1.02 9.36E-01 1.01 
Glccer(d42:0) 8.28E-02 0.85 6.87E-01 0.97 1.17E-01 1.14 
PC(40:10) 6.55E-01 0.95 5.15E-01 0.94 9.20E-01 0.99 
PS(39:3) 3.90E-01 0.92 9.12E-01 0.99 4.07E-01 1.08 
PI(35:1) 3.10E-01 0.91 4.93E-01 1.06 7.27E-02 1.17 
GlcCer(44:1) 1.43E-01 0.81 5.83E-01 0.93 1.99E-01 1.15 
PS(40:2) 9.07E-01 1.01 2.24E-01 1.08 2.84E-01 1.07 
PI(36:4) 6.46E-01 1.05 7.34E-01 1.04 9.15E-01 0.99 
PI(34:2) 5.84E-01 1.05 6.38E-01 1.05 9.56E-01 0.99 
PE(46:6) 1.56E-02 0.83 3.07E-01 0.93 8.91E-02 1.13 
PE(46:5) 5.68E-02 0.72 2.37E-01 0.83 5.16E-02 1.16 
PI(38:5) 8.92E-01 0.99 1.18E-01 0.90 1.43E-01 0.91 


































Figure 6.1 Mass spectrum of lipid internal standard-ceramide (d17:1/24:1). A) Channel 1 showing two main parent ions. B) Channel 2 showing daughter 























Figure 6.2 Mass spectrum of lipid internal standard- sphingomyeline (/d18:117:0). A) Channel 1showing parent ion. B) Channel 2 showing daughter ions.  










Figure 6.3 Boxplots showing the effect of disease status on the abundance of all SPHLs annotated (n=8) in the Cerebellum(CB), Inferior Temporal 











Figure 6.4  Boxplot of palmitic acid abundance in brain ITG region. * ANOVA kruskal wallis 
with Benjamini-Hochberg multiple correction, *outlier.  
 
 
 
 
 
 
 
